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Abstract 
 
 
CHARGE syndrome (CS) is a rare genetic disease characterized by 
numerous congenital abnormalities, mainly caused by de novo alterations 
of the CHD7 gene. It encodes a chromodomain protein, involved in the ATP-
dependent remodeling of chromatin. The vast majority of CHD7 alterations 
consists in null alleles like deletions, non-sense substitutions or frameshift-
causing variations. We report the first molecular diagnosis of an Indonesian 
CS patient by a targeted NGS (next-generation sequencing) gene panel 
(CHD7, EFTUD2, and HOXA1). We identified a novel heterozygous 
nonsense mutation in exon 34 of CHD7 (c.7234G>T or p.Glu2412Ter). 
Functional analyses to confirm the pathogenicity of CHD7 variants are 
lacking and urgently needed. Therefore, the aim of this study was to 
establish a functional test for wild-type (WT) or variants of CHD7 protein 
found in CS patients. Using an expression vector encoding CHD7, three 
variants harboring an amino acid substitution and one variant with a five-
amino acid insertion were generated via site-directed mutagenesis. Then 
CHD7 proteins, either wild-type (WT) or variants, were overexpressed in 
HeLa cell line. Protein expression was highlighted by Western blot and 
immunofluorescence. We then used real-time RT-PCR to study CHD7 
functionality by evaluating the transcript amounts of five genes whose 
expression is regulated by CHD7 according to the literature. These reporter 
genes are 45S rDNA, SOX4, SOX10, ID2, and MYRF.  We observed that, 
upon WT-CHD7 expression, the reporter gene transcriptions were 
downregulated, whereas the four variant alleles of CHD7 had no impact. 
This suggests that these alleles are not polymorphisms because the variant 
proteins appeared non-functional. Furthermore, we applied our biological 
assay in SH-SY5Y cell line in which endogenous CHD7 gene was mutated 
using the CRISPR/Cas9 technique. Then, we observed that when a CHD7 
missense variant was expressed, the transcription levels of the five reporter 
genes were non-significantly different, compared with the cells in which 
both CHD7 alleles were knocked-out. Therefore, the studied variants can 
be considered as disease-causing of CS.  
Keywords: CHARGE syndrome, CHD7, functional test, targeted gene 
panel. 
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Résumé 
Le syndrome CHARGE (CS) est une maladie génétique rare caractérisée 
par de nombreuses anomalies congénitales, majoritairement causées par 
des altérations de novo du gène CHD7. Celui-ci code pour une protéine à 
chromodomaines, impliquée dans le remodelage ATP-dépendant de la 
chromatine. La grande majorité des altérations de CHD7 consiste en 
allèles nuls tels que des délétions, des substitutions non-sens ou des 
décalages du cadre de lecture. Nous avons réalisé le premier diagnostic 
moléculaire d’un patient Indonésien atteint du CS, en étudiant un panel de 
gènes (CHD7, EFTUD2, et HOXA1) par NGS (next-generation 
sequencing). Nous avons identifié une nouvelle mutation non-sens 
hétérozygote dans l’exon 34 du gène CHD7 (c.7234G>T ou 
p.Glu2412Ter). Par ailleurs, il n’existe pas d’analyse fonctionnelle qui 
permettrait de caractériser la pathogénicité des variants de la protéine 
CHD7 rencontrés chez des patients. C’est pourquoi l’objectif de ce travail 
est de mettre au point un test fonctionnel de la protéine CHD7, sous forme 
sauvage ou mutée. Pour cela, nous avons généré par mutagénèse dirigée 
des vecteurs codant pour trois variants faux-sens de CHD7 et le variant 
présentant une insertion de cinq acides aminés. Ensuite, les protéines 
CHD7, sous forme sauvage ou variante, ont été surexprimées dans la 
lignée HeLa. L’expression des protéines a été mise en évidence par 
Western blot et par immunofluorescence. Pour étudier la fonctionnalité de 
CHD7, nous avons quantifié par RT-qPCR les transcrits de cinq gènes 
(l’ADNr 45S, SOX4, SOX10, MYRF, et ID2), dont la transcription est selon 
la littérature régulée par CHD7.  Nous avons observé que l’expression de 
CHD7 sauvage entraînait une diminution significative et reproductible des 
quantités de transcrits correspondant à tous les gènes rapporteurs. Par 
contre, l’expression des quatre allèles variants de CHD7 n’avait aucun 
impact, ce qui suggère que ces variants ne sont pas fonctionnels. Par 
ailleurs, nous avons appliqué notre test biologique dans des cellules de la 
lignée SH-SY5Y, pour lesquelles nous avons introduit une mutation faux-
sens dans le génome en utilisant la technique CRISPR/Cas9. Lorsque ce 
variant était exprimé, les niveaux de transcription des cinq gènes 
rapporteurs n’étaient pas significativement différents de ceux observés 
dans les cellules où les deux allèles de CHD7 avaient été invalidés. Par 
conséquent, les variants étudiés peuvent être répertoriés comme résultant 
de mutations causales du CS.  
Mots clés: CHD7, syndrome CHARGE, test fonctionnel, panel de gènes. 
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Mise au Point d’un Test Fonctionnel pour la Protéine CHD7 
Impliquée dans le Syndrome CHARGE 
 
Synopsis 
 
Le syndrome CHARGE (SC) est une maladie génétique rare 
caractérisée par de nombreuses anomalies congénitales, majoritairement 
causées par des altérations de novo du gène CHD7. Celui-ci code pour une 
protéine à chromodomaines, impliquée dans le remodelage ATP-
dépendant de la chromatine. La grande majorité des altérations de CHD7 
consiste en allèles nuls tels que des délétions, des substitutions non-sens 
ou des décalages du cadre de lecture. Des cas sporadiques de SC sont 
liés aux altérations d'autres gènes. Par conséquent, le séquençage ciblé 
de panels de gènes est devenu la plus simple stratégie d’analyse de 
mutations à grande échelle.  
Le diagnostic du SC est exclusivement basé sur des caractéristiques 
cliniques. Les patients présentent généralement divers signes majeurs ou 
une combinaison de signes majeurs et mineurs. Cependant, le test 
moléculaire est essentiel pour confirmer le diagnostic clinique. Il aide les 
cliniciens à identifier et à confirmer la cause des multiples anomalies 
congénitales chez les patients. Cette connaissance leur permet de fournir 
les meilleurs soins à ces patients et également de donner des informations 
sur le risque de récurrence. 
On suppose que l'haploinsuffisance pour CHD7 est le mécanisme 
pathogène responsable du SC. L’interprétation des mutations tronquées 
non-sens ou des décalages du cadre de lecture est claire. Les variants 
faux-sens et d'épissage de CHD7 sont rares dans la population et ne 
représentent respectivement que 8% et 11% des cas du SC. Ces variants 
restent de signification clinique inconnue (VUS) en raison du manque 
d'informations génétiques qui pourraient aider à déterminer leur 
pathogénicité. De plus, l'interprétation de l'effet d'un faux-sens du gène 
CHD7 reste un défi. En raison de la grande taille du gène (188 kb, avec 38 
exons) et donc de la protéine (340 kDa), le test fonctionnel de CHD7 est 
difficile à réaliser. 
Par ailleurs, les analyses fonctionnelles déjà publiées pour confirmer 
la pathogénicité des variants sont trop complexes pour une utilisation en 
routine. C’est pourquoi l’objectif principal de ce travail est de mettre au point 
un test fonctionnel simple de la protéine CHD7, sous forme sauvage ou 
mutée. Pour cela, nous avons généré par mutagénèse dirigée des variants 
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faux-sens de CHD7 et un variant présentant une insertion de cinq acides 
aminés. Nous avons d’abord développé un système de test fonctionnel 
basé sur la surexpression de CHD7 et avons également développé notre 
système pour tester l’effet des variants faux-sens de CHD7 avec un niveau 
d’expression endogène dans lequel la substitution de nucléotide a été 
introduite dans le génome par modification génomique avec la technique 
CRISPR/Cas9. 
L'objectif secondaire de cette thèse est de réaliser le premier 
diagnostic moléculaire d’un patient Indonésien précédemment 
diagnostiqué comme un SC typique, en étudiant un panel de gènes (CHD7, 
EFTUD2, et HOXA1) par NGS (next-generation sequencing). 
Dans le chapitre 2, nous présentons une revue de la littérature sur le 
SC, comprenant une brève histoire du SC et de l'association au syndrome, 
l'évolution du spectre phénotypique, la mise à jour des critères de 
diagnostic du SC et les causes génétiques impliquées dans le SC. Nous 
décrivons également les mutations de CHD7, l’organisation des domaines 
de la protéine CHD7 et sa fonction. De plus, nous résumons le mécanisme 
pathologique du SC et un nouveau système de classification permettant de 
prédire l’effet pathogène des variants faux-sens de CHD7. 
Le chapitre 3 décrit les matériels et les méthodes utilisés pour identifier 
la cause génétique du CS chez un patient Indonésien à l'aide d'un panel de 
gènes ciblé par NGS. En outre, nous décrivons les techniques utilisées pour 
développer un test fonctionnel permettant d'étudier la pathogénicité des 
variants de CHD7 en utilisant une approche par surexpression puis en 
utilisant la technologie CRISPR/Cas9 pour obtenir l’expression endogène 
des variants de CHD7. Nous fournissons également des analyses de la 
littérature de plusieurs gènes cibles de CHD7 que nous avons utilisés dans 
notre système pour étudier la fonctionnalité des variants de CHD7. Ces 
gènes cibles sont l'ADNr 45S, SOX4, SOX10, ID2 et MYRF. Dans la 
dernière partie, nous décrivons la technologie d'édition du génome 
CRISPR/Cas9 et expliquons comment nous avons développé notre 
système pour tester l'effet des variants faux-sens CHD7 avec un niveau 
d'expression endogène, pour étudier leur fonctionnalité dans un contexte 
plus physiologique. 
Le chapitre 4 porte sur un diagnostic clinique et moléculaire du SC. 
Nous décrivons le premier patient Indonésien atteint du SC qui a été 
précédemment diagnostiqué selon une combinaison de critères cliniques. 
Par ailleurs, nous avons confirmé ce diagnostic au niveau moléculaire. 
Nous avons identifié une nouvelle mutation non-sens hétérozygote dans 
l’exon 34 du gène CHD7 (c.7234G>T ou p.Glu2412Ter), qui a ensuite été 
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confirmée par séquençage selon la technique de Sanger. Le dépistage 
génétique parental a confirmé l’origine de novo de la mutation. 
Dans le chapitre 5, nous exposons les résultats. Le sous-chapitre 5.1 
présente les résultats du développement d'un test fonctionnel des variants 
de CHD7. En utilisant un vecteur d'expression codant pour CHD7, trois 
substitutions d'acides aminés p.(Gly1982Trp) ou G1982W, p.(Arg2319Cys) 
ou R2319C, p.(Leu1302Pro) ou L1302P et une insertion de cinq acides 
aminés p.(His1801_Gly1802insAspGlyHisGlyThr) ou 1801insHGHG, qui 
ont été découverts chez des patients par notre laboratoire, ont été générés 
par mutagenèse dirigée. Ensuite, les protéines CHD7, de type sauvage 
(WT) ou variants, ont été surexprimées dans la lignée cellulaire HeLa. 
L'expression des protéines a été mise en évidence par Western Blot et par 
immunofluorescence. Nous avons ensuite utilisé la RT-PCR en temps réel 
pour étudier la fonctionnalité de CHD7 en évaluant les quantités de 
transcription de cinq gènes cibles. Nous avons observé que, lors de 
l'expression de WT-CHD7, les transcriptions des gènes cibles étaient 
diminuées. En revanche, lorsque nous avons exprimé l'un ou l'autre des 
quatre allèles variants de CHD7, la quantité de transcription de chaque 
gène cible était non affectée par rapport à la condition de contrôle 
transfectée par un vecteur vide (mock). Ce résultat suggère que la capacité 
normale de la protéine CHD7 à modifier le niveau de transcription de 
plusieurs gènes a été altérée par les trois substitutions d'acides aminés et 
par l’insertion de cinq acides aminés que nous avons étudiées. Par 
conséquent, ces variations peuvent être considérées comme résultant de 
mutations causales du SC. 
Pour valider ces résultats, nous avons appliqué notre test biologique 
à deux variants de la protéine CHD7, p.(Thr894Ala) ou T894A et 
p.(Ala2160Thr) ou A2160T, classés comme non pathogènes avec l’outil de 
prédiction GnomAD, et ayant ont été rapportés comme des 
polymorphismes dans la littérature. Ceci a été confirmé par notre test. Nous 
avons conclu que la réduction de la quantité de transcription des gènes 
cibles devait résulter de la fonctionnalité normale de la protéine CHD7 dans 
les cellules HeLa. 
Le sous-chapitre 5.2 présente un test fonctionnel de variants faux-
sens de CHD7 avec un niveau endogène d’expression en utilisant la 
technique CRISPR/Cas9. Afin de perturber la fonction du gène CHD7, un 
ARN guide ciblant l’exon 3 du gène CHD7 a été dessiné. Un exon précoce 
a été choisi afin d'augmenter les chances d'occurrence d’une perte totale 
de fonction (knock-out). Dans cette expérience, nous avons induit 
l'activation de la voie de réparation de l'ADN (NHEJ) non-homologue, afin 
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de créer des insertions ou délétions (indels), de manière à obtenir des 
mutations par décalage du cadre de lecture. Nous avons d’abord évalué le 
niveau d’expression de l’ARNm des gènes cibles de CHD7 dans les cellules 
HeLa : l’expression endogène de CHD7 n’intervient pas dans la régulation 
de la transcription de ces gènes. Par contre, dans la lignée SH-SY5Y, 
l’expression endogène de CHD7 contribue à inhiber la transcription de ces 
gènes cibles. Pour générer des variants faux-sens de CHD7, un plasmide 
codant pour Cas9 et les ARN guides ciblant les exons correspondant à 
chaque variant ont été choisis. Nous avons ensuite co-transfecté dans les 
cellules SH-SY5Y une matrice de recombinaison homologue, sous forme 
de plasmide double brin linéarisé. Nous avons ainsi obtenu un clone 
contenant la mutation homozygote L1302P-CHD7. Malheureusement, 
nous n’avons pas encore obtenu les deux autres variants (G1982W et 
R2319C). Dans les cellules SH-SY5Y éditées, la quantité d'ARN transcrite 
à partir de ces gènes était régulée positivement, par rapport à la lignée 
parentale. De plus, aucune différence statistiquement significative n'a été 
observée par rapport aux cellules où les deux allèles de CHD7 ont été 
invalidés. Ce résultat confirme que la capacité normale de la protéine CHD7 
à modifier le niveau de transcription de plusieurs gènes est altérée par le 
variant L1302P. 
Le chapitre 6 propose une discussion générale. Dans ce chapitre, 
nous analysons, interprétons et décrivons de manière critique l’importance 
de nos résultats. La mutation récemment découverte c.7234G>T ou 
p.(Glu2412Ter) crée un codon de terminaison de traduction prématurée, 
conduisant vraisemblablement à la suppression de l'ARNm via un 
processus de dégradation (NMD). Par conséquent, nous supposons que 
cette mutation représente un allèle nul, causant le SC par 
haploinsuffisance. Cette nouvelle mutation a été soumis à la base de 
données CHD7 (https://www.chd7.org). De plus, nous discutons des 
raisons pour lesquelles il est essentiel d'établir un diagnostic moléculaire 
chez les patients SC diagnostiqués cliniquement et fournissons des 
arguments en faveur de l'utilisation d'un panel ciblé de gènes impliqués 
dans le SC. 
Nous avons développé un test simple par deux approches. En utilisant 
l’approche par surexpression des variants faux-sens de CHD7 dans la 
lignée HeLa, nous avons observé que l’expression de CHD7 sauvage 
entraînait une diminution significative et reproductible des quantités de 
transcrits correspondant à tous les gènes cibles. Par contre, l’expression 
des quatre allèles variants de CHD7 n’avait aucun impact, ce qui suggère 
que ces variants ne sont pas fonctionnels. Par ailleurs, nous avons appliqué 
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notre test biologique dans des cellules de la lignée SH-SY5Y, pour 
lesquelles nous avons introduit une mutation faux-sens dans le génome en 
utilisant la technique CRISPR/Cas9. Lorsque ce variant était exprimé, les 
niveaux de transcription des cinq gènes cibles n’étaient pas 
significativement différents de ceux observés dans les cellules où les deux 
allèles de CHD7 avaient été invalidés. Par conséquent, les variants étudiés 
peuvent être répertoriés comme résultant de mutations causales du SC. 
Le chapitre 7 fournit des conclusions et discute des perspectives 
futures. Le chapitre 7.1 résume les résultats décrits dans cette thèse. Dans 
le chapitre 7.2, une réflexion est donnée sur ce que nous avons réalisé et 
sur les connaissances que nous avons ajoutées au domaine du diagnostic 
moléculaire du SC et de l’analyse fonctionnelle de la protéine CHD7. Les 
résultats sont discutés dans une perspective plus large par rapport aux 
développements récents concernant le test fonctionnel de CHD7 et le 
système de classification des mutations, afin de déterminer la pathogénicité 
des variants faux-sens de CHD7. 
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1.1 General Introduction 
CHARGE syndrome (CS; OMIM 214800) is a congenital disorder that 
arises during early fetal development and affects many areas of the body 
and organ systems. The term CHARGE itself is an abbreviation for clinical 
features commonly found in the patients: Coloboma, Heart defect, Atresia 
choanae, Retarded growth and development, Genital anomalies, and Ear 
anomalies (Pagon et al., 1981). 
CS is a rare disease in which the gene encoding CHD7, a chromatin 
remodeling protein, has been identified as a genetic cause in more than 
half of all CS cases (Vissers et al., 2004; Aramaki et al., 2006; Félix et al., 
2006, Vuorela et al., 2007). In addition, sporadic CS cases are linked to 
alterations in other genes (Lalani et al., 2004; Legendre et al., 2017). CHD7 
is one of the largest human genes. Therefore, as a large-scale mutation 
scanning strategy, targeted gene panel sequencing has become the most 
straightforward approach used in the genetics laboratories (van 
Ravenswaaij and Martin, 2017). To date, clinical diagnostic criteria are still 
used in the clinical setting to establish a clinical diagnosis of CS (Verloes, 
2005; Lalani et al., 2012; Hale et al., 2016). Affected individuals usually 
have various major signs or a combination of major and minor signs. 
1.2 Background 
1.2.1 Molecular Diagnosis of CHARGE Syndrome  
In developing countries with a lack of molecular diagnostic facilities, 
the diagnosis of CS is still based exclusively upon clinical features. 
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However, molecular testing is essential to establish a molecular diagnosis. 
It helps clinicians to identify and to confirm the definitive cause of multiple 
congenital anomalies in clinically-diagnosed CS patients. This knowledge 
allows them to provide these patients with the best care and also to give 
the information on recurrence risk. Finally, the ascertainment of the causal 
nature of CS-causing gene sequence variants creates many opportunities 
to perform new research on CS and its phenotypes. 
There are several approaches to establish a molecular diagnosis of 
clinical suspicion of CS. The first options are CHD7 Sanger sequencing and 
chromosomal microarray or multiplex ligation-dependent probe 
amplification (MLPA) (Bergman et al., 2008; Lalani et al., 2012; 
Ravenswaaij et al., 2015). Currently, sequencing of panels including genes 
involved in intellectual disability (ID) is widely used (Vissers et al., 2004; 
Legendre et al., 2017; Grozeva et al., 2015; Villate et al., 2018). 
Occasionally, CS-causing CHD7 alterations are accidentally identified in 
the sequencing of large panels of ID-related genes (Grozeva et al., 2015; 
Kahmoto et al., 2016; Villate et al., 2018) since ID has been detected in 
almost all CS cases (Zentner et al., 2010; Bergman et al., 2011; Hale et al., 
2016). However, the cost-benefit balance of these methods is questionable, 
especially in developing countries with limited funding. Genetic analysis 
requires cost-effective and time-consuming strategies. In this thesis, we 
therefore favor a strategy for molecular diagnosis of CS using targeted next-
generation sequencing (NGS) gene panel. 
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1.2.2 Challenges in the Development of Functional Assay of CHD7
 Haploinsufficiency for CHD7 is hypothesized as the pathogenic 
mechanism causing CS (Delehaye et al., 2007). The interpretation of 
truncating nonsense and frameshift mutations is often clear. CHD7 
missense and splice sites variants are rare in the population and account 
for only 8% and 11-12% of CS cases, respectively (Jongmans et al., 2006; 
Zentner et al., 2010; Jenssen et al., 2012; Stenson et al., 2017). These 
variants often remain of unknown clinical significance because of the lack 
of genetic information that may help to determine their pathogenicity. 
Moreover, interpreting the effect of a missense or other variant in the CHD7 
protein amino acid sequence remains a challenge. Due to the large size of 
the gene (188 kb, with 38 exons) and the protein (340 kDa), the functional 
assay of CHD7 is challenging to be conducted. 
Although computational tools have been refined to predict putative 
deleterious effects of missense and splice variants, functional analyses 
confirming the pathogenicity of the variants are lacking (Bergman et al., 
2012; Villate et al., 2018). A biochemical method has been described to test 
in vitro the function of the CHD7 protein (Bouazoune and Kingstone, 2012). 
Two years later, another approach has been developed in a zebrafish 
model. Chd7 knock-down was achieved by injection of splice-blocking 
morpholino (MO) against chd7 (chd7-Mo). Then, phenotype rescue was 
studied following mRNA injection of WT-CHD7 or mutated alleles 
(Balasubramanian et al., 2014). Moreover, DNA methylation signature was 
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recently proposed as a diagnosis tool for disorders involving proteins that 
attend the epigenetic machinery (Butcher et al., 2017; Aref-Eshghi et al., 
2018). However, the complexity of these systems is incompatible with 
routine use. Therefore, alternative ways of predicting the pathogenicity of 
these variants are urgently needed. In this thesis, we developed a 
functional test system using techniques commonly used in most cellular 
and molecular biology laboratories, to study the impact upon protein 
functionality of the missense variants and of other mutations leading to 
change in CHD7 amino acid sequence found in CS patients. 
1.3 Objectives  
The primary objective of this thesis was to develop a functional test for 
wild-type (WT) or variants of CHD7, a protein involved in CS. In our 
laboratory, in the case of patients for whom CS has been diagnosed, the 
exploration of CHD7 consists in the search for mutations by analysis of the 
38 exons and flanking intronic sequences. If no mutation is detected, 
Comparative Genomic Hybridization (CGH) array experiment is performed 
with the aim to discover other regions containing genes whose alterations 
may be responsible for this syndrome. Mutations in the CHD7 gene such 
as deletion, nonsense, and those with an impact on RNA splicing have 
predictable consequences: the development of CS. However, the impact of 
missense variants is unclear: are these substitutions mutations or 
polymorphisms? They may have an influence upon splicing of the gene 
(which is studied in the laboratory by the minigene technique) or upon the 
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function of the CHD7 protein? Furthermore, by using our system, we 
performed a functionality test for a CHD7 protein variant resulting from an 
intronic mutation, to determine the pathogenicity of this variant. We first 
developed a functional assay system based on overexpression of CHD7. 
We also developed our system to test the effect of CHD7 missense 
variants with an endogenous expression level in cell lines in which the 
nucleotide substitution has been introduced into the genome by genetic 
engineering with CRISPR/Cas9 technique. 
The secondary objective of this thesis was to investigate the molecular 
diagnosis by NGS targeted gene panel of an Indonesian patient who was 
previously diagnosed as typical CS. We determined the whole exonic and 
flanking intronic sequences of two genes involved in CS, CHD7 (OMIM 
608892) and EFTUD2 (OMIM 603892) (Vissers et al., 2004; Aramaki et al., 
2006; Legendre et al., 2017). HOXA1 (OMIM 142955) had been included in 
the panel since alterations of this gene are involved in overlapping features 
with CS (Tischfield et al., 2005). 
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2.1 Overview of CHARGE Syndrome 
2.1.1 CHARGE: From Association to Syndrome 
CHARGE syndrome (CS; OMIM 214800) is a rare genetic disease 
characterized by a combination of various congenital malformations. It was 
first recognized in 1979 independently by a pediatrician Dr. Bryan Hall and 
an ophthalmologist Dr. Helen Hittner and colleagues (Hall, 1979; Hittner et 
al., 1979). In 1979, Hall reported a cohort of 17 patients with various 
congenital malformations including congenital heart defect, ear 
abnormality, coloboma, hypogenitalism, and bilateral or unilateral posterior 
choanal atresia. They assumed that there was an association between 
these clinical manifestations and suggested a broader clinical spectrum 
since they also identified patients with the same association of this clinical 
manifestations but without choanal atresia (Hall, 1979). In the same year, 
Hittner and colleagues studied the association that appeared in ten patients 
with colobomatous microphthalmia, congenital heart defects, ear 
abnormalities (including hearing loss), facial paralysis, and intellectual 
disability (Hittner et al., 1979). Hereafter in 1981, Roberta Pagon and her 
colleagues realized that this ‘’association’’ marked by Hall and Hittner et al. 
formed a phenotype group specific of a disorder. They also included 21 
other patients with the same manifestations to support the association. 
Finally, to make this association better distinguishable and to create 
awareness in the clinical setting, Pagon coined the term CHARGE, as an 
acronym for Coloboma, Heart defects, Atresia of choanae, Retardation of 
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growth and/or development, Genital hypoplasia and Ear abnormalities 
and/or deafness (Pagon et al., 1981). 
Furthermore, CHARGE is now accepted as a genetic syndrome, 
differentiated by the fact that one common pathologic anomaly causes all 
manifestations. This distinction was brought through the work of a group of 
geneticists from the Netherlands who published a study linking CS to a 
microdeletion on the chromosome 8q12 and a balanced translocation 
between chromosomes 6 and 8 (Vissers et al., 2004). With this new 
information, the medical community then reconsidered the use of term 
CHARGE syndrome instead of association.  
The discovery of the CHD7 gene as the major cause of CS resulted in 
a renewal of interest to this syndrome. Until 2018, there are 268 publications 
indexed in www.pubmed.org using “CHARGE syndrome and CHD7” as a 
keyword (Figure 1). 
 
Figure 1. PubMed search on CHARGE syndrome or CHD7 
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2.1.2 Prevalence and Demographics 
The precise incidence of CS is likely difficult to define since there is a 
lack of strict diagnostic parameters and since the cost of molecular analyses 
of a wide population is prohibitive. However, the prevalence is estimated 
between 1 in 8,500-12,000 live births (Kallen et al., 1999; Lalani et al., 2012; 
Issekutz et al., 2005). Several studies of individuals with genetic CS have 
shown a slight female predominance (59%:41%). However, larger studies 
are needed to establish a definitive female-to-male ratio (Jongmans et al., 
2006; Aramaki et al., 2006). 
2.1.3 Inheritance Pattern 
The CS-causing mutations mostly occur de novo, which means that 
the mutation occurs sporadically and is not inherited from the parents. 
Approximately 97% of CS cases were de novo, and only 3% were inherited 
from a parent by autosomal dominant transmission (Vissers et al., 2004; 
Jongmans et al., 2006; Wincent et al., 2008; Lalani et al., 2006; Vuorela et 
al., 2008). Moreover, advanced paternal age has been reported as a 
contributing factor in de novo cases (Goldmann et al., 2016). 
In CS cases, autosomal dominant inheritance rarely occurs due to 
infertility problems and delayed or absent puberty. A case of autosomal 
dominant inheritance has been reported in a mildly affected mother (Lalani 
et al., 2006). In another case, this type of inheritance also occurred in a 
mother with a mild presentation attributable to somatic cell mosaicism. Both 
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of her sons were affected (Vissers et al., 2004). This condition shows that 
mosaicism is responsible for some CS cases. Besides, it has been 
described that a parent with one affected child has an empiric recurrence 
risk of 1-2% due to germline mosaicism (Rothlisberger and Kotzot, 2007; 
Lalani et al., 2012). 
2.1.4 Variability in CHARGE Clinical Features 
2.1.4.1 Coloboma and ophthalmic features 
Coloboma is a fissure or segmental defect resulting from a failure to 
close the eyeball during fetal development (Schneiderman and Balogun, 
2000). Coloboma and other ocular malformations have been reported in 80-
90% of CS patients (Lalani et al., 2012; Blake et al., 1998). The presence 
of these rare anomalies has previously been perceived as a pathognomonic 
sign of clinical CS. Recent studies with confirmed genetic CS patients have 
proven a strong association between coloboma and CS (Jongmans et al., 
2006; Aramaki et al., 2006; Wincent et al., 2008; Lalani et al., 2006). This 
coloboma may occur bilaterally or unilaterally, affecting the eyelid, iris, 
retina, choroid, optic disc or macula. One typical coloboma is chorioretinal 
that predisposes to retinal detachment and has an impact on visual 
impairment (McMain et al., 2008). The variation in visual capability depends 
on the site and nature of the malformation, ranging from absent to near-
normal vision (Nishina et al., 2012).  
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In addition, anterior segment anomalies can also be involved, 
including microphthalmia, microcornea, and cataracts. Other ophthalmic 
features include refractive errors, strabismus, and ptosis which had been 
reported but less frequently (Onwochei et al., 2000). Microphthalmia is 
commonly identified in clinical CS as an isolated condition or in conjunction 
with coloboma (Blake and Prasad, 2006; Lalani et al., 2012; Sanlaville and 
Verloes, 2007). Therefore, suspected CS patients should be evaluated by 
an ophthalmologist. 
2.1.4.2 Cardiac malformations 
Cardiac defects have also been reported in the majority (75-85%) of 
clinical CS patients (Jongmans et al., 2006). Previous investigations, 
performed before CHD7 identification, showed that conotruncal heart 
anomalies such as Tetralogy of Fallot (ToF), aortic arch interruption, double 
outlet right ventricle (DORV), arch vessel anomalies, and atrioventricular 
septal defects (AVSD) were commonly detected (Wyse et al., 1993; 
Corsten-Jansen et al., 2013). Recent studies, since the discovery of the 
CHD7 gene, have identified broader phenotype with every type of cardiac 
defect (except heterotaxy and cardiomyopathy). However, AVSDs and 
conotruncal are remaining the majority (Corsten-Jansen and Scambler, 
2017).  
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2.1.4.3 Choanal atresia and other upper airway abnormalities 
Choanal atresia is a narrowing or obstruction between the nasal cavity 
and the nasopharynx. This obstruction may be bony or membranous and 
occurs in one or both nasal cavities (Blake and Prasad, 2006). This 
abnormality has been previously identified as a reliable criterion for clinical 
CS, with an incidence of 50-60% (Blake and Prasad, 2006; Lalani et al., 
2012). At birth, this condition results in breathing difficulty due to 
obstruction, and this can be detected when a nasogastric tube cannot pass 
through the nose and into the pharynx. Moreover, children with bilateral 
choanal atresia require endotracheal intubation or management with an oral 
airway until a surgical correction can be performed. 
Airway obstruction below the choanae is also present in 70% of CS 
patients: laryngomalacia (40%), tracheomalacia (20%), and subglottic 
stenosis (10%) (Morgan et al., 1993). Moreover, cleft lip and palate are 
present in 15-20% of CS cases, and tracheoesophageal fistula (TOF) is 
also reported in the same percentage (Houben and Curry, 2008). 
2.1.4.4 Growth and developmental retardation 
Children with CS usually have a normal birth weight and length. They 
are appropriate for gestational age (AGA); however, in the majority, after 
birth, they then fail to achieve optimal growth (Husu et al., 2013; Blake and 
Prasad, 2006; Lalani et al., 2012). The incidence of growth retardation in 
CS patients is estimated at 70-80% (Lalani et al., 2012). A study has 
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evaluated the growth hormone secretion by provocation testing in 25 CS 
children. The result revealed that ninety percent had a normal level of 
growth hormone and ten percent of children revealed low peak hormone 
level which was significantly shorter (height ≤2.5 standard deviation score) 
(Pinto et al., 2005). Until now, there are no published data on recombinant 
human growth hormone therapy in CS children and short stature. 
Cognitive ability is also affected in CS children. A study to access 
cognitive ability has been performed using the Adaptive Behavior 
Evaluation Scale (ABES): 50% of subjects had scores <70 (reference 
means 100, with standard deviation 15). CS children who walked earlier 
had fewer health problems, better hearing and vision, and higher ABES 
scores (Salem‐Hartshorne and Jacob, 2005). Moreover, communication 
and language abilities are also often impaired. It has been described that 
only half of 123 CS children more than 4-year-old used verbal or sign 
language in complete sentences (Hartshorne, 2012). 
2.1.4.5 Genitourinary problems 
Genital hypoplasia is a common and well-known phenotype of CS 
(Pinto et al., 2005; Wheeler et al., 2000; Asakura et al., 2008). In most 
cases, this anomaly is easily recognized in boys 
(micropenis/cryptorchidism), but females with reduced clitoral size had also 
been reported (Jongmans et al., 2006). In addition, ultrasound examination 
of females with genetic CS sometimes reveals a hypoplastic uterus 
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(Jongmans et al., 2008). In male patients with clinical CS, the manifestation 
of micropenis or cryptorchidism is approximately 50-60% (Lalani et al., 
2012). Genital hypoplasia is suggested to be secondary to 
hypogonadotropic hypogonadism (Wheeler et al., 2000), which during 
adolescence may result in pubertal delay or arrest in pubertal development. 
As a consequence, the testes or ovaries do not function properly due to an 
insufficient level of both luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) (Dauber et al., 2010). 
Moreover, renal anomalies such as renal dysgenesis, hydronephrosis, 
solitary kidney, and duplex kidneys have been reported and occurred in 
approximately 25-40% of CS patients (Blake et al., 1998; Ragan et al., 
1999). 
2.1.4.6 Ear and hearing problems 
The main inner ear abnormality in CS patients is the absence of the 
lateral semicircular canals. Besides, dysplasia of both the vestibular and 
semicircular canals, as well as the cochlear parts (Mondini malformation) 
can also occur, resulting in varying degrees of sensorineural hearing loss 
(Holcomb et al., 2013). These malformations can be detected using 
computed tomographic (CT) scan or magnetic resonance imaging (MRI) of 
the temporal bone. The semicircular canals abnormalities are highly 
suggestive of genetic CS patients. In different studies, 83 out of 85 
genetically confirmed patients had external ear malformations (98%), and 
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56 of 72 patients (78%) had a variable degree of hearing loss (Jongmans 
et al., 2006; Wincent et al., 2008; Lalani et al., 2006).  
External ear abnormalities often involve an abnormal shape and 
position of the pinnae, such as a wide helix, preauricular tag, reduced 
vertical height of the pinna and cup-shaped ears (Sanlaville and Verloes, 
2007). The ears can protrude from the head and be asymmetric (Lalani et 
al., 2012). 
2.1.4.7 Central nervous system and cranial nerve dysfunctions 
Central nervous system (CNS) abnormalities have been reported 
including arrhinencephaly, corpus callosum agenesis and posterior fossa 
anomalies (Tellier et al., 1998). Moreover, abnormalities in CNS can vary, 
resulting from an alteration of one or more cranial nerves. The alteration of 
cranial nerve I, resulting in anosmia due to the absence or hypoplasia of 
the olfactory bulbs. An absent sense of smell is present in almost all CS 
patients. Abnormality of cranial nerve VII results in facial palsy (reported in 
50% of CS cases) and alterations of cranial nerves IX, X, and XI may result 
in swallowing and aspiration problems (reported in 70-90% of CS cases), 
and/or gastroesophageal reflux. 
Feeding and swallowing difficulties are present in almost all CS cases. 
Almost 90% of CS children need tube feeding at some time (Dobblesteyn 
et al., 2005). Deformity of cranial nerve VIII may cause hearing loss (Blake 
and Prasad, 2006; Lalani et al., 2012). Among CS patients, 78% had some 
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form of hearing loss. However, that hearing loss may also result from a 
variety of inner ear, including deformity of the cochlea, aplasia of ossicles, 
or absence of the oval window among others (Lalani et al., 2012).  
2.1.4.8 Behavioral phenotype and sleep-related issues 
Several studies have been published concerning the behavioral 
phenotype of CS patients. Attention-deficit hyperactivity disorders (ADHD), 
obsessive-compulsive, aggressive, goal-directed persistent, self-abusive, 
repetitive motor behaviors have been reported in many CS patients 
(Bernstein and Denno, 2005; Hartshorne et al., 2005, Smith et al., 2005, 
Hartshorne and Cypher, 2004). 
Sleep cycles in CS children are often disturbed, including problems 
with initiating/maintaining sleep, breathing, arousal, transition, somnolence, 
and hyperhidrosis (Hartshorne and Cypher, 2004). Obstructive sleep apnea 
was found to affect 65% of CS patients (Trider et al., 2012). 
2.1.4.9 Other potential endocrine problems 
It has been reported that one out of nine CS patients had 
hypothyroidism. It was not possible to ascertain whether it was due to 
hypothalamic-pituitary dysfunction (Asakura et al., 2008). Moreover, 
secondary hypoadrenalism has been reported in one CS patient (James et 
al., 2003) but was not observed in larger cohorts of subjects (Asakura et al., 
2008; Khadilkar et al., 1999). However, routine analysis of adrenal function 
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in CS patients has not yet been recommended since there is a lack of 
evidence. 
2.1.4.10 Infections and immune deficiency 
Immune deficiency related to dysplasia of the thymus has been 
reported in CS patients (Corsten-Jansen et al., 2013). Recent studies have 
shown that immune dysfunction is an often-missed complication of CS. A 
study reported that approximately 60% of CS patients had immune 
compromise presenting as lymphopenia (Jyonouchi et al., 2009). Other 
studies have demonstrated similar results in CS patients, displaying T-cell 
lymphopenia, impaired T-cell function, low immunoglobulins, and the 
severe T-cell deficiency (Theodoropoulos, 2003). Even though the immune 
compromise is not considered as a criterion of clinical CS, clinicians should 
be aware of the high risk of cell-mediated and humoral immunity defects in 
CS patients. CS patients with severe compromise problem should receive 
irradiated blood to avoid graft versus host reaction and should not receive 
live vaccines (Jyonouchi et al., 2009). 
2.1.5 Clinical Criteria Diagnosis of CHARGE Syndrome 
Clinical diagnosis of CS was firstly established by the observation of 
an association of choanal atresia with anomalies of the heart, eyes, and 
gastrointestinal tract (Hall, 1979). Two years later, Pagon et al. proposed 
the term CHARGE to describe six cardinal features in CS. The patient may 
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have CS if displaying at least four anomalies represented in this term (Table 
1) (Pagon et al., 1981). 
Table 1. Pagon’s Diagnostic Criteria (Pagon et al., 1981) 
Clinical Features 
Coloboma 
Heart Anomalies 
Atresia choanae 
Postnatal growth deficiency 
Retarded development and/or CNS (central nervous system) anomalies 
Genital hypoplasia 
Ear Abnormalities  
Diagnosis of CHARGE if patient has 4 out of 7 criteria 
Must have coloboma and/or choanal atresia 
In 1998 Blake et al. proposed further refinements of the original 
diagnostic criteria (Table 2) (Blake et al., 1998). Although clinical diagnostic 
criteria have undergone some revision, identification of CS has remained 
largely subjective, and the probability of finding a mutation depends on the 
accuracy of the initial clinical diagnosis (Basson and van Ravenswaaij, 
2015).  
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Table 2. Blake’s Diagnosis Criteria (Blake et al., 1998) 
Major Minor Occasional 
• Coloboma of iris, 
retina, choroid, disc; 
microphthalmia  
• Genital hypoplasia 
• Development delay 
• CV (cardiovascular) 
malformation 
• Growth deficiency 
• Orofacial cleft  
• TEF (tracheoesophageal 
fistula) 
• Characteristic face 
• Thymic/parathyroid 
hypoplasia 
• Renal anomalies 
• Hand anomalies 
• General appearance 
• Abdominal defect 
• Spine anomalies 
• Choanal atresia 
• Characteristic ear 
abnormalities 
• Cranial nerve 
dysfunction 
Diagnosis of CHARGE if patient has: 
- All 4 major criteria 
- 3 major and 3 minor criteria 
- 2 major criteria and several minor criteria 
 
2.2 Cloning of CHD7 gene and Mutations in the CHD7 Gene 
To identify the molecular abnormalities in patients with CS, Vissers et 
al. have used array CGH (Comparative Genomic Hybridization) technique 
to identify microdeletions or duplications underlying CS. Their results 
evidenced a patient with a microdeletion occurring de novo in the 8q1.2 
band. This microdeletion was subsequently confirmed by FISH 
(Fluorescent in Situ Hybridization) technique. Other patients had no 
deletion in this region, so they sequenced the nine genes located in this 
region. In these patients, they found the presence of heterozygous point 
mutations in the CHD7 gene. The majority of the mutations were nonsense, 
as well as intron-exon junction mutations with a minority of missense 
mutations, all appearing de novo. Finally, they concluded that the CHD7 
gene is responsible for most cases of CS (Vissers et al., 2004). 
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CHD7 gene (OMIM 608892) is located in chromosome 8 (8q12.2) 
starting at 61.59 Mb from the p-arm telomere. The gene has a genomic size 
of 188 Kb and consists in 38 exons, of which the first is non-coding (Blake 
and Prasad, 2006; Sanlaville and Verloes, 2007; Lalani et al., 2012) (Figure 
2).  
 
Figure 2. Location of the CHD7 gene and the mutations identified in CS 
(Adapted from Balasubramanian et al., 2014; https://www.chd7.org). 
According to subsequent studies, mutations in CHD7 gene have been 
found in about 2/3 of CS cases (Vissers et al., 2004; Aramaki et al., 2006; 
Félix et al., 2006, Vuorela et al., 2007). Therefore, even today, 10-20% of 
clinical CS patients are not carriers of a mutation in this gene. CHD7 
mutations have also been identified in individuals with diseases that show 
clinical sign overlapping with CS, including Kallmann syndrome, Omenn-
like syndrome, and 22q11.2 deletion syndrome (Ogata et al., 2006; 
Gennery et al., 2008; Jongmans et al., 2009; Jyonouchi et al., 2009). 
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In the CHD7 mutation database (https://www.chd7.org, last accessed 
May 03, 2019), 554 pathogenic CHD7 mutations are listed in CS. The 
majority of the pathogenic CHD7 variants is intragenic mutations. Nonsense 
and frameshift mutation have found in over 75% of the CS patients. 
Missense and splice site mutations occur in 19%, while large 
deletions/duplications, translocation, and small in-frame deletion rarely 
occur (Figure 3) (Jongmans et al., 2006; Zentner et al., 2010; Jenssen et 
al., 2012). 
 
Figure 3. Distribution of pathogenic mutation types in the CHD7 gene 
(Adapted from https://www.chd7.org). 
Most of the CHD7 mutations are nonsense or frameshift. They are 
predicted to elicit the loss of function, and haploinsufficiency is 
hypothesized to be the pathogenic defect (Bosman et al., 2005; Hurd et al., 
44%
34%
8%
11%
2%<1%<1%
Nonsense
Frameshift
Missense
Splite sites
Large deletion and duplication
Translocation
Small in frame deletion
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2007). Invalidation studies of CHD7 gene in mouse were made: when the 
two alleles are deleted, embryonic mortality was observed, while the 
deletion of a single allele entailed the ‘CHARGE-like’ symptoms in mouse 
(Bosman et al., 2005; Hurd et al., 2007; Bergman et al., 2010). There is a 
statement that both haploinsufficiency and complete loss of CHD7 
expression leads to increased DNA methylation of the rRNA promoter, 
resulting in decreased rRNA expression (Zentner et al., 2010).  
Even though different types of mutations have been observed in CS 
patients, it remains unclear whether the type of mutation affects phenotype, 
but future studies may reveal significance (Lalani et al., 2012; Jongmans et 
al., 2006). It has been reported that monozygotic twins with an identical 
nonsense mutation in exon 16 of the CHD7 gene exhibit different 
phenotypes (Lalani et al., 2006). 
2.3 Updated Diagnosis Criteria for CHARGE Syndrome 
After the discovery of CHD7 mutations as the cause of CS, many 
groups have proposed some revision and updated criteria for diagnosing 
CS. In 2005, Verloes introduced renewal clinical criteria: coloboma and 
choanal atresia were still used as major features, in addition semicircular 
canal defect was added as a third major item, and gave a formal definition 
for partial and atypical CHARGE syndromes (Verloes, 2005). Furthermore, 
to establish a clinical diagnosis of CS, two sets of Blake’s and Verloes’ 
diagnostic criteria are still used in a clinical setting with some update and 
24 
 
revision by Blake in 2006, Sanlaville and Verloes in 2007, and by 
consortium in 2012 (Table 3) (Blake et al., 2006; Sanlaville and Verloes, 
2007; Lalani et al., 2012).  
Table 3. Diagnosis Criteria for CS defined by Verloes (2005) updated by 
Blake (2006), Sanlaville and Verloes (2007), and by Hale (2016) 
Criteria Verloes Hale 
Major • Coloboma 
• Choanal atresia and/or cleft 
lip or palate 
• Semicircular canals 
agenesis/hypoplasia 
• Arhinencephaly and/or 
anosmia 
• Coloboma 
• Choanal atresia or cleft 
palate 
• Abnormal external, middle 
or inner ears, including 
hypoplastic semicircular 
canals 
• Pathogenic CHD7 variant 
Minor • Cranial nerves VII to XII palsy 
• Hypothalamo-hypophyseal 
dysfunction 
• External- or middle-ear 
anomalies 
• Heart defects or esophageal 
anomalies 
• Intellectual disability 
• Cranial nerve dysfunction 
• Dysphagia/feeding 
difficulties 
• Structural brain anomalies 
• Developmental 
delay/ID/Autism 
• Hypotalamo-hypophyseal 
dysfunction (gonadotropin 
or growth hormone 
deficiency) and genital 
anomalies 
• Heart or esophagus 
malformation 
• Renal anomalies 
skeletal/limb anomalies 
Inclusion 
rule 
• Typical CHARGE: 
    3 major or 2 major + 2 minor 
• Partial CHARGE: 
    2 major + 1 minor 
• Atypical CHARGE: 
    2 major + 0 minor or 
    1 major + 3 minor 
    2 major + any number of 
minor 
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Recently, Hale et al. proposed to include the pathogenic CHD7 variant to 
major criteria and skeletal/limb anomalies to the minor criteria (Table 3) 
(Hale et al., 2016). 
2.4  Genetic Causes of CHARGE Syndrome 
The genetic cause of CS remains unclear in 5-10% of typical CHARGE 
patients and 40-60% of patients suspected of CS (Bergman et al., 2011; 
Jongmans et al., 2006; Lalani et al., 2006). Non-detectable rearrangements 
in CHD7 gene (e.g., deep intronic mutations that affect splicing, intra-genic 
rearrangements or mutations in regulatory regions), and whole gene or 
exon deletions/duplications may explain why CS occurred in some of these 
patients. Another possibility is that there are other genes responsible for 
CS. One of the genes that have been proven involved in the pathogenesis 
of CS is SEMA3E gene (OMIM 608166) (Ufartes et al., 2018). This gene 
was found to be mutated in one CS patient and disrupted in another patient 
with a de novo chromosomal translocation between chromosomes 2 and 7. 
Moreover, there was no CHD7 mutation detected in these patients (Lalani 
et al., 2004). Thus far, no additional SEMA3E mutation has been reported 
in CS patients. Furthermore, EFTUD2 gene (OMIM 603892) has been 
recommended to be analyzed in individuals with atypical CS who do not 
carry CHD7 mutation (Luquetti et al., 2013). In 2017 Legendre et al. 
detected rare CS cases that were linked to alterations in EFTUD2 gene 
(Legendre et al., 2017). Other candidate genes have also been studied 
without revealing any pathogenic mutations, e.g. PITX2 (OMIM 601542) 
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and PAX2 (OMIM 167409) in 29 and 34 patients with CS, respectively 
(Martin et al., 2002; Tellier et al., 2000). 
Phenocopies due to chromosomal imbalances have been reported in 
patients with a CHARGE-like phenotype. Unfortunately, most cases were 
published before 2004 so that CHD7 analysis was not performed. These 
chromosomal aberrations are duplication in 1(q25q32) and deletion in 
4(q31qter) (Dev et al., 1985; Shroff et al., 1981).  
In contrast to the unique chromosomal cases, a recurrent clinical 
overlap has been reported for 22q11.2 deletion syndrome and CS (Randall 
et al., 2009; Bergman et al., 2011; Gennery et al., 2008; Inoue et al., 2010; 
Sanka et al., 2007; Writzl et al., 2007; Devriendt et al., 1998; Emanuel et 
al., 1992). The overlapping clinical features include cleft palate, cardiac 
malformations, ear abnormalities, hearing loss, growth deficiency, 
developmental delay, renal abnormalities, hypocalcaemia and immune 
deficiency (Randall et al., 2009; Inou et al., 2010; Sanka et al., 2007; Writzl 
et al., 2007; Devriendt et al., 1998; Lonlay-Debeney et al., 1997; Jyonouchi 
et al., 2009). 
CHD7 mutations are more often, but not exclusively, associated with 
coloboma, choanal atresia, facial nerve palsy, trachea-esophageal fistula, 
and micropenis compared to 22q11.2 deletions (Jyonouchi et al., 2009). 
Hypoplastic semicircular canals are suggestive for CS, as they are present 
in almost all CS patients (Bergman et al., 2011; Verloes, 2005; Admiraal et 
al., 1998; Amiel et al., 2001). However, semicircular canal abnormalities 
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cannot exclude 22q11.2 deletion syndrome since this feature has also been 
described in patients with a 22q11 deletion, albeit very rarely (Bergman et 
al., 2011; Hopsu et al., 2007). Defects of the lateral semicircular canals 
were also noted in a mouse model for 22q11.2 deletion syndrome, the Tbx1 
(+/-) mouse (Randall et al., 2009). 
In summary, CHD7 is the major causative gene in CS. If sequence 
analysis does not reveal a CHD7 mutation, genome-wide array studies 
should be performed in patients suspected of CS. 
2.5 CHD7 Protein and Its Function 
The chromodomain helicase DNA-binding (CHD) proteins are involved 
in ATP-dependent chromatin remodeling. It is a group of nuclear proteins 
with nine members in vertebrates (Micucci et al., 2015). Generally, CHD 
proteins are classified into three subfamilies based on their constituent 
domains: subfamily I (CHD1 and CHD2), subfamily II (CHD3, CHD4, and 
CHD5) and subfamily III (CHD6, CHD7, CHD8, and CHD9) (Hall and 
Georgel, 2007; Marfella and Imbalzano, 2007). 
CHD7 protein, consisting in 2997 amino acids with a molecular weight 
of 340 kDa, is localized in both nucleoplasm and nucleolus (Zentner et al., 
2010; Kita et al., 2012). The CHD7 protein is characterized by two 
chromodomains in N-terminal, a SNF2/SWI domain, a helicase domain, a 
SANT-like domain (Switching-defective protein 3, Adaptor 2 Nuclear 
receptor corepressor, Transcription factor IIIB) and two paired BRK 
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(Brahma and Kismet) domains in C-terminal (Figure 4) (Hall and Georgel, 
2007; Marfella and Imbalzano, 2007). Chromodomains are involved in the 
recognition of lysine-methylated histone tails and DNA (and RNA) targets. 
This domain plays a role by mediating chromatin interactions in a variety of 
different protein context. SWI/SNF2 domains are characterized by DNA-
dependent ATPase activity, involved in regulating the structure of 
chromatin. Helicase domains are critical in DNA strand separation during 
replication, repair, recombination, and transcription. It has been proposed 
that the SANT domain plays a crucial role in the interaction between the 
connection ends of the histones and enzymatic catalysis involved in 
nucleosome remodeling. The function of BRK domains is unknown, but they 
are usually found in association with chromodomains (Dirscherl and Krebs, 
2004).  
 
Figure 4. Schematic representation of the domain organization of the CHD7 
protein (Adapted from http://www.ebi.ac.uk/interpro/protein/Q9P2D1). 
The CHD7 protein is highly conserved in other species and several 
orthologs have been found in xenopus, zebrafish, mouse, and chicken 
(Aramaki et al., 2007; Bajpai et al., 2010; Bosman et al., 2005). Several 
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studies had been conducted in homozygous Chd7 mutant mice; the results 
showed that the mice do not survive beyond an early embryonic stage (Hurd 
et al., 2007; Randal et al., 2009). This showed that CHD7 function is critical. 
Furthermore, recent studies have suggested that CHD7 plays a role in 
controlling gene expression program by ATP-dependent chromatin 
remodeling (Schnetz et al., 2009; Layman et al., 2010; Bajpai et al., 2010). 
These studies have discussed in vitro experiment insights into CHD7 
function and its mechanism. In 2009, Schnetz et al. mapped the distribution 
of CHD7 protein using chromatin immunoprecipitation coupled with 
microarray (ChIP-chip) approach. They used human colorectal carcinoma 
cells, human neuroblastoma cells, and mouse embryonic stem (ES) cells 
before and after differentiation into neural precursor cells. They described 
that CHD7 localizes to discrete locations along chromatin that are specific 
to each cell type, and that the cell-specific binding of CHD7 was shown to 
match the binding sites of histone H3 methylated on lysine 4 (H3K4me). 
One year later, Zentner et al. using ChIP-chip or massively parallel DNA 
sequencing (ChIP-seq) analyses demonstrated that CHD7 specifically 
associated with hypomethylated, active rDNA. They showed that siRNA-
mediated depletion of CHD7 results in hypermethylation of the rDNA 
promoter and in a concomitant reduction of 45S pre-rRNA levels. Moreover, 
Kita et al. confirmed that overexpression of full-length protein CHD7L, as 
well as of CHD7S, a short isoform of CHD7 that is generated by alternative 
splicing of exon 6, resulted in an increase in 45S pre-rRNA level (Kita et al., 
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2012). These results indicate that CHD7 protein functions as a 
transcriptional regulator in the nucleoplasm and that the protein is 
constitutively localized to the nucleolus, the site of rRNA transcription 
(Schnetz et al., 2009; Zentner et al., 2010). 
Several studies described that CHD7 cooperates with other 
transcription factors such as Oct3/4, Sox2, Nanog, and p300 for the 
development of neural stem cells in mouse ES cells (Engelen et al., 2011; 
Schnetz et al., 2010). Moreover, interactions between Chd7 and Chd8 have 
been demonstrated using a yeast two-hybrid library screen: Chd8 was 
found as a binding partner of Chd7 and disruption of this interaction could 
be involved in a pathomechanism of CS (Batsukh et al., 2010). Although 
CHD7 has been involved in transcriptional activation or suppression of 
tissue-specific genes throughout differentiation, it has remained unclear 
whether changes in such gene expression are sufficient to give rise to 
CHARGE syndrome (Layman et al., 2009; Bajpai et al., 2010; Hurd et al. 
2010). 
Studies on the function of CHD7 have suggested a role in controlling 
the programming of gene expression by ATP-dependent chromatin 
remodeling in embryonic stem cells and other cell types (Schnetz et al., 
2009; Bajpai et al., 2010; Basson and van Ravenswaaij, 2015). CHD7 
intervenes at two levels: first, by binding to histone H3 methylated at lysine 
4 in the promoter regions of genes, depending on the developmental stage 
and cell type, and it would then play a role of transcription activator (Schnetz 
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et al., 2009). Second, it is involved in the upregulation of rRNA synthesis in 
the nucleolus in a tissue-specific manner (Zentner et al., 2010). An 
explanation for CHD7 influence upon rRNA concentrations is as follows: 
CHD7 is assumed to have an activity of chromatin remodeling because of 
its SNF2/helicase type domains. It was studied in vitro by Bouazoune and 
Kingston in 2012. Thus, a likely scenario is that CHD7 initiates or maintains 
the opening of chromatin regions containing repeated sequences that are 
transcribed into rRNA, to promote the association of factors involved in the 
transcription of the rDNA. Moreover, the latest studies have shown that 
overexpression of the wild-type CHD7 protein causes an increase in the 
expression of the 45S rRNA precursor (Zentner et al., 2010; Kita et al., 
2012). 
Another study in Xenopus embryos has shown that CHD7 cooperates 
with transcription factors Sox9, Twist, and Slug in the migration of neural 
crest cells. Moreover, CHD7 and PBAF (polybromo- and BRG1-associated 
factor containing complex) bind together to the neural crest cell-specific 
regulatory elements of TWIST1 (OMIM 601622) and SOX9 (608160). This 
cooperation promotes neural crest gene expression and cell migration 
(Bajpai et al., 2010). 
Other studies in a mouse model described that Chd7 is required for 
the differentiation of neural stem cells in the basal olfactory epithelium 
(Layman et al., 2009). Chd7 is also necessary for the proliferation of 
neuroblasts and the expression of several genes that are involved in inner 
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ear morphogenesis such as Ngn1, Itx2, and Fgf10 (Hurd et al., 2010). 
Another study has suggested that Chd7 affects GnRH (Gonadotropin-
releasing hormone) neurogenesis and signaling by influencing the 
transcriptional regulation of target genes involved in the BMP and FGF 
pathways (Layman et al., 2011). Furthermore, several studies have shown 
that Chd7 cooperates with Sox2 in activating the expression of Sonic 
Hedgehog (Gli2, Gli3, Mycn, and Tulp3) and Notch pathway (Jag1, Rbpj, 
Hes5) (Engelen et al., 2011; Puc and Rosenfeld, 2011). Moreover, CHD7 
protein regulates the expression of genes during embryonic development 
in a tissue-specific and stage-specific manner (Layman et al., 2010) (Figure 
5). Together, these studies allow the emergence of a global pattern 
concerning the function of CHD7 and its interaction with other proteins.  
 
Figure 5. The function of CHD7. According to recent studies, CHD7 protein 
has been shown to have a tissue-specific and stage-dependent function in 
enhancer-mediated transcription (Layman et al., 2010). 
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2.6 Pathomechanism of CHARGE Syndrome 
The reason for the phenotypic variation in CS remains unknown. A 
hypothesis is that the CHD7 gene influence over a broad variety of other 
genes may explain the variability of clinical features in CS (Basson and van 
Ravenswaaij, 2015). CHD7 have an effect on several signaling pathways in 
control development. The developmental alterations involve the midline 
structures of the body and affect the craniofacial structures. Despite the fact 
that the roles of CHD7 gene in the development of the eye, olfactory 
epithelium, inner ear, and vascular tissues have been demonstrated, the 
variability of expression of this gene is not yet fully understood (Sanlaville 
and Verloes, 2007). In a fetus harboring a CHD7 mutation, the problems 
begin with arrest in embryologic differentiation at the first trimester (between 
the third- and ninth-week post conception) (Blake and Prasad, 2006; 
Verloes, 2005). Several malformations including eye, ear, and cranial nerve 
occur between days 33-34 of gestation. Moreover, conotruncal heart 
malformations and abnormalities in cephalic neural crest cell migration 
occur between the fourth and the fifth weeks post-conception. Failure of the 
primitive bucconasal membrane to rupture between the fifth- and sixth-
weeks post conception results in choanal atresia (Blake and Prasad, 2006).  
The pathomechanisms underlying CS are briefly suggested: (1) 
disruption of the neural crest cells development, (2) alteration of the 
interaction between neural crest cells and mesoderm, and (3) alteration of 
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the interaction between mesenchymal and epithelial cells (Williams, 2005; 
Moccia et al., 2018). 
 
Figure 6. Developmental and disease-associated pathways regulated by 
CHD7. Studied interactions are in black and presumed hypothetical 
associations are in blue (Basson and van Ravenswaaij, 2015). 
CHD7 is a key regulator of some developmental transcription factors 
(TFs) genes and control the activity of several signaling pathways (Figure 
6). CHD7 controls BMP4 expression or cooperate with SMAD1 to control 
growth factor BMP pathway genes involved in heart development (Liu et al., 
2014; Jiang et al., 2012). CHD7 protein plays a role as a positive regulator 
of transcription factor Otx2 expression during ear development, a decrease 
of expression of this gene resulting in downregulation of growth factor Fgf8 
expression and cerebellar vermis hypoplasia during early cerebellar 
development (Hurd et al., 2010; Yu et al., 2013). 
CHD7 inhibits retinoic acid signaling in neuronal progenitor cells, so 
the loss of function of CHD7 leads to hyperactive retinoic acid signaling 
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resulting in inner ear defects (Micuci et al., 2010). Moreover, CHD7 interacts 
with transcription factor SOX2 in neural stem cells. The SOX2 gene controls 
some genes that regulate notch and hedgehog signaling pathways and cell 
proliferation pathways such as Jag1, Gli3, and Mycn (Engelen et al., 2011). 
A study reported that de novo mutations in SOX2 gene results in some CS 
phenotypes including eye, external ear abnormalities or deafness, 
esophageal atresia, and hypogonadotropic hypogonadism (Numakura et 
al., 2010). 
A recent study described that transcriptionally inactive variant of p53 
during mouse development resulted in typical CHARGE phenotypes (Van 
Nostrand et al., 2014). Moreover, they demonstrated evidence that CHD7 
can repress p53 gene expression, otherwise in Chd7-null mouse neural 
crest cells and fibroblast from CS patients showed increased p53 signaling. 
Accordingly, haploinsufficiency of CHD7 leads to defects in ribosome 
biogenesis via p53 pathway hyperactivation and affects rDNA transcription 
(Van Nostrand et al., 2014; Zentner et al., 2010). CHD7 also regulates 
SEMA3E expression, which may be involved in neural crest cell migration 
and olfactory development (Schutz et al., 2014). 
CHARGE and 22q11deletion syndromes have been known to show 
clinical overlap, presumably due to the interaction between CHD7 and 
TBX1 that involved in a molecular pathway or both CHD7 and TBX1 
controlling the same genes in affected organs (Randal et al., 2009). 
CHARGE and Kabuki syndromes also show significant clinical overlap. 
36 
 
Mutation of KMT2D or KDM6A gene has been associated with Kabuki 
syndrome (KS) (Wessels et al., 2002). These genes encode proteins that 
play a role as histone methyltransferase and as histone demethylase, 
respectively. KS shows significant phenotype overlapping with CHARGE 
because both KS-associated genes might regulate CHD7 recruitment to 
histone H3 methylated at lysine 4 (H3K4me1)-marked enhancer regions. In 
mammalian cells, H3K4me1 is an epigenetic mark that plays a role at 
enhancers to regulate the gene expression (Local et al., 2018). Therefore, 
CHD7, KMT2D, and KDM6A taken together are assumed to control the 
same target genes (Schulz et al., 2014). 
2.7  Novel Classification System to Predict the Pathogenicity of CHD7 
Missense Variants and Prospective 
Although the missense mutations in the CHD7 gene occurs only in 8% 
of all CS cases, their challenging interpretation results in difficulties for 
genetic counseling. Furthermore, Bergman et al. have developed a novel 
algorithm to predict the pathogenicity of CHD7 missense variants. They 
combined the results of two computational algorithms (PolyPhen-2 and 
Align-GVGD), prediction of the structural model of CHD7 protein and 
phenotypic data (Table 4). 
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Table 4. A novel algorithm to predict the pathogenicity of CHD7 missense 
variants (Bergman et al., 2012) 
Computational algorithms (summed score between 0 and +2) 
Polyphen-2: benign = 0, possibly damaging = +0.5 and probably 
damaging = +1 
Align-GVGD: C0 = 0, C15/C25/C35 = +0.5 and C45/C55/C65 = +1 
Structural model (summed score between -1 and +1) 
Minor effect = -1, undetermined effect = 0, detrimental effect or located 
close to the ATP binding site = +1 
Segregation analysis (summed score between -10 and +4) 
Variant occurred de novo in one patient with features of CHARGE 
syndrome = +3 
OR 
Variant occurred at least twice de novo in patients with features of 
CHARGE syndrome = +4 
Asymptomatic carrier of the varianta = -2 
Variant found in a homozygous state = -5 
Variant found in combination with a pathogenic CHD7 mutationb = -3 
Prediction based on total summed score (total score between -11 
and +7) 
Probably benign: total score 0 or less 
Unknown: total score between 0 and +4 
Probably pathogenic: total score +4 or more  
a This means that the variant is present in one or more clinically well‐
characterized persons without features of CHARGE syndrome, or the 
variant is found in two or more persons reported to be normal, but for 
whom no detailed clinical information is available (e.g., controls reported 
in the NCBI SNP database or not thoroughly investigated family 
members). 
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b A pathogenic CHD7 mutation is defined as a truncating, missense, or 
splice site mutation in the CHD7 gene that is clearly pathogenic (this 
category does not include unclassified variants or benign variants). 
 
The combination of these variables leads to a more confident 
pathogenicity prediction than previously available methods (Bergman et al., 
2012). They used this system to classify 145 CHD7 missense variants. 
Furthermore, they compared the clinical phenotypes of patients harboring 
the missense variants that were classified as probably pathogenic with the 
phenotypes of patients harboring truncating mutations. They concluded that 
CHD7 missense alterations are generally associated with a milder 
phenotype than truncating alteration  (Bergman et al., 2012).  
Although computational tools have been developed to classify the 
pathogenicity of missense variants, functional analyses to confirm their 
pathogenicity are lacking (Bergman et al., 2012; Villate et al., 2018). 
Interpreting the effect of amino acid variations in CHD7 protein remains a 
challenge. Moreover, the expression of the large CHD7 protein (2997 amino 
acids, 340 kDa) to perform functional assay may be difficult due to an 
increased potential of degradation.  
A biochemical method has been described to test in vitro the function 
of the CHD7 protein: first, the authors purified CHD7 protein expressed in 
insect cells using a baculoviral vector. Then, they used these recombinant 
proteins to study in vitro their chromatin remodeling properties (Bouazoune 
and Kingstone, 2012). Two years later, another approach has been 
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developed in a zebrafish model. Chd7 knock-down was achieved by 
injection of splice-blocking morpholino (MO) against chd7 (chd7-Mo). Then, 
phenotype rescue was studied following injection of mRNA encoding WT-
CHD7 or mutated alleles (Balasubramanian et al., 2014). Moreover, DNA 
methylation signature was recently proposed as a diagnosis tool for 
disorders involving proteins that attend the epigenetic machinery (Butcher 
et al., 2017; Aref-Eshghi et al., 2018). However, the complexity of these 
systems is incompatible with routine use. Therefore, in this thesis, we 
developed a novel and simple approach to accurately assess the functional 
impact of CHD7 variants. 
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3.1 Molecular Diagnosis of CHARGE Syndrome  
3.1.1 Chromosome Analysis 
Chromosome analysis was conducted at the laboratory of Central 
Biomedical Research (CEBIOR), Diponegoro University, Semarang, 
Indonesia using GTG-banding technique from peripheral blood 
lymphocytes. Ten drops of heparinized blood were cultured under an 
atmosphere of 5% CO2 at 37°C for 72 hours in two different 5 mL media, 
TC199 and Minimum Essential Media (MEM) (Gibco, Carlsbad, California, 
USA), supplemented with 5% Fetal Bovine Serum (FBS) and 0.025 mL 
Phytohemaglutinin-P (Gibco). In a MEM media tube, 0.1 mL thymidine (final 
concentration of 0.3 μg/mL) and 3 drops of colchicine (concentration of 1 
μg/mL) were added and incubated for 24 hours and 25 minutes before cell 
harvesting. A TC199 tube was treated with colchicine (concentration of 1 
μg/mL) but without thymidine. After the culture process was finished, the 
culture tube was centrifuged at 1,000 rpm for 10 minutes, and the 
supernatant was removed. A warm hypotonic solution (0.075 M KCl) was 
added to the cell pellet and then resuspended until homogeneity and 
subsequently incubated at 37°C in a water bath for 15-30 minutes. 
Afterward, the cell suspension was centrifuged at 1,000 rpm for 10 minutes, 
the supernatant was removed, and 5 mL Carnoy’s solution (3:1 
methanol:glacial acetic acid) was added slowly through the tube wall, and 
shaken well. These steps were repeated constantly until clear precipitation 
was obtained and fresh Carnoy’s solution was added to suspended 
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residues. Subsequently, two drops of cell suspension were released onto a 
glass slide from a height of around 20 cm.  
Finally, the slides were stored for approximately 3 days. After that, the 
slides were rinsed with water and put into warm Hanks solution, put into 
0.1% trypsin (in warm Hanks buffer) for 10-25 seconds, depending on the 
sensitivity and slide age, and again rinsed with water. After that, the slide 
was flooded with 10% Giemsa staining in phosphate buffer PH 6.8 for 1 
minute. 
3.1.2 DNA Extraction 
DNA extraction was performed at the laboratory of Central Biomedical 
Research, Diponegoro University, Semarang, Indonesia using a salt 
saturation method. Genomic DNA was isolated from peripheral blood of 
patient. Two mL of blood were resuspended in 5-10 mL lysis buffer (155 
mM NH4Cl, 10 mM NH4CO3, 1 mM EDTA), incubated for 10-30 minutes at 
room temperature and centrifuged at 3,500-5,000 rpm for 5 minutes. The 
supernatant was removed, and lysis buffer was added again. These steps 
were repeated three times. Pellets were resuspended with 2 mL of TE 
buffer, 10mg/mL Proteinase-K and 100 μL of 10% sodium dodecyl sulfate 
(SDS) and then incubated overnight in a water bath at 50°C. Subsequently, 
6 M NaCl approximately one-third of the volume of the tube was added to 
the suspension and centrifuged at 4,000 rpm for 10 minutes. DNA was 
precipitated by adding absolute ethanol. DNA that looked like white 
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substance was removed by a fine needle. To wash the DNA, 70% of ethanol 
drops were added and left to dry out. The DNA was transferred to a sterile 
Eppendorf tube with 250 μL of TE buffer and let to dissolve overnight at 
room temperature. Purified DNA was stocked at 4oC. 
3.1.3 Targeted NGS Gene Panel  
The amount of DNA and its purity were measured by 
spectrophotometric absorbance reading at both 260 nm and 280 nm using 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA). Sequencing was performed on the instrument PGM Hi-Q View 
Sequencing (Thermo Fisher Scientific). To achieve targeted gene panel 
sequencing, we used an Ion AmpliSeq™ (Thermo Fisher Scientific) CHD7, 
HOXA1, and EFTUD2 gene panel, containing 209 primer pairs in two pools. 
Multiplex polymerase chain reaction (PCR) was performed using 10 ng/μL 
genomic DNA in a final volume of 10 μL, with a premixed primer pool and 
Ion AmpliSeq™ HiFi master mix (Ion AmpliSeq™ Library Kit 2.0) for 2 
minutes at 99°C, followed by 19 cycles at 99°C for 15 seconds and 60°C 
for 4 minutes, ending with a holding period at 10°C. The PCR amplicons 
were treated with 2 μL of FuPa reagent to partially digest primer sequences 
and phosphorylate the amplicons at 50°C for 10 minutes, followed by 55°C 
for 10 minutes, then 60°C for 20 minutes. The amplicons were ligated to 
adapters with the diluted barcodes of the Ion Xpress™ Barcode Adapters 
kit (Life Technologies) for 30 minutes at 22°C, then 72°C for 10 minutes. 
Adaptor-ligated amplicon libraries were purified using Agencourt AMPure 
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XP reagents (Beckman Coulter). Next, we quantified the library on Qubit 
instrument (Thermo Fisher Scientific), and then realized dilutions at 100 pM 
in TE buffer. After obtaining the library, the next step was performed on the 
One Touch 2 device. PCR was performed using the Ion OneTouch™ 
System and Ion OneTouch™ 200 Template Kit v2 (Life Technologies) 
according to the manufacturer’s instructions. Template-positive Ion 
Sphere™ Particles were then enriched with Dynabeads MyOne™ 
Streptavidin C1 Beads (Life Technologies) using an Ion OneTouch™ ES 
system (Life Technologies). Purified Ion Sphere particles were loaded on 
Ion 316 Chip V2. Sequencing was carried out on a Personal Genome 
Machine (PGM) sequencer (Ion Torrent™) using the Ion PGM™ 
Sequencing 200 Kit V2 according to the manufacturer’s instructions. The 
variants were evaluated using the Alamut Visual 2.11 software (Interactive 
Biosoftware, Rouen, France). 
3.1.4 Mutation Confirmation by Sequencing Analysis 
The method used is derived from that described by Sanger in 1977. 
The incorporation, during the reaction, of four dideoxyribonucleotides 
(ddNTPs) labeled with four different fluorochromes results in stopping of the 
elongation. Sequencing analysis of CHD7, targeting the exon 34, was 
performed using the primers CHD7-F 5’-GCCAGCCCATATAGCAGTAC-3’ 
and CHD7-R 5’-AACACAGCCCAGCATCGTGA-3’. Approximately 20 ng of 
DNA solution (2.5 µL) was added to 22.5 µL of PCR mixture. This PCR 
mixture contained 0.25 µL of 25 mM deoxyribonucleotide triphosphates 
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(dNTPs), 3 µL of 25 mM MgCl2, 0.25 µL of 20 µM for each primer, 2.5 µL of 
10X PCR buffer, 0.125 µL of 5 U/µL Diamond® high fidelity Taq DNA 
polymerase (Eurogentec, Seraing, Belgium), and 16.13 µL of H2O. PCR 
was initiated with denaturation at 94°C for 5 minutes, followed by 35 PCR 
cycles (at 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 
seconds) and 7 minutes final elongation at 72°C. The amplified products 
were detected by electrophoresis on a 1.5% agarose gel with 0.5 mg/mL 
ethidium bromide and visualized under ultraviolet (UV) light. Furthermore, 
5 µL of the PCR product was cleaned-up with 2 µL ExoSAP reagent 
(ThermoFisher) to remove excess primers and unincorporated nucleotides 
enzymatically. Hereafter, samples are incubated at 37°C and 80°C for 15 
minutes, consecutively. Finally, 2 µL of the PCR product was used for the 
sequence reaction (BigDye Terminator Cycle Sequencing Kit Version 3.3; 
Applied Biosystems), on an ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems), following the manufacturer’s directions. Sequencing was 
performed bidirectionally using the forward and reverse PCR primers. The 
obtained sequence was compared to a published reference nucleotide 
sequence (RefSeq CHD7 NM_017780.3) using Chromas software 2.6.4. 
3.2 Development of Functional Assay of CHD7 Variants  
3.2.1 Patients and Bioinformatic Prediction Tools 
The index cases were referred to our laboratory because of clinical 
features characteristic of CS according to Verloes’ updated criteria. CHD7 
mutation screening was realized as previously described (Bilan et al., 2012; 
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Legendre et al., 2017). Nucleotide RefSeq CHD7 NM_017780.3 and exon 
numbering NG_007009.1 were used. Pathogenicity of CHD7 variants was 
classified according to the American College of Medical Genetics (ACMG) 
recommendations (Richards et al., 2015). To investigate the potential 
impact of missense mutations upon CHD7 protein, we have used 10 
software embedded in the VarSome tool (https://varsome.com/), PolyPhen-
2 (http://genetics.bwh.harvard.edu/pph2/), and Align-GVGD 
(http://agvgd.hci.utah.edu). To establish the potential impact on the splicing 
mechanism, missense variants were studied by using Human Splicing 
Finder (HSF) software (http://www.umd.be/HSF3/). 
Familial CHARGE with c.5944G>T or p.(Gly1982Trp) variant: the 
female index patient (9 years old) presented with a typical form of CS 
(notably semi-circular canal hypoplasia, atresia of the choanae, tetralogy of 
Fallot and typical cup-shaped ears). This variant was found in her affected 
brother (intellectual deficiency, unilateral deafness, cryptorchidism) and 
was not found in her mother. Her late father presented with unilateral 
deafness; unfortunately, CHD7 molecular analysis had never been done. 
Nevertheless, her paternal uncle (53 years old) who also harbor this 
variation presented with a typical CS form (complete clinical features were 
previously reported by Legendre et al., 2017). Gly1982Trp variation affects 
the SANT (switching-defective protein 3, adaptor 2, nuclear receptor co-
repressor, transcription factor IIIB) domain of the protein and is predicted 
pathogenic by all software. The variation was not found in any public 
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database. Taken together, these data sustain a class 3 (uncertain 
significance) variation. It could be noticed that HSF predicted no significant 
impact upon the splicing mechanism. 
Patient harboring c.6955C>T or p.(Arg2319Cys): this young male 
baby (9 months old) presented with a partial CS form with a bilateral 
choanae atresia, right semi-circular canal hypoplasia, and typical dysplastic 
ears. Ophthalmologic, cardiac and abdominal examinations were normal. 
This variant has been previously published in two studies (Félix et al., 2006; 
Jongmans et al., 2006). This missense variant is predicted pathogenic by 
all software and arose de novo. It is reported one time as pathogenic in 
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), five times in the CHD7 
database (http://www.chd7.org) and is not reported in control databases like 
Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/) or 
gnomAD (http://gnomad.broadinstitute.org/). Moreover, another variant 
affecting the same amino acid p.(Arg2319Ser) is also reported twice as 
pathogenic in ClinVar and twice in CHD7 database. Taken together, these 
data are consistent with p.(Arg2319Cys) belonging to class 5 (disease-
causing) variation. HSF predicted no significant impact upon the splicing 
mechanism. 
Patient harboring c.3905T>C or p.(Leu1302Pro): this male patient (13 
years old) presented with a typical form of CS including semi-circular canal 
hypoplasia, cleft lip and/or palate, heart defect, intellectual disability, 
pituitary defect, hypogonadism, genital anomaly, deafness, ear anomaly, 
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and kidney anomaly. Clinical features of the patient have been previously 
reported (Legendre et al., 2017). This variant, localized in Helicase C 
domain, is predicted pathogenic by all software and arose de novo. It was 
reported once as pathogenic in the CHD7 database and was not reported 
in the control databases like EVS or gnomAD. All these data are consistent 
with a class 5 (disease-causing) variation. HSF predicted no significant 
impact upon the splicing mechanism. 
Our laboratory has previously described familial cases displaying 
c.5405-17G>A variation, which lies in a recurrent hotspot of mutation in 
intron 25 of CHD7 (Legendre et al., 2018). Family one: the male index 
patient (5 years old) born from unrelated parents. He had a typical CS with 
2 major criteria (uveo-retinal coloboma and semi-circular canal agenesis) 
and 3 minor criteria. His affected mother had unilateral ptosis and moderate 
myopia, mild facial asymmetry, lachrymal canal anomaly, and partial 
syndactyly on the left foot. Family two: the male patient born from unrelated 
parents. Typical CS was diagnosed in early childhood as he had 2 major 
criteria (microphthalmia with coloboma and semi-circular canal hypoplasia) 
and 4 minor criteria. The alteration was inherited from a mildly affected 
mother who had unilateral deafness, uropathy and congenital dislocation of 
the hip (complete clinical features were previously published by Legendre 
et al., 2018). This variant is also reported twice as pathogenic in ClinVar 
and five times in the CHD7 database. We showed by minigene assay that 
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it elicits a splicing defect, leading to the synthesis of a protein harboring a 
five-amino acid insertion, p.(His1801_Gly1802insAspGlyHisGlyThr).  
3.2.2 Plasmids 
In this study, we transfected various cell lines with different plasmids 
to overexpress CHD7. The pCI-neo, plasmid encoding untagged wild-type 
CHD7 protein, and pCIneo-CHD7-HA, plasmid encoding CHD7 tagged with 
HA at the C-terminus, are a generous gift from Cynthia Bartels and Peter 
Scacheri (Case Western Reserve University, Cleveland, Ohio, USA). The 
other plasmid, pcDNA3-FLAG-CHD7, given by Dr. Nakayama (Kyushu 
University, Fukuoka, Japan), encodes CHD7 tagged with FLAG at the N-
terminus. Plasmid DNA is purified using the QIAprep Spin Miniprep or 
Maxiprep Kits (Qiagen) according to the supplier's instructions. Plasmids 
were assayed by measuring their absorbance at 260 nm with a 
spectrophotometer BIOMATE 3 (Thermo Fisher Scientific). 
3.2.3 Site-Directed Mutagenesis 
To go further in the understanding of amino acid change consequence 
upon CHD7 function, we modified CHD7 cDNA sequence in order to 
analyze the effect of these amino acid changes by introducing the mutated 
gene in cell lines, which then will express the variant protein. We used a 
site-directed mutagenesis method called circular mutagenesis to create 
mutations exactly where we want for each mutation. We first designed pairs 
of 25-45 bases oligonucleotides that were complementary to the target 
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sequence, with the changed nucleotide in the center position. We then 
selected the plasmid with the mutated sequence with the restriction enzyme 
Dpn I which will only digest methylated parental plasmid DNA. 
The nucleic acid substitutions were generated using the Quick-
Change II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa 
Clara, California, USA). We conducted the reaction mixture according to the 
instructions but doubling the amount of DNA template (20 ng) due to the 
large size of the plasmid (16 Kb). The DNA sequences of the 
oligonucleotides (Eurogentec) are listed in table 5.  
Table 5. Sequences of Site-Directed Mutagenesis Primers 
Variant Oligonucleotide sequences 
G1982W 
Forward: CGTGTGGTATCCACCTTTTGGGTTATTTTTGACCCTG 
Reverse: CAGGGTCAAAAATAACCCAAAAGGTGGATACCACACG 
R2319C 
Forward: 
CCTAAGGATAGAGTAATGATAAACTGCTTAGACAACATCTGTGAAGCAG 
Reverse: 
CTGCTTCACAGATGTTGTCTAAGCAGTTTATCATTACTCTATCCTTAGG 
L1302P 
Forward: CTGCTGCCAAAACCGAAGGCTGGTGGC 
Reverse: GCCACCAGCCTTCGGTTTTGGCAGCAG 
T894A 
Forward: GACTTTGCACGTAGCGCAGATGACCGGGGAG 
Reverse: CTCCCCGGTCATCTGCGCTACGTGCAAAGTC 
A2160T 
Forward: CTCCTCCAGTCATCTCATCTACTCATATTCAAGATGAGAGG 
Reverse: CCTCTCATCTTGAATATGAGTAGATGAGATGACTGGAGGAG 
1801insD
GHGT 
Forward: ATGGGCACGGCACAGGCTATGAGAAGTACAACTCCATG 
Reverse: CCTGTGCCGTGCCCATCATGTTTGAACACTCCAATTAAG 
Substituted or inserted nucleotides are indicated in red. 
The reaction was performed in a ProFlex PCR system (Thermo Fisher 
Scientific). The reaction was initiated by preheating the mixture reaction at 
95°C for 1 minute and then 18 cycles were carried out under the following 
conditions: denaturation at 95°C for 50 seconds, annealing at 60°C for 50 
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seconds and extension at 68°C for 20 minutes (1 minute and 15 seconds 
per kb of plasmid), followed by incubation at 68ºC for 7 minutes. 
To generate a five-amino acid insertion, we applied a modified 
mutagenesis protocol (Liu et al., 2008). The reaction was initiated by 
preheating the mixture reaction at 94°C for 7 minutes and then was carried 
out in two PCR steps consisting in 12 and 3 cycles respectively, under the 
following conditions: 12 cycles of denaturation at 94°C for 1 minute, 
annealing at 57°C for 1 minute and extension at 68°C for 34 minutes, 3 
cycles of denaturation at 95°C for 1 minute, annealing at 49°C for 1 minute 
and extension at 68°C for 34 minutes, followed by incubation at 68ºC for 20 
minutes. The amplification products are then treated with 1 µL of Dpn I 
restriction enzyme for 1 hour at 37°C.  
In each case, the mutagenesis reaction product was precipitated using 
ethanol then dissolved in 5 µL of water. The total was used to transform 
One Shot TOP10 chemically competent E. coli bacteria (Thermo Fisher). 
The plasmids contained in the bacterial colonies were isolated using 
Miniprep (Qiagen) and then subjected to restriction analysis using the Bgl I 
enzyme. After electrophoresis on a 1% agarose gel, the clones with the 
same restriction profile as the original plasmid and appearing in sufficient 
concentration were then sequenced on both strands. 
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3.2.4 Confirmation of Mutated Variants by Sequencing Analysis 
The sequencing reactions used for this analysis are as follows: 2 µL 
of BigDye® Terminator Mix (Applied Biosystems, Foster City, California, 
USA), 1 µL of 3.2 µM primer, 200 ng of purified plasmid DNA in a total 
volume of 5 µL. The selected primers allowed to verify whether the 
mutagenesis worked well, and the plasmids contained the desired variants. 
The DNA sequencing primers (Eurogentec) are listed in table 6. 
Table 6. Forward and Reverse Sequencing Primers 
Variant Primer Sequence 
G1982W 
Forward: GCTATAAACGCCAACTCACTGA 
Reverse: ATTGCTGTTTCACAGGGTCAA 
R2319C 
Forward: CCCGAAGCAGGAGCTGTCT 
Reverse: TCTGCATTCTTTGGTACATAACTT 
L1302P 
Forward: GGGAAAAACTATCCAGTCCATTA 
Reverse: TATCAGAATCAGGTTTGGAGAAT 
T894A 
Forward: TAAGAAACCTGACTCAGAAGCAA 
Reverse: CCATGATACACAACCACGTTC 
A2160T 
Forward: CCCGAAGCAGGAGCTGTCT 
Reverse: TCATGAAGGAGCTGAGCTACT 
1801insDGHGT 
Forward: GCTATAAACGCCAACTCACTGA 
Reverse: ATTGCTGTTTCACAGGGTCAA 
 
The reaction carried out in a thermocycler comprises 25 cycles under 
the following conditions: denaturation at 95°C for 10 seconds, annealing at 
50°C for 5 seconds and elongation at 60°C for 4 minutes. After 25 cycles of 
elongation, the amplified products were purified using the X-Terminator 
purification kit (Applied Biosystems), then the sequences are analyzed with 
the sequencer ABI 3130 Genetic Analyzer (Applied Biosystems). The 
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forward and reverse sequences were analyzed using the Chroma Lite 
version 2.6.4 software and compared with the reference sequence of the 
CHD7 gene (GenBank number NM_017780). 
3.2.5 Cell Culture and Transfection 
In this research, we used various human cell lines: HeLa (derived from 
a carcinoma cervix uterus), HEK293 (embryonic kidney cells), and SH-
SY5Y (neuroblastoma) cells. These cells were cultured under an 
atmosphere of 5% CO2 at 37ºC in Dulbecco’s Modified Eagles Medium 
(DMEM) for HeLa and HEK cells, and DMEM/F-12 for SH-SY5Y cells 
(Invitrogen, Carlsbad, California, USA), supplemented with 10% fetal 
bovine serum (Invitrogen) and 1% penicillin-streptomycin (10,000 U/mL, 
Invitrogen).  
The culture medium was changed every two days to prevent 
impoverishment and to remove dead cells. When cells are reaching 
confluency, they must be subcultured: they are detached from the bottom 
of the dish by treatment with trypsin. The culture medium was removed, and 
the cells were washed with PBS (Phosphate Buffered-Saline: 140 mM 
NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 1.8 mM KH2PO4 pH 7.3), thereby 
removing the serum elements which can inhibit the action of trypsin. The 
cells were then covered with 2 mL of 0.5 g/L trypsin 0.2 g/L EDTA 
(Invitrogen) and were incubated at 37°C for two minutes. The reaction was 
then stopped by adding 8 mL of culture medium. The suspension was 
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centrifuged for 5 minutes at 1,500 rpm. The cells were subcultured in culture 
medium and redistributed in culture plats at the appropriate dilution. The 
number of viable cells is determined by counting after staining with trypan 
blue. 
For transitory transfection, HeLa, HEK293, and SH-SY5Y cells were 
seeded at a density of 4x105, 1.6x105, 8x105 cells per well in 6-well culture 
plates, respectively. Then, the cells were incubated overnight at 37°C to 
obtain 70-80% confluence. Transfection was performed with 5 µL of 
Lipofectamine 2000 (Invitrogen) mixed with 4 µg of plasmid DNA. On the 
one hand, we tested a range of 1, 2, 4 and 8 µg of plasmid with 5 or 10 µL 
of Lipofectamine 2000 (Invitrogen) reagent per well; on the other hand, we 
tried 1 or 2 µg of the plasmid with 3 µL of FuGENE (Roche, Basel, 
Switzerland) per well. Two different exposure times of cells to the 
complexes were applied: 48 hours and 72 hours. 
3.2.6 Cell Lysis and Protein Assay 
Forty-eight hours after transfection, the cells were washed three times 
with PBS to remove the culture medium and dead cells. They were lysed 
using lysis buffer containing 10 mM Tris-HCl pH 7.5, 1% NP-4O and 0.5% 
DOC (Sodium Deoxycholate) and supplemented with 1 mM AEBSF (4-
benzenesulfonyl fluoride hydrochloride) (Sigma-Aldrich, St. Louis, Missouri, 
USA) and a protease inhibitor cocktail (Roche). The lysate was clarified by 
centrifugation at 14,000 rpm for 5 minutes at 4°C. Total protein 
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concentration obtained after extraction was measured by the BCA method: 
50 volumes of bicinchoninic acid (BCA, Sigma-Aldrich) were mixed with 1 
volume of 4% copper sulfate solution (Sigma-Aldrich). A reference range 
was also performed to obtain a correspondence between absorbance and 
amount of protein contained in the sample: 5 tubes were made with range 
0, 2, 5, 10 and 20 µg of bovine serum albumin (BSA) (total volumes 50 µL). 
An assay of the proteins in the range and in the samples was performed 
using spectrophotometer BIOMATE 3 at 562 nm. Then, the next step was 
denaturation of protein lysates, wherein a mixture of 1 volume of Laёmmli 
buffer (62.5 mM Tris-HCl pH 6.8; 2.3% SDS (v/v), 5% α-monothioglycerol 
(v/v), 15% glycerol (v/v), 0.001% bromophenol blue (v/v)) and 3 volumes of 
lysate were incubated at 95°C for 5 minutes. 
3.2.7 Western blot Analysis 
The samples were separated on SDS-polyacrylamide gel (SDS-
PAGE) prepared according to the proportions described in annex 1. The 
concentration in acrylamide of the gel depends on the relative molecular 
mass (Mr) of the studied proteins. The migration of the proteins was carried 
out at a current of 34 mA in the SDS-PAGE buffer (SDS-10TGX, Amresco). 
The progress of the migration can be followed by a colored mass marker 
(Kaleidoscope, Bio-Rad, Hercules, California, USA). After that, the 
separated proteins were transferred from the gel onto a Hybond ECL 
nitrocellulose membrane (GE Healthcare, Chicago, Illinois, USA) in the 
presence of transfer buffer (ethanol 1 L; TG SDS- 10X 250 mL; H2O 3.75 
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L). The transfer takes place at 200 mA for a period adapted to the relative 
molecular mass of the studied proteins (2 hours for CHD7 and 30 minutes 
for actin) at 4°C. After rinsing the membrane in 0.1% PBS-Tween (v/v), a 
step of blocking was performed. The membrane was covered with 10 mL of 
0.1% PBS-Tween with 5% lyophilized skimmed milk at 4°C with stirring to 
prevent antibody binding to non-specific sites. Then three 5 minutes 
washes were carried out in 0.1% PBS-Tween. The primary antibody diluted 
in PBS Tween supplemented with 5% skimmed milk was applied to the 
membrane at 4°C with stirring overnight. After three times of washing in 
0.1% PBS-Tween, the membrane was incubated with secondary antibody 
coupled to peroxidase, diluted in 0.1% PBS-Tween supplemented with 5% 
skimmed milk for one hour. Then three washes are made in the same 
buffer. Finally, the bindings of antibody to the membranes were recognized 
using chemiluminescence detection with ECL Plus Western blotting 
Detection System (GE Healthcare), and the proteins of interest were 
detected by exposure to photographic films Hyperfilm ECL (GE 
Healthcare). 
3.2.8 Immunofluorescence 
The cells were cultured on a glass coverslip. Forty-eight hours after 
transfection, they were washed three times in PBS to remove the culture 
medium and then fixed for 10 minutes at room temperature with 3.7% 
paraformaldehyde in PBS. The cells were rinsed two times with PBS, and 
permeabilized in PBS containing 0.5% Triton X-100 (Sigma-Aldrich) for 10 
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minutes to permit entry of antibodies into cells. Unspecific antigen sites 
were blocked with PBS containing 0.5% BSA (Sigma-Aldrich) for one hour 
at room temperature. The cells were incubated overnight with 30 µL primary 
antibody diluted 1/100 in PBS-BSA at room temperature in a humid 
chamber. The next day, the coverslips were washed three times in PBS-
BSA and incubated 1 hour in the presence of 30 µL of secondary antibody 
(diluted 1/100 in PBS-BSA) supplemented with DRAQ5 (eBioscience, 
Waltham, Massachusetts, USA) to mark the nucleus. The coverslips were 
washed two times with PBS and once with distilled water. Coverslips were 
mounted with Mowiol (Sigma-Aldrich) mounting medium. 
Immunofluorescent localization of the proteins was visualized using a 
spectral confocal microscope Olympus FV1000 (Shinjuku, Tokyo, Japan). 
3.2.9 Antibodies 
The following primary antibodies were used in this study: rabbit 
monoclonal antibody anti-CHD7 (clone D3F5, Cell Signaling, Danvers, 
Massachusetts, USA); mouse monoclonal antibodies anti-HA, anti-FLAG, 
anti-β-actin (clone AC-74, Sigma-Aldrich) and anti-UBF, anti-nucleolin 
(C23, clone MS-3, Santa Cruz Biotechnology, Dallas, Texas, USA). 
Peroxidase-linked secondary antibodies for Western blot were obtained 
from Sigma-Aldrich: goat anti-mouse IgG (Fc-specific) and goat anti-rabbit 
IgG (whole molecule). For fluorescent imaging, we used RRX-conjugated 
goat anti-mouse IgG (H+L) and FITC-conjugated donkey anti-rabbit IgG 
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(H+L) (Jackson ImmunoResearch Laboratories, Cambridgeshire, United 
Kingdom). 
3.2.10 RNA Extraction and cDNA Synthesis 
RNA extraction was performed using the procedure of Chomczynski 
with the RNABle reagent (Eurobio, Courtaboeuf, France). Attached cells in 
6-well culture plates were lysed by adding 1 mL of RNABle directly into the 
culture dish. The cells were homogenized by pipetting and transferred to a 
1.5 mL Eppendorf tube. The cell homogenate was stored for 5 minutes at 
room temperature to permit the complete dissociation of nucleoprotein 
complexes. Next, 100 µL of chloroform was added to 1 mL of RNABle 
homogenate, shaken vigorously for 30 seconds and the resulting mixture 
was stored at room temperature for 5-10 minutes and centrifuged at 14,000 
rpm for 15 minutes at 4°C. The aqueous phase was transferred into a fresh 
tube and RNA was precipitated by mixing with 500 µL of isopropanol. 
Samples were incubated at room temperature for 5-10 minutes and 
centrifuged at 14,000 rpm for 5 minutes at 4°C. After centrifugation, the 
supernatant was removed, and RNA pellet was washed once with 500 µL 
of 75% ethanol and subsequently centrifuged at 7,500 rpm for 5 minutes at 
4°C. After removal of the supernatant, RNA pellet was air-dried for 5 
minutes, and RNA was dissolved in H2O by passing the solution a few times 
through a pipette tip. The RNA concentration was measured with a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). 
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Reverse transcription was performed by mixing the following reagents: 
2 µg of RNA, 5 µL of 5X buffer (Thermo Fisher Scientific), 2.5 µL of 100 mM 
DTT (Thermo Fisher Scientific), 1.5 µL of 1,600 ng/µL random 
hexanucleotides (Invitrogen), 1 µL of 25 mM dNTPs (Promega, Madison, 
Wisconsin, USA), 40 U of RNAguard (Euromedex, Strasbourg, France) and 
400 U of M-MLV RT (Promega). cDNA synthesis was performed at 37°C 
for one hour, then denaturation of the enzyme was carried out by heating 
at 100°C for 2 minutes. The cDNA solution was stored at -20ºC. Finally, the 
cDNA was diluted 1/10 for subsequent use in quantitative PCR. 
3.2.11 Quantitative RT- PCR 
3.2.11.1 General Protocol 
The PCR reactions were performed in 96-well plates containing a final 
volume of 15 µL: 7.5 µL of TaqMan Universal PCR Master Mix (Applied 
Biosystems), 0.675 µL of 20 µM forward and reverse primers, 0.2 µL of 10 
µM specific TaqMan probe, 0.95 µL of distilled water and 5 µL of cDNA 
diluted in 1:10. The PCR amplification program is successively composed 
of activation of Taq polymerase for 10 minutes at 95°C followed by 40 PCR 
cycles: 15 seconds at 95ºC and 1 minute at 60°C. PCR reactions were 
performed in triplicate on a 7500 Fast Real-Time PCR System (Applied 
Biosystems). The sequence of oligonucleotides (Eurogentec) used for real-
time PCR are listed in table 7.  
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Table 7. Sequences of qRT-PCR Oligonucleotides 
Gene Primers Sequences 
GAPDH 
Forward GCTCCTCCTGTTCGACAGTCA 
Reverse ACCTTCCCCATGGTGTCTGA 
Internal probe CCGCATCTTCTTTTGCGTCGCC 
45S 
rDNA 
Forward GGAAGGAAGGAGGTGGGT 
Reverse CGGTACGAGGAAACACCTG 
Internal probe CCTCGAGCGTTCGCGTTCAG 
SOX4 
Forward AGGCGAATTCCCGTTTGG 
Reverse TTCCTAGCGCCGGTCACA 
Internal probe TTTTCCTCCCTCTTTTCCCCTTGCCC 
SOX10 
Forward TCTGAAGGCAGGAAGGAGTTG 
Reverse TCTCAGACAAAGAATGAGGTTATTGG 
Internal probe CACAGAGGCCCCCTGATCCAATTCTG 
ID2 
Forward CAACACGGATATCAGCATCC 
Reverse CGCTTATTCAGCCACACAGT 
Internal probe TCCTTGCAGGCTTCTGAATTCCCT 
MYRF 
Forward AAAGACACCGGAGACATGGT 
Reverse GTTGTCTGTCAGCTTGCACA 
Internal probe CAAGGAGCGCATCTTCATGG 
Internal probes are labeled with 6-FAM in 5’ and with TAMRA in 3’. 
A comparative threshold cycle (CT) was used to determine relative 
gene expression. The concept of the threshold cycle (CT), corresponding to 
the middle of the exponential amplification phase, is the basis of accurate 
and reproducible quantification. Then, to compare the different values of 
transcript levels of RNA, a CT between the studied gene and the 
housekeeping gene is calculated: 
CT = CT target - CT GAPDH 
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Then the CT of the samples and the reference cDNA are compared. The 
expression ratio (R) is determined using the formula below: 
Ct = ΔCT samples - ΔCT ref 
      R = 2- ΔΔCT 
Hence, the value used to plot relative gene transcription level was 
determined using the expression 2-∆∆CT (Livak and Schmittgen, 2001). RNA 
amounts were expressed as an n-fold difference relative to the mock-
transfected condition. Results are displayed as the means and standard 
deviation corresponding to three independent transfections. To compare 
sets of data, we used the Student’s t-test. All statistical tests were 
performed using GraphPad Prism version 7.0 software for Windows 
(GraphPad Software Inc., La Jolla, California, USA). 
3.2.11.2 Choice of Reporter Genes 
In this thesis, we propose a simple assay, in which CHD7 protein 
variants are expressed in cell models. Then, the impact upon the 
transcription of several genes, whose expression is controlled by CHD7 
protein according to the literature, is evaluated by qRT-PCR. 
As we mentioned previously, the CHD7 gene is involved in the fine-
tuning of gene transcription in the early steps of the development of various 
tissues. It has been described that CHD7 protein plays a role as a positive 
regulator of the nucleolar expression of the 45S ribosomal RNA precursor 
in a colorectal cancer cell line. In mouse embryonic stem cells (ES), the 
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overexpression of wild-type CHD7 shows an increased expression levels 
of 45S pre-rRNA compared with control. Moreover, depletion of CHD7 also 
reduced cell proliferation and protein synthesis. Last, compared with wild-
type ES cells, the levels of 45S pre-rRNA are reduced in both Chd7 (+/-) 
and Chd7 (-/-) mouse ES cells (Zentner et al., 2010).  
The rRNA genes are transcribed by RNA polymerase I, and each 
gene produces a primary RNA transcript. In humans, the RNA transcript 
known as 45S rRNA, is about 13,000 nucleotides. Before it leaves the 
nucleus in assembled ribosomal particles, the 45S rRNA is cleaved to give 
the 28S rRNA (about 5,000 nucleotides), the 18S rRNA (about 2,000 
nucleotides), and the 5.8S rRNA (about 160 nucleotides) of the final 
ribosome. The derivation of these three rRNAs from the same primary 
transcript ensures that they will be made in equal quantities. The remaining 
part of each primary transcript (about 6,000 nucleotides) is degraded in the 
nucleus (Figure 7). Some of these extra RNA sequences are thought to 
play a transient part in ribosome assembly, which begins immediately as 
specific proteins bind to the growing 45S rRNA transcripts in the nucleus 
(Albert et al., 1994). The oligonucleotides and the internal probe hybridize 
on the 45S rRNA cDNA upstream of that corresponding to the 28S rRNA. 
This fragment of the 45S rRNA is degraded during the processing of 28S, 
18S and 5.8S rRNA: thus, the amplified product corresponding to the 
precursor rRNA but not to the mature rRNAs. 
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Figure 7. Processing of a 45S rRNA precursor molecule into three 
separates ribosomal RNAs. Nearly half of the nucleotide sequences in the 
primary RNA transcript is degraded in the nucleus (Alberts et al., 2002).  
  
In another study in mice, genome-occupancy analyses coupled with 
transcriptome profiling, revealed that Chd7 interacted with Sox10 and 
targeted the enhancers of key myelinogenic genes such as myrf and Id2/4. 
So, CHD7 coordinates with Sox10 to regulate the initiation of 
myelinogenesis and acts as a molecular nexus of regulatory networks in 
the development. Quantitative real-time PCR (qRT-PCR) showed an 
increased expression of Id2/4 and a decreased expression of Myrf or Sox10 
genes in Chd7 knock-out mouse (He et al., 2016). Among them, we have 
chosen as reporter genes MYRF and SOX10 itself, whose transcription was 
decreased in the spinal cord of Chd7 knock-out mice, and ID2 which was 
upregulated. 
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Furthermore, it has been studied in mouse neural stem cells (NSCs) 
that CHD7 also stimulates the expression of Sox4 and Sox11 genes via the 
remodeling of their promoters to an open chromatin state (Feng et al., 2013). 
Therefore, we selected SOX4 as a reporter gene. From these shreds of 
evidence, it would be possible to study the relationship between 
overexpression of CHD7 gene variant alleles and the transcription variations 
of these reporter genes: 45S rDNA, SOX4, SOX10, ID2, and MYRF. 
3.2.12 Sensitivity and Specificity Test 
The accuracy of this functional test system was determined by 
calculating sensitivity and specificity values. Sensitivity and specificity were 
calculated from a cross classification table (Table 8). For our study, 
sensitivity was defined as the proportion of CHD7 pathogenic variants (CS-
causing) who were tested positive by the functional assay and were proven 
as CS-causing as well. Specificity was defined as the proportion of CHD7 
non-pathogenic variants which were tested negative by the functional assay 
and were proven as functional as wild-type CHD7. 
Table 8. Sensitivity and Specificity Test 
 Pathogenic variant Non-pathogenic variant 
Functional assay 
positive 
A 
True Positive 
B 
False Positive 
Functional assay 
negative 
C 
False Negative 
D 
True Negative 
Total A + C B + D 
 
Sensitivity =     A     x 100%                      Specificity =     D     x 100% 
                     A + C                                                         B + D 
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3.3 Genome Modification Technologies 
Genome modification is a milestone of modern research in genetics 
and molecular biology. These technologies were used widely to create cell 
models (Bauer et al., 2014; Cong et al., 2013; Jiang et al., 2013; Maeder et 
al., 2013), plants (Miao et al., 2013) and animals (Jao et al., 2013; Li et al., 
2013) genetically modified by inserting, deleting, modifying or replacing the 
DNA in their genomes for research purposes. Recently, by making model 
organisms regarding biological pathways in disease and health, it appeared 
potentially suitable for gene therapy in humans (Xue et al., 2014; Yin et al., 
2014; Schwank et al., 2013; Xie et al., 2014). 
Various genome editing technologies have evolved rapidly in recent 
years, including zinc-finger nucleases (ZFNs) (Porteus and Baltimore, 
2003; Miller et al., 2007; Sander et al., 2011; Wood et al., 2011), 
transcription activator-like effector nucleases (TALENs) (Wood et al., 2011; 
Christian et al., 2010; Zhang et al., 2011; Hockemeyer et al., 2011; Reyon 
et al., 2012; Boch et al., 2009; Moscou and Bogdanove, 2009; Sanjana et 
al., 2012) and the Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR/Cas9) technology. The ZFN and TALEN techniques use 
an approach of tethering endonuclease catalytic domain to modular DNA-
binding proteins for inducing targeted DNA double-stranded breaks (DSBs) 
at specific genomic loci. By contrast, CRISPR/Cas9 involves a nuclease 
guided by small RNAs pairing with target DNA (Garneau et al., 2010; Jinek 
et al., 2012; Gasiunas et al., 2012; Ran et al., 2013; Doudna and 
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Charpentier, 2014). These technologies enabled the direct study of protein 
function by modulating or editing the expression of its endogenous genes. 
In this study, we aimed to develop a biological functional test of CHD7 
protein with an endogenous expression level, both in wild-type form and 
missense variants. For this purpose, we implement the CRISPR/Cas9 
technique for genome modification due to its design simplicity, specificity, 
and efficiency compared to ZFN and TALENT (Ran et al., 2013).  
3.3.1 CRISPR/Cas9 System 
Recent advances in molecular techniques and bioinformatic analysis 
have allowed for the isolation and the sequencing of a large number of 
prokaryotic genomes which has led to the discovery of many unknown 
genes. First discovered in 1987 in the K12 strain of Escherichia coli, the 
CRISPR term was previously identified as an independent family of DNA 
repetitive regions. These regions are interspaced by similar-sized non-
repetitive (spacer) DNA, associated with Cas genes (Figure 8) (Ishino et al. 
1987, Jansen et al., 2002; Mojica et al., 2005). The CRISPR and the 
CRISPR associated (Cas) genes are found in approximately 40% of 
bacterial genomes and in nearly 90% of sequenced archaeal genomes 
(Zhang et al., 2014). This finding elicits the breakthrough of this technology 
and its rapid evolution within the scientific community. 
The CRISPR/Cas locus has a unique architecture. Firstly, the AT-rich 
leader sequence contains a promoter and different sites for several 
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regulatory elements (Jansen et al., 2002).  Secondly, a specific set of Cas 
genes are located upstream to each CRISPR locus. Thirdly, repeated 
sequences are interspaced by specific DNA sequences named spacers. 
The palindromic repeat sequences are 21-48bp in length identical through 
each CRISPR/Cas locus and separated by 26- to 72-bp spacers 
(Wiedenheft et al., 2012). The DNA spacer unique sequences have been 
shown to be virus-derived and to protect the host against an invading 
organism containing the foreign nucleic acid called protospacers (Cady et 
al., 2012; Zhang et al., 2014). 
 
Figure 8. Architecture of the CRISPR/Cas locus. The locus consists of a 
leader sequence, identical repeat sequences, unique spacer regions and 
Cas genes ( Zhang et al., 2014). 
3.3.2 Stages and Types of the CRISPR/Cas  
Due to the rapid evolution of this system, it has been a challenge to 
group CRISPR/Cas systems, however three major types have been 
established: type I (6 subtypes A-F), II (2 subtypes, A-B), and Ill (2 subtypes, 
A-B) (Makarova et al., 2011). The type II system has fewest components, 
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making it the simplest system for use in genetic engineering (Gasiunas et 
al., 2012). Type II from S. pyogenes requires only the Cas9 protein 
compared to type I (cascade proteins) and III (Csm), has been adapted for 
targeted genome editing (Sander and Joung, 2014). This is the CRISPR 
system described in this study. 
CRISPR/Cas immunity as described in S. pyogenes involves three 
following stages: acquisition, expression, and interference  (Figure 9) 
(Bikard et al., 2012). 
Stage 1 - CRISPR adaptation: S. pyogenes integrates a new spacer 
sequence from the foreign DNA into its chromosome at one end of the 
CRISPR locus (Barrangou et al., 2007). The integrated sequence needs to 
contain a short sequence known as Protospacer Adjacent Motif (PAM) to 
be recognized by the host cell (Zhang et al., 2014). SpCas9 recombinant 
Cas9 protein is the most widely used which requires a 5´-NGG-3´ PAM 
sequence and resulting in a blunt-ended double-strand break (DSB) 
(Anders et al., 2014). The DSB has typically created three base pairs 5' of 
the PAM sequence. This guide sequence is coupled to the scaffold 
sequence (tracrRNA) to form the sgRNA (Ran et al., 2013). The 
researchers are still investigating the mechanism of spacer integration 
(Levy et al., 2015). 
Stage 2 – CRISPR expression: The CRISPR/Cas9 system includes 
two RNA called CRISPR RNA (crRNA) and the trans-activated crRNA 
(tracrRNA). During this process, the CRISPR locus is transcribed by an 
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RNA polymerase into a long primary transcript, the premature CRISPR 
RNA (pre-crRNA) made up of multiple spacer-repeat units in tandem. It is 
then cleaved and processed into small mature crRNAs. The tracrRNA forms 
a duplex structure with the crRNA which anneals with the target DNA and 
guide the Cas9 endonuclease to cleave the invader's DNA (Makarova et 
al., 2011; Bikard et al., 2012). 
Stage 3 – CRISPR interference: In the last stage, the foreign DNA is 
destroyed using the processed crRNA complexed with Cas proteins (Bikard 
et al., 2012). The CRISPR interference stage involves the cleavage and the 
degradation of the target nucleic acid. The mature crRNA is loaded into the 
Cas9 endonuclease which is then activated. The complex crRNA/Cas9 
targets complementary DNA and Cas9 perform the cleavage of the 
complementary and non-complementary strands of the DNA target using 
its two nuclease motifs: RuvC at the N-terminal and an HNH-domain at the 
C-terminal (Gasiunas et al., 2012, Jinek et al., 2012). The binding of the 
complex to the protospacer sequence is mediated by the recognition of an 
obligatory PAM sequence by Cas9 located immediately downstream of the 
protospacer. In this way, the bacteria acquire an efficient system to defend 
itself against future invaders (Karvelis et al., 2013). 
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Figure 9. CRISPR mechanism of action overview. Here are graphically 
represented the three stages of CRISPR mechanism of action; (i) 
acquisition, (ii) crRNA processing and (iii) interference in the three major 
types (Bhaya et al., 2011). 
3.3.3 Application of CRISPR/Cas9 System for Genome Modification 
in Functional Study 
The CRISPR/Cas9 system is a powerful tool to create mutations or to 
make deletion and/or insertions at specific sites in the genome. Therefore, 
this technique had known rapid development these past few years in the 
scientific community. The simplicity of the Streptococcus pyogenes 
CRISPR/Cas9 type Il system (Figure 10), has allowed scientists to engineer 
it for research purposes. In this aim, they constructed two component 
genome editing tool consists of 1) a guide RNA (gRNA), a single sequence 
combination of crRNA and tracrRNA (scaffold); and 2) NLS sequences and 
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Cas9 endonuclease which cleaves both stands of the DNA target using its 
two nuclease motifs, RuvC and HNH (Jinek et al., 2012; Li et al., 2013). 
 
Figure 10. Natural vs. engineered CRISPR systems. A) Natural CRISPR 
pathway starting from the transcription of each pre-crRNA and tracrRNA. 
Next, tracrRNA binds to pre-crRNA followed by cleavage of guide RNA from 
pre-crRNA. Finally, to produce the active Cas9 nuclease, inactive Cas9 
nuclease binds to the guide RNA. B) Engineered CRISPR start from the 
transcription of guide RNA as a single sequence. After that, transcription 
and translation of Cas9 nuclease occur followed by binding of guide RNA 
to Cas9 that permits activation of Cas9 (Sander and Joung, 2014). 
The CRISPR/Cas system has the following features 1) target design 
simplicity, 2) assembly speed, 3) efficiency and 4) multiplexed mutations 
(Ran et al., 2013). Online web-based software provides CRISPR target 
selection and off-target prediction. The scientific continues to investigate 
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the biochemistry and the mechanism of Cas9 and guide RNA (Hsu et al., 
2013). 
In this thesis, the main workflow involves the perturbation of CHD7 
gene function (knock-out or knock-in the desired variants) to investigate the 
consequence on the transcription of our reporter genes. For this application, 
guide sequences can be designed using various on-line design tools (Cui 
et al., 2018). Designing a guide sequence require several information 
including the type of Cas protein used, the target sequence and the 
organism that is targeted. To achieve the best guide sequence, the GC 
content of a guide must be balanced: low or high numbers of G or C 
especially proximal to the PAM will decrease the activity of the guide (Ran 
et al., 2013). Finally, in order to edit the genome, a vector carrying the Cas9 
gene and engineered sequences which will be transcribed to produce 
specifically targeted RNA guides should be delivered into the cells (Thurtle-
Schmidt and Lo, 2018). However, expression from a DNA vector may cause 
increased off-target effects due to overexpression of the Cas9 components 
(Jacobi et al., 2017).  
3.3.4 DNA Reparation Systems 
When the Cas9/sgRNA are delivered and have successfully identified 
the target, Cas9 will break the DNA strand. There are two possible repair 
pathways (Figure 9). The first choice is the Non-Homologous End Joining 
(NHEJ). The NHEJ is an error-prone repair in which the cells simply ligate 
the two strands together via the end-joining repair system (Wilson and 
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Lieber, 1999). However, this mechanism often fails to join the DNA without 
modification of the sequence. This results in random insertions or deletions 
(indels) of nucleotides in the targeted sequence (Rodgers and Mcvey, 
2016). For this reason, in genome engineering, the mistakes produced by 
NHEJ are used for generating targeted gene knock-out. When random 
indels, with a length that is not multiple of three, are produced in genes 
especially at the early exons, it generally results in frame-shift which leads 
to the creation of premature stop codon, hence loss of function. 
The second possible option is to rely on Homology-Directed Repair 
(HDR). A homologous DNA sequence will be used as a template to mediate 
a custom repair of the DNA strand. By this process, introducing desired 
sequence modification can be performed by delivering an engineered 
double-stranded donor template with homologous flanking regions to the 
DSB region. Alternatively, it is possible to use an oligonucleotides 
(ssODNs) harbors desired modifications as a template for HDR (Jasin and 
Rothstein, 2013). The frequency of these modifications is various, generally 
higher than 1% and can even reach 50% (Sander and Joung, 2014). A 
recent study described that approximately about 15% gene editing using 
CRISPR/Cas9 fails due to persistent binding of the Cas9 protein to the DNA 
at the cut site, which blocks the DNA repair enzymes from accessing the 
cut (Figure 11) (Clarke et al., 2018). 
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Figure 11. Persistent Cas9 binding to double-strand DNA breaks (DSBs) 
blocks DNA break repair (Clarke et al., 2018). 
Several studies of the HDR process with different kinds of donor 
templates have shown that asymmetrical single-stranded DNA (ssDNA) 
donors of 127 nucleotides are highly efficient (Richardson et al., 2016). 
These donors need to be complementary to the strand that is released from 
the Cas9 complex first following DNA cleavage (Figure 12). However, it 
should be noticed that the use of a DNA template does not restrict the cell 
to use HDR alone. As a result, a mixture of reparations by the two different 
mechanisms sometimes arises in the cell.  
75 
 
 
Figure 12. Fixing the DSB: NHEJ vs. HDR. Non-Homologous End Joining 
(NHEJ) is the primary DNA repair mechanism which may cause gene 
disruption. Homology-Directed Repair (HDR) will mediate a strand-
exchange process to repair DNA damage accurately, based on the 
availability of the homologous DNA template (Sander and Joung, 2014). 
Validation of mutations and analysis of off-target effects are 
challenging because Cas9 targets single cells and a population of cells will 
thus contain a collection of different edits in the target gene. Even within the 
cell, it is likely that two alleles are mutated differently. To verify the desired 
modifications, PCR amplification of the target sequence and subsequent 
cloning of this product are required.  
A genetically mosaic population of cells can also be analyzed with T7 
Endonuclease I (T7E1). The method consists of 4 steps: genomic DNA 
isolation, PCR on the desired locus, denaturation and reannealing, and T7 
endonuclease I cleavage. This assay detects heteroduplex DNA that results 
from annealing of DNA strands that have been modified after a 
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sgRNA/Cas9-mediated cut to DNA strands without modifications. Besides, 
there are multiple other assays available that do essentially the same thing 
(e.g., Surveyor assay) (Guschin et al., 2010). 
3.4 Functional Assay of Endogenously Expressed CHD7 Missense 
Variants using CRISPR/Cas9 System 
3.4.1 Choice of CHD7 Gene Sequence to Target with the 
CRISPR/Cas9 
The exons chosen to be targets were: exon 3 (for generating knock-
out), exon 16, 30, and 33 (for generating missense variants) of the CHD7 
gene. Blast analysis of the chosen targets was performed against the 
human genome to ensure specificity. The sequence of each exon was input 
into the online software CRISPR Design (http://tools.genome-
engineering.org), to search for protospacer target sequences with the form 
5′(N)20-NGG-3′, NGG being the PAM sequence necessary for the Cas9 to 
cut the protospacer DNA. The output included several 20 bp target options, 
with different specificity values, based on a statistical logarithm of off-target 
hits. The option with the best specificity was chosen in order to minimize 
the chances of off-target binding of the sgRNA and therefore to cut by the 
nuclease Cas9. 
3.4.2 Cas9 Nuclease and Single Guide RNA (sgRNA) Constructs  
The plasmid pSpCas9(BB)-2A-Puro was purchased from Addgene 
(#62988). Spacer selection for targeting by Cas9 and subsequent 
generation of PCR amplicon was performed as described in Ran et al., 
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2013. The vector harbors the sequences encoding NLS-Cas 9, puromycin 
resistant, and the crRNA: tracrRNA backbone, preceded by a multiple 
cloning site, to make it possible to insert the specific spacer for each target 
region, downstream of a T7 promoter. The specific protospacer sequence 
was generated by annealing short oligonucleotides which were designed to 
be complementary to the CHD7 gene target in the human genome. The 
design of the primers consisted in leaving overhangs to enable cloning into 
the vector (Figure 13). The oligonucleotides are indicated in table 9. 
 
Figure 13. Schematic for cloning of the guide sequence oligos into 
pSpCas9(BB)-2A-Puro plasmid containing the sequence allowing the 
expression of Cas9 and the sgRNA scaffold. The guide oligos for the top 
and bottom strands example (blue) contain overhangs for ligation into the 
pair of BbsI sites in the plasmid. Plasmid digestion with BbsI permits the 
replacement of the type II restriction sites (blue outline) with direct insertion 
of annealed oligos (Ran et al., 2013). 
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Table 9. Target sequences of the three sgRNA and complementary oligo 
sgRNAs 
Exon Target Site PAM Oligonucleotides 
Exon 3 ACCTGAGTCATATCCGGCAC TGG 
Top: 
CACCGACCTGAGTCATATCCGGCAC 
Bottom: 
AAACGTGCCGGATATGACTCAGGTC 
Exon 16 TGGCCACCAGCCTTCAGTTT TGG 
Top: 
CACCGTGGCCACCAGCCTTCAGTTT 
Bottom: 
AAACAAACTGAAGGCTGGTGGCCAC 
Exon 30 ACCGTGTGGTATCCACCTTT GGG 
Top: 
CACCGACCGTGTGGTATCCACCTTT 
Bottom: 
AAACAAAGGTGGATACCACACGGTC 
Exon 33 CTTCACAGATGTTGTCTAAG CGG 
Top: 
CACCGCTTCACAGATGTTGTCTAAG 
Bottom: 
AAACCTTAGACAACATCTGTGAAGC 
 
The annealing of the primers occurred in a total volume of 20 µL with 
5µL of 200 µM top and bottom oligos, 2 µL of 10x oligo annealing buffer 
(Invitrogen) under the following conditions: incubation at 95°C for 4 minutes 
and store at room temperature for 5-10 minutes. Finally, the annealed 
products were diluted 1/200 for subsequent use in the ligation process. The 
cloning of the oligonucleotides in the vector consisted of a one-step 
digestion and ligation reaction as follow: pSpCas9(BB)-2A-Puro plasmid 
was digested with BbsI (New England Biosciences). 50 ng of linearized 
plasmid was used for subsequent ligation. The extremities of the plasmid 
were ligated with 250 nM annealed oligonucleotides by T4 DNA ligase 
(Thermo Fisher Scientific) by incubation overnight at 15°-4°C. The ligated 
plasmid was transformed into TOP10 chemically competent E. coli bacteria 
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(Thermo Fisher Scientific) by using 2 µL of ligation product and plating 50 
µL in an LB-agarose plate with ampicillin for selection. For identification of 
the correct clones, 15 colonies of each construct were selected and cultured 
to extract the plasmid DNA by using the QIAGEN MiniPrep kit according to 
the manufacturer’s instructions. Finally, the plasmids from each construct 
were sequenced with the sequence primers to confirm the presence of the 
insert (Table 5). The correct clones were then extracted using QIAGEN 
MidiPrep, according to the manufacturer’s instructions.  
3.4.3 Repair-Template Design: Single-stranded DNA Oligo-
nucleotides (ssODNs) and Double-stranded Targeting Plasmid 
For a targeted DNA base change purpose, HDR must be the repair 
pathway. For each of the three different sgRNA targeted sites (located in 
the exon 16, exon 30, and exon 33 of the CHD7 gene), we designed three 
single-stranded DNA oligonucleotides (ssODNs) repair templates. These 
templates contained symmetrical homology arms, flanking the theoretical 
Cas9 cut site (located 3 base pairs upstream of the PAM), with total lengths 
of 108, 110, and 110 nucleotides, respectively, and sharing sequence 
identity with the sgRNA-binding strands. The substituted nucleotides are 
listed in table 10. 
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Table 10. List of single-stranded oligo deoxynucleotides (ssODNs) used as 
HDR templates 
Variant ssODN 
G1982W 
5’ATAATCTTTCTAACAGGTGGACAAGAAGAGAAGAGGCTGA
TTTTTACCGTGTGGTATCCACCTTTTGGGTTATTTTTGACCC
TGTGAAACAGCAATTTGACTGGAACCAA-3’ 
R2319C 
5’CTTGTGACTTTTCTTCTCCCTCCAGGATAGAGTAATGATA
AACTGCTTAGACAACATCTGTGAAGCAGTGTTGAAAGGCA
AATGGCCAGTAAATAGGCGCCAGATGTTTG-3’ 
L1302P 
5’TCCAGGCTGCTGGCAAGCTAGTGCTGATTGACAAGCTG
CTGCCAAAACCGAAGGCTGGTGGCCACAGGGTGCTTATC
TTTTCCCAGATGGTGCGCTGCTTGGACATAC-3’ 
Substituted nucleotides are indicated in red. 
As an alternative, we constructed HDR template plasmids, a 
conventional double-stranded DNA with homology arms flanking the 
mutated sequence.  For L1302P variant, the exon 16 of CHD7 gene from 
patient’s DNA harboring this variant was amplified and ligated with pGEM-
T Easy vector using T4 DNA ligase by incubation overnight at 4°C. The 
ligated plasmid was transformed into TOP10 chemically competent E. coli 
bacteria kit (Thermo Fisher Scientific) by using 2 µL of ligation product and 
plating 50 µL in an LB-agarose plate with Isopropyl β-D-1-
thiogalactopyranoside (IPTG) along with X-gal for blue-white screening and 
100 µg/mL ampicillin. For identification of the correct clones, 5 white 
colonies were selected for Miniprep (Qiagen). The plasmids were 
sequenced using T7 universal primer 5′-d(TAATACGACTCACTATAGGG)-
3′ and SP6 universal primer 5′-d(TATTTAGGTGACACTATAG)-3′ to confirm 
the presence of the desired mutation. The correct plasmid was then 
linearized using Pst1 enzyme. 
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For G1982W and R2319C variants, the constructions were made with 
the same procedure as described above, but the DNA templates for 
amplification of exon 30 and exon 33 were obtained from healthy human 
DNA. The desired mutations were introduced into the ligated plasmids 
using site-directed mutagenesis. The DNA sequences of the 
oligonucleotides (Eurogentec) are listed in table 5. Finally, plasmids with 
desired mutations were linearized using Pst1 enzyme. 
3.4.4 Transfection and Clonal Cell Isolation 
In this experiment, we used HeLa and SH-SY5Y cells. The cells were 
cultured under steady-state culture conditions as described above. Twenty-
four hours before transfection, the cells seeded at a density of 8x105 cells 
per well into 6-well culture plates. On the day of transfection, 70-90% 
confluency is optimal. Transfection was performed with 5 µL of 
Lipofectamine 2000 (Invitrogen) mixed with 4 µg of pSpCas9(sgRNA) to 
generate CHD7 knock-out, and co-transfected with 80 µM of ssODN or 4 
µg of linearized HDR template plasmids to obtain desired missense 
variants. Forty-eight hours after transfection, Puromycin selection 
(Invivogen, Toulouse, France) was applied at a concentration of 10 µg/mL 
and 4 µg/mL for HeLa and SH-SY5Y cells, respectively. Furthermore, the 
cells were incubated for 72 hours with puromycin and then grown in a 
selection-free medium. 
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Isolation of clonal cell lines with specific modifications is often desired. 
Isolating single cells were achieved through serial dilution to a final 
concentration of 0.5 cells per well in 96-well plate to reduce the likelihood 
of having multiple cells per well, followed by an expansion period to 
establish a new clonal cell line. 
3.4.5 T7 Endonuclease I Assay 
The T7E1 assay was performed as previously described (Guschin et 
al., 2010). We used this assay to get a first estimate of whether our 
targeting was successful or not. Genomic DNA was extracted by using 
QIAamp DNEasy Blood and Tissue Kit (Qiagen) according to the 
manufacturer’s instructions. The DNA was assayed by measuring the 
absorbance at 260 nm using spectrophotometer Nanodrop ND 1000 
instrument (Thermo Fisher Scientific). PCR amplification of exon 3 was 
performed using the intronic primers CHD7-F 5’-GCCAGCCCA 
TATAGCAGTAC-3’ and CHD7-R 5’-AACACAGCCCAGCATCGTGA-3’. 
Approximately 100 ng of DNA solution (1 µL) was added to 49 µL of PCR 
mixture. This PCR mixture contained 0.5 µL of 25 mM deoxyribonucleotide 
triphosphates (dNTPs), 4 µL of 25 mM MgCl2, 0.5 µL of each 20 µM primer, 
5 µL of 10X PCR buffer, 0.25 µL of 5 U/µL Diamond® high fidelity Taq DNA 
polymerase (Eurogentec), and 38.25 µL of H2O. PCR was initiated with 
denaturation at 94°C for 5 minutes, followed by 35 PCR cycles (at 94°C for 
30 seconds, 60°C for 30 seconds, and 72°C for 45 seconds) and 10 minutes 
final elongation at 72°C. The amplified products were detected by 
83 
 
electrophoresis on a 1.5% agarose gel with 0.5 mg/mL ethidium bromide 
and visualized under ultraviolet (UV) light. Next, PCR products were 
purified using the QIAquick PCR purification kit (Qiagen) according to the 
manufacturer’s instructions. The PCR products were eluted in 50 µL of 
water, then quantified using NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific). 
T7 Endonuclease I assay was performed using 200 ng of purified PCR 
products and 2 µL 10X NE Buffer in 19 µL reaction mixture. The 
hybridization of PCR products conducted in conditions as follows: initial 
denaturation at 95°C for 5 minutes, denaturation from 95° to 85°C with -
2°C/second ramp rate, followed by incubation from 85° to 25°C with -
0.1°C/second ramp rate. Afterward, 1 µL of T7 Endonuclease I (New 
England Biolabs) was added to the annealed PCR products and incubated 
at 37°C for 15 minutes. The reaction was stopped by adding 1.5 µL of 0.25 
M EDTA. Finally, the reaction products were analyzed by electrophoresis 
on a 1.5% agarose gel to resolve full-length DNA and cleavage products 
(Figure 14). Bands were quantified by densitometry using Scion Image 
software. The percentage of nuclease-specific cleavage products (fraction 
cleaved) was determined. 
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The estimation of gene modification was calculated using the following 
formula: 
    % gene modification = 100 x [1 - (1 - fraction cleaved)1/2] 
     Fraction cleaved =            [sum of cleaved band intensities] 
                                  [sum of the cleaved band + parental band intensities] 
 
 
Figure 14. Schematic of the T7EI assay. Genomic DNA (blue) from treated 
cells containing WT and modified DNA (mutation in red). PCR amplification 
generates WT and modified PCR products (black). Denaturing and 
reannealing of these PCR products generates mismatch are cleaved by 
T7E1 nuclease (Adapted from https://dharmacon.horizondiscovery.com). 
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3.4.6 Verification of the Mutations 
The genomic DNA of 12-24 isolated clones was extracted using the 
DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer’s 
instruction. DNA concentrations were measured by NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). The desired missense 
variants were detected by PCR followed by Sanger sequencing using 
sequencing primers (Table 5). To confirm the CHD7 knock-out, exon 3 of 
the CHD7 gene was amplified and ligated in pGEM-T Easy vector as 
described previously. The PCR products of targeted exon were cloned into 
the vector in order to verify the modification occurred in both alleles. In 
general, each allele carrying a different mutation. For identification, 16 white 
colonies of each clone were selected for Miniprep. The plasmids were 
sequenced with the T7 and SP6 universal primers to confirm the indel 
mutations. 
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CHAPTER IV 
 
IDENTIFICATION OF A NOVEL CHD7 
MUTATION IN AN INDONESIAN 
CHARGE SYNDROME PATIENT 
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4.1 Case Presentation 
In Indonesia, only one case of clinically diagnosed CS has been 
reported to date, without further investigation (Pramudita et al., 2017). We 
provide a retrospective report of the molecular diagnosis of this patient 
based on next-generation sequencing (NGS). To our knowledge, this is the 
first report on the molecular diagnosis of CS in an Indonesian patient.  
A five-year-old boy with multiple deformities was born from non-
consanguineous Indonesian healthy parents. The pregnancy was without 
complications, and delivery was spontaneous. The mother was 37-year-
old, and the father was 36-year-old. His birth weight was 2600 gram. He 
had two healthy brothers, and there was no family history of similar 
complaints, nor any other congenital abnormality in the three-generation 
family pedigree (Figure 15). 
 
Figure 15. Pedigree of an Indonesian CS patient. The patient (indicated 
with black arrow) is the only affected individual in a three-generation 
pedigree. He has two healthy siblings from healthy parents; thus, the 
pattern of inheritance is de novo. 
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Since the first week of life, the infant had feeding problems, short 
stature, and failure to thrive. A feeding tube was placed through the patient’s 
nose into the stomach in order that he would receive adequate nutrition. 
Subsequent examinations revealed multiple malformations such as iris 
coloboma on the left eye, microphthalmia and bulbous atrophy on the right 
eye, hypoplasia and abnormal pinnae on both ear cartilages, small nostril 
on the right side, and high arched palate (Figure 16).  
 
Figure 16. Facial gestalts of an Indonesian CS patient. The 5-year-old 
patient showed striking facial gestalts of CS such as (A) microphthalmia on 
the right eye, (B) small nostril especially on the left side, (C) prominent anti-
helix discontinuous with antitragus, rudimentary right ear lobe and (D) thin 
and unfold helix, prominent anti-helix discontinuous with antitragus, and 
rudimentary left lobe. 
In addition, he had type 1 laryngomalacia and neurogenic dysphagia. 
An audiologic BERA (brainstem evoked response audiometry) test was 
applied and revealed severe hearing loss in his right ear and profound 
hearing loss (deafness) in his left ear. The cardiac defect showed 
cardiomegaly, DORV (double outlet right ventricle) and severe pulmonary 
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stenosis. Other abnormalities were found, including horseshoe kidney, 
micropenis, and absence of testicles in the scrotum and inguinal region. 
Cerebral scan using MSCT (multiple slice computer tomography) showed 
arachnoid cyst in the sellar region. 
4.2 Clinical Diagnosis and Chromosome Analysis  
The clinical diagnosis of CS is based on combinations of phenotypic 
signs and symptoms that are sorted as major and minor criteria. The patient 
met the diagnostic criteria of CS defined by Hale et al. presenting both major 
and minor criteria, including 2 major and 7 minor characteristics (Table 11). 
The clinical diagnosis of CS was established in the first year by pediatricians 
at Diponegoro National Hospital, Semarang, Indonesia. Furthermore, to 
exclude large chromosomal aberrations, the patient’s karyotype was 
analyzed, revealing a normal male karyotype of 46, XY (Figure 17).  
 
Figure 17. Patient’s karyotype showed a normal male karyotype of 46, XY. 
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Table 11. Clinical features of the patient 
Abbreviations: DORV, double outlet right ventricle 
4.3 Molecular Analysis by Targeted NGS Gene Panel 
We determined the whole exonic and flanking intronic sequences of 
two genes involved in CS, CHD7 and EFTUD2. HOXA1 (OMIM 142955) 
was included in the panel as alterations in this gene are involved in features 
Diagnostic criteria 
Clinical features 
of the patient 
Frequency in 
CS patients 
(Hale et al., 
2016) 
Major   
- Coloboma + (iris coloboma, 
microphthalmia) 
75% 
- Choanal atresia or cleft lip or 
palate 
- 44% 
- Abnormal external, middle or 
inner ears, including hypoplastic 
semicircular canals 
+ (hypoplasia and 
abnormal pinnae 
on both ear 
cartilage) 
100% 
- Pathogenic CHD7 variant + 67-90% 
Minor   
- Cranial nerve dysfunction 
including hearing loss 
+ (IX/X) 70-90% (IX/X) 
- Dysphagia/feeding difficulties + 80% 
- Structural brain anomalies + (arachnoid cyst 
in the sellar 
region) 
50% 
- Developmental delay/intellectual 
disabilities/autism 
+ 100% 
- Hypothalamo-hypophyseal 
dysfunction (gonadotropin or 
growth hormone deficiency) and 
genital anomalies 
+ (micropenis, 
cryptorchidism) 
64-100% 
- Heart or esophagus 
malformation 
+ (DORV) 75% 
- Renal anomalies + (horseshoe 
kidney) 
46% 
- Skeletal/limb anomalies - 80% 
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overlapping with CS (Tischfield et al., 2005). These analyses identified two 
non-pathogenic variants in the HOXA1 gene, eleven non-pathogenic 
heterozygous variants in the EFTUD2 gene, and detected sixteen non-
pathogenic heterozygous variants in the CHD7 gene (Table 12). Moreover, 
we identified a heterozygous nonsense variant in exon 34 of the CHD7 
gene: NM_017780.3:c.7234G>T or p.(Glu2412Ter) (Figure 18A). We 
confirmed this finding by PCR amplification of exon 34 followed by Sanger 
sequencing. This variant was confirmed as de novo because we did not 
detect it in the DNA of either of his parents (Figure 18B). As this novel 
variant has not been reported before, we deposited it in the CHD7 database 
(https://www.chd7.org, last accessed October 02, 2018). 
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Table 12. Detected nonpathogenic variants in HOXA1, CHD7 and EFTUD2 
genes in the patient 
No. Gene Variant Location Allele Call RefSNP (rs) 
1. HOXA1 c.907T>C Exon 2 Heterozygous rs76826100 
2. HOXA1 c.218C>T Exon 1b Homozygous rs10951154 
3. CHD7 c.1665+34G>A Intron 2 Homozygous rs7836586 
4. CHD7 c.1666-147C>A Intron 2 Homozygous rs6471901 
5. CHD7 c.1666-103_1666-96del Intron 2 Heterozygous rs142885557 
6. CHD7 c.2238+39G>A Intron 4 Homozygous rs4540437 
7. CHD7 c.2376+42_2376+48ins Intron 5 Homozygous rs201756536 
8. CHD7 c.2442-93A>G Intron 6 Homozygous rs10448027 
9. CHD7 c.2614-45A>G Intron 8 Homozygous rs6471902 
10. CHD7 c.3779-217G>A Intron 15 Homozygous rs6471905 
11. CHD7 c.3989+51C>A Intron 16 Homozygous rs7005873 
12. CHD7 c.4186-225A>G Intron 17 Homozygous rs11986059 
13 CHD7 c.4533+46A>G Intron 19 Homozygous rs7844902 
14. CHD7 c.5666-189G>T Intron 28 Heterozygous rs3763591 
15. CHD7 c.*1189A>C Exon 38 Heterozygous rs4738834 
16. CHD7 c.*1444T>G Exon 38 Heterozygous rs4237040 
17. CHD7 c.*1728T>C Exon 38 Heterozygous rs2280917 
18. CHD7 c.*1797C>T Exon 38 Heterozygous rs6985168 
19. EFTUD2 c.1014A>G Exon 28 Heterozygous rs2231647 
20. EFTUD2 c.588T>C Exon 28 Heterozygous rs2304986 
21. EFTUD2 c.2562-40T>C Intron 25 Heterozygous rs2289673 
22. EFTUD2 c.2046-102A>G Intron 20 Heterozygous rs16971033 
23. EFTUD2 c.2045+71A>G Intron 20 Heterozygous rs6503405 
24. EFTUD2 c.2045+28T>C Intron 20 Heterozygous rs58089352 
25. EFTUD2 c.1059-31A>G Intron 12 Heterozygous rs2120276 
26. EFTUD2 c.620-133C>T Intron 8 Heterozygous rs2289676 
27. EFTUD2 c.619+67A>G Intron 8 Heterozygous rs1443463 
28. EFTUD2 c.272-91T>C Intron 3 Heterozygous rs75343286 
29. EFTUD2 c.-735T>G 5’UTR Heterozygous rs2277617 
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Figure 18. Pathogenic CHD7 variant identified as the genetic cause of CS 
in an Indonesian patient. (A) Heterozygous nucleotide substitution at 
NM_017780.3:c.7234G>T identified by next-generation sequencing. (B) 
Sanger sequencing confirmed a de novo heterozygous nucleotide 
substitution (c.7234G>T) in exon 34 of CHD7. This change resulted in a 
premature stop codon p.(Glu2412Ter). 
According to the American College of Medical Genetics and Genomics 
and the Association for Molecular Pathology (ACMG-AMP) Standards and 
Guidelines for the Interpretation of Sequence Variants (Richards et al., 
2015), this variant is classified as pathogenic: PVS1 (very strong evidence 
of pathogenicity because it is a null variant), PS2 (de novo, both paternity 
and maternity confirmed), PM2 (variant absent in control population), PP3 
(deleterious effect confirmed by multiple computational evidence). Thus, we 
identified the genetic cause of CS in this patient, and we added this disease-
causing CHD7 variant as a third major criterion for CS diagnosis (Table 11). 
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CHAPTER V 
 
RESULTS 
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5.1 Development of a Functional Assay for CHD7 Protein  
5.1.1 Site-Directed Mutagenesis 
The objective of this study was the development of a functional test 
for CHD7 protein involved in the CHARGE syndrome. For this purpose, we 
have expressed in human cell lines the CHD7 protein, either wild-type or 
missense or any amino acid sequence variant found in CHARGE patients, 
to look for functional consequences of the expression of these variants. In 
the initial experiment, we have used two plasmids for expressing CHD7: 
pCIneo-CHD7-HA, expressing CHD7 HA-labeled in C-terminal and 
pcDNA3-FLAG-CHD7, expressing CHD7 FLAG-labeled in N-terminal. 
Briefly, using both plasmids, three missense variants (G1982W, R2319C, 
L1302P) that found in patients by our laboratory were generated. We also 
generated these variants, an insertion variant (1801insDGHGT), and two 
other CHD7 protein variants (T894A and A2160T) using pCIneo-CHD7, 
encoding untagged native CHD7. The two latter variants presenting one 
amino acid substitution but classified as benign using GnomAD software 
predictive tool and have been reported as polymorphisms (Vuorela et al., 
2007; Wincent et al., 2008; Bartels et al., 2010). All of the studied CHD7 
variants are summarized in table 13. 
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Table 13. Denomination of the Studied CHD7 Variants  
Nucleotide 
Change 
Amino Acid Change Abbreviation 
c.5944G>T p.(Gly1982Trp) G1982W 
c.6955C>T p.(Arg2319Cys) R2319C 
c.3905T>C p.(Leu1302Pro) L1302P 
c.2680A>G p.(Thr894Ala) T894A 
c.6478G>A p.(Ala2160Thr) A2160T 
c.5405-17G>A p.(His1801_Gly1802insAspGlyHisGlyThr) 1801insDGHGT 
 
To confirm the desired CHD7 variants, the plasmids were 
subsequently sequenced. We found that in each mutagenesis reaction, all 
transformants contained the desired variants (Figure 19-21).  
 
 
 
 
 
 
 
 
 
Figure 19. Partial electropherogram results of site-directed mutagenesis 
for missense variants. The arrow indicates the nucleotide change and the 
yellow shading indicates the impacted codon. The missense variants 
obtained are as follows: p.(Gly1982Trp) (or G1982W), p.(Arg2319Cys) (or 
R2319C) and p.(Leu1302Pro) (or L1302P). 
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Figure 20. Partial electropherogram results of site-directed mutagenesis 
for polymorphism variants. The arrow indicates the nucleotide change and 
the yellow shading indicates the impacted codon. The obtained missense 
variants are as follows: p.(Thr894Ala) (or T894A) and p.(Ala2160Thr) (or 
A2160T). These nucleotide changes have been classified as non-
pathogenic variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Partial electropherogram result of site-directed mutagenesis for 
the insertion variant. The yellow shading indicates the 15-intronic-
nucleotide-insertion resulting from c.5405-17 G>A mutation in intron 25. 
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5.1.2 Optimal Transfection Condition 
In the initial experiments, we studied several conditions to establish 
an optimal transfection condition in 6-well culture plates. The plasmid 
encoding CHD7-HA was transiently transfected into HeLa cells. As a 
negative control, an expression vector that does not contain the desired 
gene (mock) was used. Various plasmid DNA concentrations, volumes of 
lipofection reagent, and incubation times post-transfection were tested. On 
the one hand, we tested a range of 1, 2, 4 and 8 µg plasmid with 5 or 10 µL 
of Lipofectamine reagent per well; on the other hand, we tried 1 or 2 µg of 
the plasmid with 3 µL of FuGENE per well. Two different exposure times of 
cells to the complexes were applied: 48 hours and 72 hours. 
The transfection efficiency was assessed in HeLa cells by Western 
blot using an anti-HA primary antibody to test CHD7 protein expression 
(expected molecular weight of 340 kDa). We subjected the protein lysates 
on a 5% SDS-PAGE gel to study the protein of interest, CHD7. In parallel, 
the detection of β-actin protein was also performed on a 10% SDS-PAGE 
gel to verify the quality of the protein lysate and the uniformity of the protein 
amount loaded into each well. Indeed, we noted the presence of a band 
above 250 kDa that corresponds to the CHD7 protein (340 kDa), this band 
is absent from the control transfection (mock). This protein is therefore 
expressed, and we concluded that HeLa cells are transfected under these 
conditions. The highest transfection efficiency in HeLa cells was obtained 
within 48 hours by using 4 μg of plasmid DNA with 10 μL of Lipofectamine 
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2000 per well (Figure 22). On the contrary, the transfection using FuGENE 
was unsuccessful, although it had been repeated in various concentrations 
of plasmids. As a conclusion, the transfection of cultured HeLa cell is 
effective only when using Lipofectamine 2000 reagent. 
 
Figure 22. CHD7-HA protein expression. HeLa cells were transfected with 
an empty vector (mock) or with a plasmid encoding CHD7-HA (4 µg). 100 
µg of protein lysates were separated by SDS-PAGE and analyzed by 
immunoblotting with an anti-HA antibody and anti-actin as a loading control. 
Maximum expression was obtained 48 hours after transfection. 
In the next experiment, we tested FLAG-CHD7 encoding plasmid to 
overexpress CHD7 in HeLa, HEK293, and SH-SY5Y cells using the optimal 
transfection conditions established for the preceding plasmid. We analyzed 
the expression of the CHD7 protein by Western blot using anti-FLAG 
primary antibody. As predicted, FLAG-CHD7 was also evidence by 
Western blot in all cell models (Figure 23). 
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Figure 23. FLAG-CHD7 protein expression. HeLa (A), HEK293 (B), and 
SH-SY5Y (C) cells were transfected with an empty vector (mock) or with a 
plasmid encoding FLAG-CHD7. 100 µg (or 30 µg for actin control) of protein 
lysates were separated by SDS-PAGE and analyzed by immunoblotting 
with an anti-FLAG antibody or anti-actin as a control. 
According to these results, in the further transfection experiments, we 
always used 4 µg of plasmid DNA with 10 µL of Lipofectamine 2000 
followed by incubation of cells for 48 hours. 
5.1.3 Localization of Overexpressed Wild-Type CHD7 Protein 
To investigate the subcellular localization of the protein, HA-tagged 
CHD7 was expressed in HeLa and HEK293 cells. Double immunostaining 
was performed against HA and endogenous UBF, a protein expressed in 
the nucleoplasm and highly concentrated in the nucleolus (Figure 24). 
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Figure 24. Localization of CHD7-HA protein. CHD7-HA was expressed in 
HeLa (top) and HEK293 cells (bottom). Immunostaining was visualized 
using confocal microscopy. The CHD7 protein was detected in green and 
UBF protein in red. The DRAQ5 dye was used to color the nuclei (blue). 
CHD7-HA protein was identified only in the nucleoplasm. Bar: 10 µm. 
We observed that CHD7-HA was present throughout the nucleoplasm 
but absent of the nucleolus. As it was contradictory to some data of the 
literature, we hypothesized that the C-terminus tag might interfere with the 
trafficking of CHD7. Therefore, we performed in both cells a co-transfection 
experiment, to express FLAG-tagged CHD7 and a fusion protein between 
nucleolin (localized exclusively in the nucleolus) and the red fluorescent 
protein mCherry (Figure 25). This result confirmed that, in our hands, tagged 
CHD7 proteins localize exclusively in the nucleoplasm, but not in the 
nucleolus. 
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Figure 25. Localization of FLAG-CHD7 protein. HeLa (top) and HEK293 
cells (bottom) were co-transfected to express FLAG-CHD7 and mCherry-
nucleolin. The fluorescence was visualized using confocal microscopy. 
FLAG-CHD7 protein was detected in green and nucleolin in red. DRAQ5 
dye was used to color the nuclei (blue). FLAG-CHD7 protein was localized 
only in the nucleoplasm. Bar: 10 µm. 
Moreover, we continued to investigate the subcellular localization of 
the CHD7 protein in SH-SY5Y cells since CHD7 protein is highly expressed 
in neuronal progenitor cells (Feng et al., 2013). HA- and FLAG-tagged 
CHD7 were co-transfected with a fusion protein between nucleolin and the 
red fluorescent protein mCherry (Figure 26). However, HA- and FLAG-
CHD7 protein were identified exclusively in the nucleoplasm. We concluded 
that the position of the tag was not involved in the localization of CHD7. 
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Figure 26. Localization of CHD7-HA and FLAG-CHD7 proteins. SH-SY5Y 
were co-transfected to express CHD7-HA or FLAG-CHD7 and mCherry-
nucleolin. The fluorescence was visualized using confocal microscopy. 
CHD7 protein was detected in green and nucleolin in red. DRAQ5 dye was 
used to color the nuclei (blue). CHD7 protein was identified only in the 
nucleoplasm. Bar: 10 µm. 
To check whether the tags were responsible of the results, we also 
performed immunostaining of endogenous CHD7 protein compared with 
untagged-CHD7 protein that we co-transfected with a fusion protein 
between nucleolin and the red fluorescence protein mCherry in HeLa cells 
(Figure 27). Contrary to the literature, repeated experiments performed the 
same results showing that, in our hands, CHD7 proteins localize exclusively 
in the nucleoplasm, but not in the nucleolus. 
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Figure 27. Localization of endogenous and overexpressed wild-type CHD7 
protein. Immunostaining was visualized using confocal microscopy. CHD7 
protein was detected in green and nucleolin in red. Arrow indicates a cell 
that overexpresses. CHD7 protein is localized mostly in the nucleoplasm, 
but not in the nucleolus. Bar: 10µm. 
We have performed the experiments under the following conditions: 
we expressed untagged (UT)-, C- or N-terminal labeled CHD7 proteins in 
three cell lines (HeLa, HEK293, and SH-SY5Y) and used two different 
nucleolar markers (UBF or mCherry-nucleolin). In conclusion, we did not 
find in any case colocalization of CHD7 with a nucleolar protein, but the 
CHD7 protein was localized in the nucleoplasm. For further experiments, 
we have chosen pCIneo-UT-CHD7 plasmid to perform CHD7 functional 
analysis. 
5.1.4 Expression and Localization of CHD7 Missense Variants  
After plasmid transfection in HeLa cells, we evaluated the efficiency of 
CHD7 overexpression by Western blot using CHD7 rabbit monoclonal 
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antibody; then we analyzed the expression of the five missense CHD7 
variants: T894A, A2160T, G1982W, R2319C, and L1302P (Figure 28). As 
expected, for WT and all variant forms of CHD7 protein, a specific protein 
band appeared at a position corresponding to a relative molecular mass of 
approximately 340 kDa. Hence, each of the plasmids that we used elicited 
the expression of the corresponding allele of CHD7 protein. 
 
Figure 28. Expression of wild-type and variant forms of CHD7 protein in 
HeLa cells. For each transfection, 100 µg of protein lysates were separated 
by SDS-PAGE and analyzed by Western blot with anti-CHD7 antibody, or 
anti-actin as a loading control. The expected relative molecular mass of the 
CHD7 protein is 340 kDa. 
To investigate the subcellular localization of the different forms (WT or 
missense variants) of CHD7 protein expressed in HeLa cells, we performed 
immunofluorescent staining followed by confocal microscopy imaging. We 
observed that the five missense variants, T894A-, A2160T-, G1982W-, 
R2319C- and L1302P-CHD7, exhibited the same localization as the WT 
form of the protein (Figure 29). In each case, CHD7 appeared localized 
exclusively in the nucleoplasm. In several cells, the intensity of CHD7 
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staining appeared higher but the localization remained confined to the 
nucleoplasm: therefore, higher overexpression level did not alter the 
observed localization. Moreover, the three amino acid substitutions found 
in patients had no impact upon CHD7 trafficking. 
 
 
107 
 
 
Figure 29. Nucleoplasmic localization of wild-type and variant forms of 
CHD7 protein expressed in HeLa cells. Immunostaining was visualized 
using confocal microscopy. CHD7 protein was detected in green and 
nucleolin in red. DRAQ5 dye was used to color the nuclei (blue). We 
observed no colocalization between both proteins, suggesting that none of 
the CHD7 protein variants are nucleolar. Bar: 10 µm. 
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5.1.5   Expression and Localization of CHD7 Insertion Variant  
We previously described the finding in several CS patients of the 
c.5405-17G>A splicing mutation, localized in a hotspot of intronic mutation 
(Legendre et al., 2017). This substitution leads to create a new 3’ splice site 
(3’ss) (Figure 30). We assessed by minigene assay that it results in a fifteen 
intronic nucleotide insertion in the mRNA, presumably leading to the 
synthesis of a protein with five-amino acid insertion: 
p.(His1801_Gly1802insAspGlyHisGlyThr) or 1801insDGHGT.  
 
Figure 30. Mutation of c.5405-17G>A. The arrow indicates the nucleotide 
change form G>A in intron 25 resulting in a 15 intronic nucleotides insertion 
(Adapted from Legendre et al., 2018). 
We generated a plasmid encoding this variant, and we used it to 
transfect HeLa cells. We checked by Western blot that it elicited 
overexpression of the protein (Figure 31A). Furthermore, we also 
performed immunofluorescent staining followed by confocal microscopy 
imaging and revealed the same localization as the WT or missense variants 
of CHD7, localized exclusively in the nucleoplasm (Figure 31B).  
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Figure 31. Expression and localization of an insertion variant of CHD7 
protein in HeLa cells. (A) For each transfection, 100 µg of protein lysates 
were separated by SDS-PAGE and analyzed by Western blot with anti-
CHD7 antibody, or anti-actin as a loading control. (B) Immunostaining was 
visualized using confocal microscopy. CHD7 protein was detected in green 
and nucleolin in red. DRAQ5 dye was used to color the nuclei (blue). CHD7 
protein was localized only in the nucleoplasm. Bar: 10 µm. 
5.1.6 Assessment of Wild-Type CHD7 Protein Functionality 
First, we aimed to establish a functional test to evidence the 
functionality of normal CHD7 protein and subsequently to observe putative 
dysfunctions of CHD7 variants expressed in CS patients. CHD7 was 
proposed to regulate the transcription of numerous genes throughout 
development, by binding regulatory regions of the chromatin prior to 
remodeling. To investigate the functionality of CHD7 alleles, we measured 
by qRT-PCR the consequences of CHD7 overexpression upon the RNA 
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transcript amount for several genes whose transcription can be modulated 
by CHD7 according to the literature. We quantified 45S pre-ribosomal RNA 
(Zentner et al., 2010), and the mRNA of SOX4, SOX10, ID2, and MYRF 
genes (Feng et al., 2013; He et al., 2016). 
When we overexpressed WT-CHD7 in HeLa cells, the amount of RNA 
transcribed from these genes were downregulated, compared to the mock-
transfected cells (Figure 32): the transcript amounts were reduced to 
39.4±4.5% of control for 45S rDNA, 60.5±1.5% for SOX4, 48.9±2.7% for 
SOX10, 23.2±4.2% for ID2 and 40.6±1.3% for MYRF gene. 
To validate these results, we applied our biological assay to two CHD7 
protein variants, T894A and A2160T, that are classified as non-pathogenic 
variant. After transfection in HeLa cells, we quantified the transcript 
amounts of the five reporter genes: in both cases, mRNA amounts were 
significantly decreased compared with the mock-transfection (Figure 32). 
Moreover, no statistically significant difference was observed compared 
with WT-CHD7 expression condition. Overall, we concluded that the 
reduction of the transcript amount of the reporter genes should result from 
the normal functionality of CHD7 protein in HeLa cells. 
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Figure 32. Impact of functional CHD7 alleles expression upon the 
transcription of five reporter genes. After transfection of wild-type or variant 
forms of CHD7, we performed qRT-PCR to evaluate the impact upon the 
transcription of genes regulated by CHD7: 45s rDNA, SOX4, SOX10, ID2, 
and MYRF. RNA amounts are displayed as an n-fold difference relative to 
the mock-transfected condition. Data represent means and standard 
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deviation corresponding to at least three independent transfections. ns: 
non-significant, **P < 0.01, ***P < 0.001. 
5.1.7 Functional Assay of CHD7 Missense Variants  
When we expressed WT-CHD7 in HeLa cells, the amounts of RNA 
transcribed from reporter genes were downregulated, compared to the 
mock-transfected cells. By contrast, when we expressed either one of the 
three missense CHD7 variant alleles, the transcript amount of each reporter 
gene was unaffected, compared with mock-transfected control condition 
(Figure 33). This result suggests that the normal ability of CHD7 protein to 
modify the transcription level of several genes was impaired by the three 
amino acid substitutions that we investigated. 
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Figure 33. Impact of missense variants expression upon the transcription 
of five reporter genes. After transfection of wild-type or variant forms of 
CHD7, we performed qRT-PCR to evaluate the impact upon the 
transcription of genes regulated by CHD7: 45s rDNA, SOX4, SOX10, ID2, 
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and MYRF. RNA amounts are displayed as an n-fold difference relative to 
the mock-transfected condition. Data represent means and standard 
deviation corresponding to at least three independent transfections. ns: 
non-significant, **P < 0.01, ***P < 0.001. 
5.1.8 Functionality of CHD7 Insertion Variant 
We evaluated the impact of 1801insDGHGT-CHD7 overexpression 
upon the transcription of the five reporter genes: we observed that their 
mRNA level was not significantly different from the mock-transfection 
condition (Figure 34). This suggests that the 1801insDGHGT-CHD7 protein 
variant is non-functional. 
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Figure 34. Impact of insertion variant expression upon the transcription of 
five reporter genes. After transfection of wild-type or insertion variant of 
CHD7, we performed qRT-PCR to evaluate the impact upon the 
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transcription of genes regulated by CHD7: 45s rDNA, SOX4, SOX10, ID2, 
and MYRF. RNA amounts are displayed as an n-fold difference relative to 
the mock-transfected condition. Data represent means and standard 
deviation corresponding to at least three independent transfections. ns: 
non-significant, **P < 0.01, ***P < 0.001. 
5.1.9 Sensitivity and Specificity Test 
The sensitivity and specificity of the functional assay for CHD7 variants 
has been calculated using a set of 3 known pathogenic and 2 known non-
pathogenic variants. Sensitivity has been estimated at 100% and specificity 
at 100%. However, the number of tested variants is still small.  
Sensitivity =      3     x 100% = 100% 
                      3 + 0 
 
Specificity =     2      x 100% = 100% 
                     0 + 2 
5.2 Functional Assay of Endogenously Expressed CHD7 Missense 
Variants using CRISPR/Cas9 System 
5.2.1 Generation of CHD7 Gene Knock-out using CRISPR/Cas9 
System 
To disrupt the function of CHD7 gene, a sgRNAs targeting the third 
exon of the CHD7 gene was designed. This early exon was chosen in order 
to increase the chance of full loss-of-function occurrence (knock-out). In this 
experiment, we induced the activation of the NHEJ pathway to create small 
insertions or deletions (indels), so that frameshift mutations were obtained. 
The target sites are shown in figure 35.  
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Figure 35. Generation of the CHD7 gene knock-out using the 
CRISPR/Cas9 system. Schematic diagram of the sgRNA target site located 
in the exon 3 of the CHD7 locus. CHD7 exons are indicated by rectangles; 
target sites of the sgRNA sequence is highlighted in green; protospacer-
adjacent motif (PAM) sequence is highlighted in red. 
Furthermore, to generate CHD7 knock-out, a plasmid encoding Cas9 
and the sgRNA was transfected firstly into HeLa cells and then SH-SY5Y 
cells, subsequently. Puromycin selection was applied for 72 hours and 
isolated single cells were obtained through serial dilution. 
5.2.2 Determining Genome Targeting Efficiency using T7 
Endonuclease I 
The genome targeting efficiency or mutation hit-rate at a specific locus 
needs to be evaluated. For this analysis, we used the enzyme mismatch 
cleavage method using T7 endonuclease I (T7EI). The enzyme recognizes 
and cleaves structural deformities in DNA heteroduplexes. 
In this experiment, HeLa cells first transfected with Cas9/sgRNA 
plasmid and then puromycin selection was applied for 72 hours. Afterward, 
the cells were cultured several days with culture medium without puromycin 
to obtain a sufficient number of cells. Genomic DNA of a population of HeLa 
cells was extracted and amplified by PCR surrounding the CRISPR guide 
RNA target site. The PCR products were then annealed and digested with 
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T7 Endonuclease I. This enzyme recognized and cleaved DNA mismatches 
in those heteroduplexes. By running the cleavage products on a 1.5% 
agarose gel, full-length and cleavage products were resolved (Figure 36).  
 
Figure 36. DNA mismatch detection assay. PCR products were treated with 
T7EI nuclease. Then, full-length and cleavage products were resolved by 
agarose gel electrophoresis. Gel shows DNA marker (ΦX174 DNA-Hae III), 
untreated (-), and edited cells (+).  
The intensity of the respective bands allowed to calculate the gene editing 
percentage that has occurred as follows: 
                      Fraction cleaved =         128,32          = 0.766 
                                                      128,32 + 39,25 
 
 
                     % gene modification = 100 x [1 - (1 – 0.766)1/2] 
                                                      = 51.6% 
As a conclusion, the genome targeting by CRISPR/Cas9 system functioned 
properly, and the efficiency rate of this system was coherent with the 
literature, that is 51.6% (Sander and Joung, 2014). Therefore, the cells were 
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subsequently cloned to verify the genome modification in the specific 
targeted locus. 
5.2.3  Verification of the CHD7 Knock-Out in HeLa Cells 
Clonal selection of edited HeLa cells was performed. Genomic DNA 
from 12 clonal cells was extracted, and the exon 3 of CHD7 was amplified. 
Five of 12 PCR products were ligated with pGEM-T Easy vector to be 
transformed into E. coli. Finally, 16 independent colonies of each clone 
were selected and sequenced. These results are summarized in table 14. 
Table 14. Nucleotide Changes in Exon 3 of CHD7 in Edited HeLa Cells 
Clones Nucleotide Changes 
3.2 
-  21 nucleotides deletion 
- 6 nucleotides deletion 
3.4 204 nucleotides insertion 
5.8 
- 11 nucleotides deletion 
- 2 nucleotides insertion 
5.9 
- 30 nucleotides deletion 
- 8 nucleotides deletion 
5.11 2 nucleotides deletion 
Briefly, in HeLa cell we have chosen clones 5.8 and 5.11 since they have 
11-nucleotide deletion (c.1702_1712delCCGGATATGAC) and 2-
nucleotide insertion (c.1702_1703insTC) for the first one, and homozygous 
2-nucleotide deletion (c.1702_1703delCC) for the second one, in exon 3 of 
CHD7. These variations would change the reading frame and cause 
premature termination of translation at a new nonsense codon (Figure 37).  
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Figure 37. Insertion deletion (indels) identification in exon 3 of CHD7 by 
Sanger sequencing. Deletions (A), (B), and insertion (C) were detected in 
HeLa cells. Arrow indicates the deletion site and yellow shading indicates 
the nucleotides insertion. This insertion or deletions will lead to a frameshift. 
5.2.4 Functionality of CHD7 Knock-out in HeLa Cells 
After having successfully generated CHD7 (-/-) HeLa cells, we first 
evaluated the CHD7 mRNA expression level by qRT-PCR to validate the 
two clones (5.8 and 5.11). As expected, compared with the parental HeLa 
cell line, the CHD7 mRNA level was reduced to 34.2±2.4% in both CHD7 (-
/-) HeLa clones (Figure 38). The decrease of mRNA amount is likely caused 
by indel that created a premature stop codon, presumably leading to mRNA 
removing via nonsense-mediated mRNA decay (NMD) process. 
We then quantified the transcript amounts of the five reporter genes in 
both CHD7 (-/-) clones. Unexpectedly, in both clones, the mRNA amount of 
each reporter gene appeared unaffected and the expression levels were 
not different from the parental HeLa cells (Figure 38). As a conclusion, in 
the HeLa cell line, the endogenous expression of CHD7 is not involved in 
121 
 
regulating the transcription of these reporter genes. From this result, we 
assumed that HeLa cells model may not suitable for functional assay of 
endogenous CHD7. We then tried generating CHD7 knock-out in SH-SY5Y 
neuroblastoma cells. 
 
Figure 38. Impact of CHD7 knock-out in HeLa cells upon the transcription 
of CHD7 and five reporter genes. We performed qRT-PCR using clones 5.8 
and 5.11 of HeLa cells in which we invalidated CHD7 gene to evaluate the 
impact upon the transcription of CHD7 and of genes regulated by CHD7: 
45s rDNA, SOX4, SOX10, ID2, and MYRF. RNA amounts are displayed as 
an n-fold difference relative to the 100% reference levels measured in the 
parental HeLa cells. 
5.2.5 Verification of the CHD7 Knock-Out in SH-SY5Y Cells 
Clonal selection of edited SH-SY5Y cells was performed. Genomic 
DNA from 12 clonal cells was extracted and the exon 3 of CHD7 was 
amplified. Three of 12 PCR products were ligated with pGEM-T Easy vector 
to be transformed into E. coli. Finally, 16 independent colonies of each 
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clone were selected and sequenced. The results are summarized in table 
15. 
Table 15. Nucleotide Changes in Exon 3 of CHD7 in Edited SH-SY5Y Cells 
Clones Nucleotide Changes 
1 2 nucleotides deletion 
2 1 nucleotides deletion 
3 
- 2 nucleotides deletion 
- 9 nucleotides deletion 
We have selected clones 1 and 2 since they have homozygous deletion: 2 
nucleotides (c.1702_1703delCC) and 1 nucleotide deletions (c.1701delG), 
respectively (Figure 39).  
 
Figure 39. Deletions identification in exon 3 of CHD7 by Sanger 
sequencing. Deletions (A) and (B) were detected in edited SH-SY5Y cells. 
Arrow indicates the deletion site. These deletions will lead to a premature 
termination codon. 
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5.2.6 Functionality of CHD7 Knock-out in SH-SY5Y Cells 
After having successfully generated CHD7 invalidation in SH-SY5Y 
cells, we further measured the CHD7 mRNA expression level by qRT-PCR 
using clone 1. As expected, compared with the parental SH-SY5Y cell line, 
the CHD7 mRNA level was reduced to 27.2±0.6% in CHD7 (-/-) SH-SY5Y 
cells (Figure 40). We tested the transcript amounts of the five reporter 
genes in this CHD7 (-/-) SH-SY5Y cells. The amount of RNA transcribed 
from these genes was upregulated, compared to parental SH-SY5Y cells 
(Figure 40). The transcript amounts were increased to 253±9.1% of 
reference for 45S rDNA, 194±3.3% for SOX4, 240±23.4% for SOX10, 
231±0.4% for ID2 and 544±6.4% for MYRF gene. 
 
Figure 40. Impact of CHD7 knock-out in SH-SY5Y cell upon the 
transcription of CHD7 and five reporter genes. After invalidation of CHD7 
gene in SH-SY5Y cells, we performed qRT-PCR using clone 1 to evaluate 
the impact upon the transcription of CHD7 and genes regulated by CHD7: 
45s rDNA, SOX4, SOX10, ID2 and MYRF. RNA amounts are displayed as 
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an n-fold difference relative to the 100% reference levels measured in the 
parental SH-SY5Y cells. Data represent means and standard deviation 
corresponding to at least three independent transfections. **P < 0.01, ***P 
< 0.001. 
According to these results, we assumed that in SH-SY5Y cell line, the 
endogenous expression of CHD7 contributes to inhibiting the transcription 
of these reporter genes. Therefore, to generate an endogenous expression 
of CHD7 missense variants, we determined to use the SH-SY5Y 
neuroblastoma cell line. 
5.2.7 Generation of Endogenously Expressed CHD7 missense 
variants in SH-SY5Y Cells using CRISPR/Cas9 System 
Having successfully used CRISPR/Cas9 to knock-out CHD7 gene in 
SH-SY5Y cells, we further performed CRISPR/Cas9 for targeted CHD7 
gene modification to obtain the missense variants that we studied 
previously. The target sites are shown in figure 41. 
 
Figure 41. Generation of the CHD7 missense variants using the 
CRISPR/Cas9 system. Schematic diagram of the sgRNA target site located 
in the exon 16, 30, and 33 of the CHD7 locus. CHD7 exons are indicated 
by rectangles; target sites of the sgRNA sequence are highlighted in green; 
protospacer-adjacent motif (PAM) sequences are highlighted in red. 
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To generate CHD7 missense variants, in each case, a plasmid 
encoding Cas9/sgRNA and ssODN, used as HDR template, were co-
transfected into SH-SY5Y cells. Puromycin selection was applied for 72 
hours and isolated single cells were obtained through serial dilution. The 
genomic DNA from 16 cell clones was isolated. We performed PCR 
amplification using these genomic DNAs as a template. Finally, to verify the 
results, each PCR product was sequenced. However, repeated 
experiments using ssODNs shown that the cell clones did not contain the 
desired variants. Therefore, alternatively we performed these experiments 
with the same protocol but using linearized double-stranded targeting 
plasmid as a repair template. By using this type of HDR, we obtained a clone 
containing the homozygous mutation L1302P (Figure 42). 
 
Figure 42. Partial electropherogram result of targeted DNA base change 
using CRISPR/Cas9. The arrow indicates the nucleotide change and the 
yellow shading indicates the changed codon p.(Leu1302Pro) or L1302P. 
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Unfortunately, until now we have not yet obtained the two other 
variants (G1982W and R2319C) even though we repeated transfections 
twice to generate these variants. 
5.2.8 Functional Assay of Endogenously Expressed CHD7 Missense 
Variant 
To investigate the functionality of L1302P-CHD7 missense variant, we 
measured by qRT-PCR the RNA transcript amount for several genes (45S 
rDNA, SOX4, SOX10, ID2, and MYRF) as we previously described. In 
edited SH-SY5Y cells, the amount of RNA transcribed from these genes 
were upregulated to 235±38.4% compared to WT-CHD7 for 45S rDNA, 
190.2±13.8% for SOX4, 191.1±8.5% for SOX10, 232.4±1.4% for ID2, and 
544.1±5.5% for MYRF gene (Figure 43).  
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Figure 43. Impact of endogenously expressed L1302P-CHD7 variant upon 
the transcription of five reporter genes. We performed qRT-PCR to evaluate 
the impact upon the transcription of genes regulated by CHD7: 45S rDNA, 
SOX4, SOX10, ID2, and MYRF. RNA amounts are displayed as an n-fold 
difference relative to the WT-expression condition. Data represent means 
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and standard deviation corresponding to at least three independent 
transfections. ns: non-significant, *P < 0.05, **P < 0.01, ***P < 0.001. 
After having successfully modified genomically both alleles of CHD7 gene 
to encode the L1302P variant, we quantified the transcript amounts of the 
five reporter genes: mRNA amounts were significantly increased compared 
with the WT-CHD7 (Figure 43). Furthermore, no statistically significant 
difference was observed compared with CHD7 (-/-) cells. This result 
suggests that the normal ability of CHD7 protein to modify the transcription 
level of several genes was impaired by the L1302P variant. 
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CHAPTER VI 
 
GENERAL DISCUSSION 
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6.1 Novel CHD7 Mutation in an Indonesian CHARGE Syndrome Patient 
The CS diagnosis is primarily based on combinations of 
clinicopathological findings that are sorted as major and minor criteria. Our 
patient presented both major and minor characteristics of CS, including 4 
major and 7 minor characteristics (Table 11). The patient was therefore 
clinically diagnosed as CS according to the novel clinical criteria (Hale et 
al., 2016). Most CS patients have a normal karyotype; however, a 
cytogenetic analysis must be performed first to exclude chromosomal 
abnormalities and other syndromes overlapping CS. Although this patient 
showed similar dysmorphism to previously reported cases of CS, we 
resorted to molecular analysis to establish a conclusive diagnosis. 
The newly found mutation c.7234G>T or p.(Glu2412Ter) resulted in a 
premature stop codon, presumably leading to mRNA removing via 
nonsense-mediated mRNA decay (NMD) process. Therefore, we assume 
that this mutation represents a null allele, causing the disorder due to 
haploinsufficiency. It has been noted that nine other nonsense mutations 
have been found in exon 34 of CHD7 so far. However, the mutation 
p.(Glu2412Ter) was not present in the CHD7 database, suggesting it to be 
novel. This novel mutation was subsequently submitted to the CHD7 
database (https://www.chd7.org). This novel mutation was sporadic, as in 
most CS cases described to date (Lalani et al., 2006; Jongmans et al., 
2006).  
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The birth of a child with a severe genetic disease poses considerable 
psychological, social, and economic problems. A genetic counselor should 
provide recurrence-risk estimates to the parents in such cases. Even if the 
parents have had a child affected by apparently de novo CHD7 alterations, 
there is still a recurrence risk of 1-2% because of germline mosaicism 
(Lalani et al., 2012). Therefore, prenatal genetic testing should be 
recommended to the mother during subsequent pregnancies to determine 
whether the fetus has a risk of having CS. 
There are several approaches to establish a molecular diagnosis of 
clinically suspected CS. Sanger sequencing of 38 exons and flanking 
intronic sequences of the CHD7 gene is considered obsolete, as it is more 
time-consuming and eventually more expensive than NGS (Frank et al., 
2013). Currently, sequencing of large panels of genes involved in 
intellectual disability (ID) is widely used, occasionally leading to the 
identification of CS-causing CHD7 mutations (Grozeva et al., 2015). 
However, as the clinical diagnosis of CS relies on well-established criteria, 
sequencing of CS-targeted gene panels appears more straightforward. 
Moreover, as this approach requires the use of lower-capacity NGS 
equipment, it allows testing at a lower cost than sequencing of large gene 
panels or genome-wide analysis. Therefore, this approach could be applied 
in low- and middle-income countries as a cost-effective strategy for routine 
diagnosis of CS. 
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6.2 Functional Assay of CHD7 Variants 
6.2.1 Patients and CHD7 Alterations 
The G1982W variant results from a substitution in exon 30 of the 
CHD7 gene. This variant was identified in a rare familial CHARGE with 
multiple affected members due to a segregating CHD7 mutation. We 
identified this missense variant c.5944G>T or p.(Gly1982Trp) in two siblings 
with typical CS. Molecular analysis of their mother shows normal CHD7 
sequence. Their late father had unilateral deafness, and it is unfortunate 
that the CHD7 molecular analysis had never been done. Nevertheless, an 
uncle from the father side also harbors this variant. From the pedigree 
analysis, we assumed that the variant must have been inherited from the 
father side (Figure 44). 
 
Figure 44. Pedigree of a familial CHARGE with G1982W-CHD7 alteration. 
Healthy members are illustrated with open symbols, established cases of 
CS harboring c.5944G>T variant marked with filled symbols (I-1, II-1, II-4). 
The patient (index case) is indicated with black arrow.  
The G1982W variant is located in the SANT-like domain (Figure 45), 
which is present in many subunits of the chromatin remodeling complexes. 
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Its precise function is unclear, but it could be involved in binding to DNA 
and histones (Hall and Georgel, 2007).  
 
Figure 45. Position of studied amino acid sequence variants. Arrows 
indicate the positions of the amino acid sequence (Adapted from 
http://www.ebi.ac.uk/interpro/protein/Q9P2D1). 
The amino acid in position 1982 is changed from a glycine (a nonpolar-
neutral amino acid) to a tryptophan (a polar-neutral amino acid). In addition, 
the substitution of a glycine, the smallest amino acid, to a tryptophan, the 
largest amino acid, is probably deleterious because it may destabilize the 
folding of the SANT domain (Figure 46).  
 
Figure 46. Computational modeling of SANT domain of CHD7 (amino acid 
position: 1962-2021) (Isabelle Callebault, personal communication, 2012). 
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The R2319C variant was identified in a case of partial CHARGE. The 
nucleotide substitution in the variant is CG to TG, in which is a most frequent 
substitution in the human genome due to deamination of 5’ methyl-cytosine 
(Antonarakis et al., 2000). The substitution affects amino acid 2319, from 
an arginine (a polar-basic amino acid) to a cysteine (a polar-neutral amino 
acid). These two amino acids having different properties, it may result in a 
modification of the three-dimensional conformation of CHD7. However, this 
mutation lies in a CHD7 region whose sequence presents no homology with 
any consensus domain (Figure 45). 
The L1302P missense variant was identified in a patient with typical 
CS. The amino acid 1302 is changed from a leucine to a proline, which may 
cause a strain in the folding of the protein. Moreover, this substitution is 
localized in a helicase domain (Figure 45), whose integrity may be essential 
for the normal function of CHD7. The pathogenicity of this variant is 
consistent with a previous report stating that pathogenic missense 
mutations were mainly found in the highly conserved middle exons 
including the chromo-, helicase- and SANT domains (Bergman et al., 2012). 
The variation c.5405-17G>A, lies in a recurrent hotspot of intronic 
mutations. This substitution leads to the creation of a new 3’ acceptor splice 
site (3’ss) that can overcome the weakness of the natural acceptor site. This 
elicits the maturation of an mRNA encoding the 1801insDGHGT-CHD7 
protein variant, presenting a five-amino acid insertion between the helicase 
and the SANT domains (Figure 45). This nucleotide substitution has been 
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found in some individuals, who exhibited either atypical or typical CS with 
various combinations of clinical anomalies (Jongmans et al., 2006; 
Legendre et al., 2018). 
In our laboratory, the c.5405-17G>A variant has been found in two 
familial CHARGE (Figure 47). In both families, the variant was previously 
reported with a maternal inheritance from their mildly affected mother that 
failed to fulfill Verloes’ diagnostic criteria (Legendre et al., 2018). However, 
when we applied an updated Hale’s criteria, these mothers were diagnosed 
to have CS. The mother in the family one had two major criteria (inner ears 
anomaly and pathogenic CHD7 variant) and two minor criteria (unilateral 
deafness and limb anomaly). The mother in the family two had two major 
criteria (bilateral coloboma and pathogenic CHD7 variant) and three minor 
criteria (developmental delay, unilateral deafness, and kidney anomaly). 
Her daughter was studied and concluded to have CS based on Hale’s 
criteria. Her sons were completely asymptomatic (according to the French 
law, CHD7 analysis was not performed for these asymptomatic minor 
children). Moreover, a new pregnancy began and prenatal diagnosis 
showed that the fetus inherited the same mutation. 
These familial cases suggested that a splicing defect could occur with 
various intensities according to the patients, leading to differences in variant 
protein amount during early development. This may account for the 
diversity of clinical features in patients presenting this variant. 
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Figure 47. Pedigrees of two familial CHARGE with CHD7:c.5405-17G>A 
alteration. Family one (A) and family two (B) inherited the variant from their 
mildly affected mothers (I-2). Both index cases, indicated by a black arrow, 
had typical CS (II-1, II-4) (Legendre et al., 2018). 
6.2.2 Localization of Overexpressed Wild-Type and Variant CHD7  
Several teams have shown in various cell types that CHD7 protein is 
localized in the nucleoplasm but is essentially concentrated in the nucleolus 
(Zentner et al., 2010; Kita et al., 2012). We have also performed some 
experiments to point out the localization of CHD7 protein by indirect 
immunofluorescence. Therefore, we transfected HeLa and HEK293 cells 
with a plasmid encoding CHD7-HA, then performed an immunostaining of 
CHD7 and UBF, a transcription factor which is involved in the expression of 
the rRNAs and whose localization is nucleolar. A merge of the images 
makes it possible to see the putative co-localization of CHD7 and UBF. 
These experiments have always revealed a nucleoplasmic but non-
nucleolar localization of CHD7-HA (Figure 24). We hypothesized that the 
HA tag we used could disrupt CHD7 addressing. 
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Further, we performed the same experiments in HeLa and HEK293 
cells using a plasmid encoding FLAG-CHD7 (labeled at the other end of the 
protein), co-transfected with a fusion protein between the nucleolin (located 
exclusively in the nucleolus) and mCherry (a red fluorescent protein). 
However, we obtained the same result as before: the CHD7 protein was 
localized exclusively in the nucleoplasm (Figure 25). 
In brief, we expressed in HeLa and HEK239 cells two forms of CHD7 
protein, tagged in N- or C-terminus, and we used two distinct nucleolar 
markers, but we did not observe any nucleolar localization for CHD7 protein. 
Nevertheless, it may be more appropriate to carry out this study in cellular 
models in which CHD7 is endogenously expressed:  for example, CHD7 is 
selectively expressed in neuronal stem cells (NSC) and neuronal progenitor 
cells (Feng et al., 2013). However, the use of primary cultures of this type of 
cells would make our technique too cumbersome to use since primary 
mammalian neurons derived from embryonic central nervous system 
present the limitation that, once terminally differentiated into mature 
neurons, the cells can no longer be propagated. Thus, it may be more 
suitable to use neuronal cell lines for further development. That is why we 
determined to use SH-SY5Y neuroblastoma cells for further experiments. 
To confirm this finding, we expressed in SH-SY5Y cells two forms of CHD7 
protein, tagged in N- or C-terminus, however the localization of CHD7 
protein is identical to the previous results (Figure 26). 
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Moreover, N- or C-terminus fusion tags may interfere with the 
addressing of CHD7. Therefore, it may be more appropriate to express the 
CHD7 protein using a plasmid encoding untagged CHD7 and perform 
immunostaining with an anti-CHD7 antibody. So, to verify these results, we 
performed immunostaining of endogenous CHD7 protein compared with 
untagged-CHD7 protein that we co-transfected with a fusion protein 
between nucleolin and the mCherry in HeLa cells. Contrary to the literature, 
repeated experiments gave the same results showing that endogenous or 
overexpressed CHD7 proteins localize exclusively in the nucleoplasm, but 
not in the nucleolus (Figure 27). We concluded that the tag in either position 
was not involved in the localization of CHD7 protein. It is still unclear why 
CHD7, in our hands, was always localized exclusively in the nucleoplasm 
and not in the nucleolus. In our functional test system, we chose to express 
untagged CHD7 in HeLa cells to compare the localization of CHD7 protein 
in WT or variant forms, and next to assess their functionality. 
Whatever the structural consequence of these changes in amino acid 
sequence upon CHD7 folding, we designed a simple functional assay 
based on CHD7 ability to regulate gene transcription. First, we checked the 
overexpression of wild-type and variants form of CHD7 by Western blot and 
immunofluorescence. We observed that all variant forms of CHD7 exhibit 
the same nucleoplasmic localization compared with the wild-type. This 
suggests that these changes in CHD7 amino acid sequence have no 
consequence upon the intracellular trafficking of the protein. 
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6.2.3 Evaluation of Pathogenicity by Computational Tools for CHD7 
Missense Variants 
Bioinformatic computational tools have been widely used to assign the 
functionality of a protein, including CHD7 protein variants (Bergman et al., 
2012; Yao et al., 2018; Gonçalves et al., 2019). Moreover, the reported 
information about CHD7 variations and their pathogenicity have been 
archived in several databases such as CHD7 database, ClinVar, VarSome, 
EVS, gnomAD. It allows to easily identify the pathogenicity of a CHD7 
variant found in a patient. However, interpreting de novo CHD7 variants 
(missense or other variants in the CHD7 protein amino acid sequence) that 
have not yet been reported before remains a challenge. Sometimes, in-
silico CHD7 pathogenicity analysis using several tools even give different 
results. To resolve this problem, Bergman et al. had proposed an algorithm 
that combines two computational tools, structural model and phenotypic 
data (Bergman et al., 2012). Furthermore, to confirm the bioinformatic 
prediction of CHD7 missense variants that we studied, we applied this 
algorithm to evaluate their pathogenicity using published data (Table 16). 
Unfortunately, we had to classify the G1982W variant as a Variant remain 
of Unknown clinical Significance (VUS) due to a lack of segregation data 
and structural model. However, this classification is coherent with what was 
previously described in chapter 3. Therefore, for this VUS variant, a 
biological functional test is highly required and must be conducted to 
confirm its pathogenicity.  
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Table 16. Pathogenicity of five studied missense variants according to 
Bergman et al. 
 
PolyPhen-2 output: benign; prob, probably damaging. Align-GVGD output: 
C0, benign; C55/C65, probably pathogenic. Structural model: minor, minor 
effect; detrimental, detrimental effect; undeterm, undetermined. 
1 Félix et al., 2006; 2 Jongmans et al ; 3 Bergman et al., 2012 ; 4 Wincent 
et al., 2008; 5 Bertels et al., 2010 ; 6 Vuorela et al., 2007. 
6.2.4 Functionality of CHD7 Variants 
In this work, we describe a straightforward approach to evaluate the 
impact of amino acid sequence variations upon the functionality of CHD7 
protein. We applied this method to six variants that found in CS patients: 
five variants harboring an amino acid substitution, T894A, A2160T, 
G1982W, R2319C and L1302P, and one variant with a five-amino acid 
insertion, 1801insDGHGT. 
To compare the functionality of the variants with that of WT-CHD7, we 
quantified the consequence of CHD7 overexpression in HeLa cells upon 
the transcript amounts of genes whose transcription was published to be 
CHD7 Variant Poly 
Phen-2 
Align-
GVGD 
Structural 
Model 
Segregation 
Analysis 
Total Score; 
Classification 
Ref. 
c.5944G>T; 
G1982W 
Prob/1 C65 Undeterm N/A +2; VUS  
c.6955C>T; 
R2319C 
Prob/1 C65 Detrimental >1 de novo +7; Pathogenic 1, 2, 3 
c.3905T>C; 
L1302P 
Prob/1 C65 Detrimental de novo +6; Pathogenic 3, 4 
c.2680A>G; 
T894A 
Benign/ 
0.126 
C55 Minor 
parent 
carrier 
-2; Benign 3, 5 
c.6478G>A; 
A2160T 
Benign/ 
0.002 
C0 Minor 
parent 
carrier, 
homozygous 
-8; Benign 3,6 
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regulated by CHD7. When we transiently expressed WT-CHD7 in HeLa 
cells, the transcription of the five reporter genes was downregulated: the 
mRNA amount levels were decreased to 23.2-48.9% of the levels quantified 
in mock-transfected cells. When we expressed T894A and A2160T 
variants, the transcript amounts of the five reporter genes were decreased 
and no statistically significant difference was observed compared with WT-
CHD7 (Figure 32). These results confirmed that both variants are 
polymorphism. In contrast, when we expressed any of the four CHD7 
variants: G1982W, R2319C, L1302P, and 1801insDGHGT, the 
transcription levels of the five reporter genes were non-significantly different 
from the control levels. This suggests that these CHD7 variants have lost 
their functionality of chromatin remodeler and gene transcription regulator. 
Hence, these amino acid changes are not polymorphisms but are likely 
loss-of-function variants, leading to haploinsufficiency in patients.  
The replicates of each sample (WT and variants) were included within 
each independent experiment, and each independent transfection was 
repeated three times. The sensitivity and specificity of this functional assay 
system have been evaluated using a set of 3 pathogenic and 2 non-
pathogenic variants. Sensitivity has been estimated at 100% and specificity 
at 100%. These results suggest that this functional assay system is reliable 
to predict the pathogenicity of CHD7 variants. However, our study had 
certain limitations due to the low number of studied variants. Therefore, 
evaluation and validation of our functional assay system should be 
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improved by performing this assay using a larger set of either various 
pathogenic and non-pathogenic, as well as VUS variants that are reported 
in the literature or in the CHD7 database. 
6.2.5 Technical Consideration for Functional Assay using 
Overexpression Approach 
In overexpression approach, the modulation of transcription elicited by 
CHD7 appeared sometimes contradictory with previously published data 
obtained in various ex vivo or in vivo models, in which CHD7 was either 
overexpressed or depleted. However, in a transformed cell line like HeLa 
cells, the chromatin packing status and epigenetic tagging may differ largely 
compared to these models.  
What are the expected clinical consequences of studying the 
functionality of CHD7 missense or other variants using our system? This 
system could determine whether a substitution is a polymorphism or a 
disease-causing alteration. Moreover, if we detect functional alterations of 
different magnitudes between several variants, we will have to consider 
correlations with the different phenotypes of patients with CS or other 
diseases involving the CHD7 gene. 
The functional analysis may also be useful for genetic counseling in 
some cases. Indeed, even if the majority of CHD7 mutations appear de 
novo, there are rare cases of family mutations. This is the case of the 
nucleotide substitution giving rise to the variant G1982W. This is why, 
especially in this case, genetic counseling is really necessary to explain the 
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probabilities of transmitting the CS to the offspring or to inform the parents 
of the possibility to perform a prenatal diagnosis. 
The G1982W and L1302P variants were found in typical CS patients, 
while the R2319C variant was identified in a partial CHARGE case. It would 
therefore be consistent to observe different functional consequences of 
studied variants expression by our system. Therefore, the use of in vitro 
assays that evaluate the consequence of CHD7 variants encountered in CS 
patients on the structure and function of the protein is an essential 
alternative approach to predict the pathogenicity of CHD7 variants. The 
results of functional assay in G1982W and L1302P variants (typical CS) 
and R2319C variant (partial CS) are similar in our system by using 
overexpression approach. As a perspective, to validate these results, the 
functional assay in genomically modified cell line should be realized and 
compared with the previous results. 
6.3 Reclassification of CHD7 Variants 
Previous studies have shown that the pathogenicity of variants may 
be reclassified when additional information becomes available (Mersch et 
al., 2018). According to the functional tests performed using our system, we 
therefore recommend updating the classification of G1982W-, R2319C-, 
L1302P-, and 180insDGHGT-CHD7 variants according to the International 
Agency for Research on Cancer (IARC) and American College of Medical 
Genetics (ACMG) classifications. Based on IARC classification, for 
R2319C, L1302P, and 1801insDGHGT variants, our data confirm the in-
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silico predictions that they should be classified as class 5 (disease-causing) 
variations. As for G1982W, we propose that this variation should be 
upgraded from class 3 (variant of uncertain significance) to class 4 
(probably affecting function). 
Furthermore, according to ACMG classification, R2319C is classified 
as pathogenic: PS1 (same amino acid change as a previously established 
pathogenic variant), PP3 (multiple lines of computational evidence support 
a deleterious effect on the gene). L1302P and 1801insDGHGT variants are 
also classified as pathogenic: PS1, PP3, and PM1 (located in a mutational 
hot spot and/or critical and well-established functional domain). G1982W 
variant can be reclassified as likely-pathogenic: PS1, PM1, PP4 (patient’s 
phenotype or family history is highly specific for a disease with a single 
genetic etiology). 
It is important to conduct a functional test and to communicate its 
results, mainly for class 3 (uncertain significance) variants. It will allow 
discussing the collection of additional information and material with the 
patient and their family that can eventually lead to a better assessment of 
the variants (for example, in our case of G1982W variant with a familial 
mutation). A consequence of not communicating this variant is that 
potentially pathogenic variant would go unrecognized and remain classified 
as class 3. 
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6.4 Functional Assay of Endogenously Expressed CHD7 Missense 
Variants Using CRISPR/Cas9 System 
Having successfully developed a biological functional test using 
overexpression approach, we further developed our system using 
CRISPR/Cas9 technology to obtain genomically expressed CHD7 variants 
and study their functionality in a more physiological context. We 
successfully applied the CRISPR/Cas9 genome editing system to target 
genome location within the cell models and to generate CHD7 knock-out 
cells. Therefore, we showed in this study that the customized sgRNA/Cas9 
system could be used to induce CHD7 gene mutations in cell models. The 
results shown an achievement of sgRNA/Cas9 mediated mutagenesis with 
an efficiency of 51.6% for a knock-out in HeLa cells. 
HeLa cells are frequently used in cell manipulation since there are 
many advantages, such as a rapid growing, easy transfection, easiness and 
speed in generating mutant lines. However, HeLa cells cannot be used as 
a physiologic model of differentiated cells. On the other hand, CHD7 is 
highly expressed in neuronal progenitor cells such as SH-SY5Y cells (Feng 
et al., 2013). By using CRISPR/Cas9, we generated CHD7 (-/-) cells in both 
HeLa and SH-SY5Y lines. We then evaluated the CHD7 mRNA expression 
level by qRT-PCR using verified clones. In both cell models, the CHD7 
mRNA expression level was reduced compared with the parental cell line 
confirming the knocking-out of the gene. We further measured the transcript 
amounts of the five reporter genes in both CHD7 (-/-) cell models. In the 
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HeLa cell line, the endogenous expression of CHD7 is not involved in 
regulating the transcription of these reporter genes. However, in SH-SY5Y 
cells, the amount of RNA transcribed from these genes were upregulated 
when CHD7 was knocked-out. From this result, we assumed that CHD7 
plays a role as a regulator of transcription in SH-SY5Y cells, but not in the 
HeLa cells. This result is consistent with previous description that CHD7 is 
highly expressed in neuronal cells and that the selective expression of 
CHD7 may be involved in the development of the neurons (Feng et al., 
2017; Micucci et al., 2014). Therefore, to introduce the CHD7 missense 
variant into the genome, we determined to use SH-SY5Y neuroblastoma 
cells. 
In the first experiment, we used ssODNs as an artificial repair template 
for HDR repair, which was homologous to the target sequence and 
containing base-pair substitutions of interest (to encode G1982W, R2319C, 
or L1302P variants). Several researchers have described their preference 
to use ssODNs for genomic modification due to its simplicity, for being less 
time- and less cost-consuming than using a double-stranded template 
(Leonetti et al., 2016; Mikuni et al., 2016). Recently, several methods such 
as ‘easi-CRISPR’ have been developed. This method permits to generate 
long HDR template (more than 1 kb of sequence) and enables to insert 
longer sequences (e.g. reporters or gene tags) (Miura et al., 2018). 
Moreover, using the ssODNs for HDR repair could prevent random 
integration of the exogenous DNA products into the organism's genome 
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(Würtele et al., 2003; Zorin et al., 2005; Won and Dawid, 2017). Briefly, 
single-stranded template has shown higher efficiency than dsDNA template 
(Beumer et al., 2013; Miura et al., 2015; Yoshimi et al., 2016). 
However, in our experiments, ssODNs did not work as expected. It 
might be because its efficiency can vary widely depending on the cell type 
and status, as well as on the genomic locus and repair template, even if we 
targeted three different loci. Previous studies have discovered the impact 
of adaptations to the length, symmetry and strand complementarity of the 
ssODN repair template on genome-editing efficiency, although the 
consensus concerning the impact of these different adaptations is lacking 
(Richardson et al., 2016; Yang et al., 2013). Alternatively, by using 
linearized double-stranded targeting plasmid as HDR template, we 
obtained a clonal cell line containing the L1302P variant. Unfortunately, the 
two other missense variants (G1982W and R2319C) have not yet been 
obtained, although repeated transfections to generate these variants had 
been performed. 
For further experiments, the CRISPR/Cas9 plasmid transfection 
efficiency should be improved. CRISPR/Cas9 plasmid containing green 
fluorescence protein (GFP) could be used to detect the transfected cells 
and to make a selection by cytometry before cloning. Moreover, some 
modifications should be considered, such as adding chemicals 
(SCR7, NU7441 and KU0060648) that could block the NHEJ pathway (Ma 
et al., 2016; Maruyama et al., 2015; Singh et al., 2015; Srivastava et al., 
148 
 
2012) or stimulate the HDR pathway (Jayathilaka et al., 2008; Pinder et al., 
2015; Song et al., 2016; Yu et al., 2015) to improve the success rate of 
HDR.  
A study has shown that various cells have different abilities to repair 
DSBs using either NHEJ or HDR. The phase of the cell cycle is involved in 
the choice of pathway: NHEJ dominates DNA repair during G1, S and G2 
phases, while HDR occurs only in the late S and G2 phases (DNA 
replication is completed, and sister chromatids are available to be used as 
repair templates) (Heyer et al., 2010). Therefore, a strategy combining well-
established synchronization methods with direct nucleofection of pre-
assembled Cas9 ribonucleoprotein (RNP) complexes could be performed 
to increase the efficiency of HDR (Lin et al., 2015).  
In CHD7 knock-out and in the L1302P variant SH-SY5Y cells, the 
transcription amount of the five reporter genes was increased to 253-544% 
of the levels quantified in parental SH-SY5Y cells. The modulation of 
transcription elicited by endogenous CHD7 is different with the one that we 
observed previously using overexpression approach. This condition can be 
explained as follows. The cell lines that we used in each approach are 
different. In overexpression approach, we transiently transfected the 
plasmids encoding WT-CHD7 or variants into HeLa cells. On the other 
hand, by using CRISPR/Cas9, SH-SY5Y cells were genomically modified 
to obtain desired missense variants. The latter approach allows to obtain 
CHD7 missense variant at the genome level. As we mentioned previously, 
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CHD7 is highly expressed in neuronal cell lines; for this reason, 
endogenous level expression of WT or variant CHD7 in SH-SY5Y cells may 
have different consequence compared with overexpression approach in 
HeLa cells. However, the use of both approaches in different cell lines 
revealed similar results: for L1302P variant, the transcription levels of the 
five reporter genes were non-significantly different of the control (mock) or 
CHD7 knock-out levels. This confirms that L1302P-CHD7 variant is not 
polymorphism but is likely a loss-of-function variant, leading to 
haploinsufficiency in patients. 
The genomic modification approach may allow to observe the 
functionality of CHD7 when heterozygous substitution occurred in CS 
patients. For that purpose, it would be interesting to obtain cell lines 
containing heterozygous mutations, to compare with homozygous one. 
However, this approach has certain limitations. It will be difficult to obtain 
the heterozygous genomically modified cell to study the functionality in the 
same conditions as in patients. In 2016, a method for introducing mutation 
at single alleles to obtain a model of genetic disease caused by 
heterozygous mutations had been described, however, the complexity of 
this method will require months of work to complete (Paquet et al., 2016). 
In our experiments, after the SH-SY5Y cells were treated by 
CRISPR/Cas9 complex and incubated with puromycin, the cells require 
more time than usual to grow. Long waiting time in this approach could 
make difficult to use it as a routine assay. Therefore, we recommend using 
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the overexpression approach to investigate the functionality of CHD7 
variants. 
It has been described in previous studies that the expression of CHD7 
is selective in different types of mature neuronal cells. For example, CHD7 
is tuned off in most of the mature neurons in the brain during neurogenesis. 
In contrast, CHD7 is highly expressed in some interneuron cells in the 
olfactory bulb and in cerebellar granule neurons of adult mouse and human 
brain (Feng et al., 2017; Micucci et al., 2014). A remaining question 
concerning the function of CHD7 is whether CHD7 is required for the 
differentiation of neuronal cells.  Therefore, we propose to use SH-SY5Y 
neuroblastoma cell line that we generated to investigate the role of CHD7 
in the differentiation of neurons. This future study is expected to advance 
our understanding of neuronal behavior abnormality that is frequently found 
in CS patients.   
 
 
 
 
 
 
 
151 
 
CHAPTER VII 
 
CONCLUSIONS  
AND FUTURE PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
7.1 Conclusions 
This thesis favors a strategy for molecular diagnosis of CS using next-
generation sequencing (NGS) of targeted gene panel and provided new 
insights on developing a functional test to better interpret some CHD7 
variants. 
7.1.1 Novel CHD7 Mutation in an Indonesian CHARGE Syndrome 
Patient 
We report a novel heterozygous nonsense mutation of the CHD7 gene 
c.7234G>T or p.(Glu2412Ter) in an Indonesian CS patient. Clinical 
stigmata coupled with molecular analysis is important to determine the 
disease-causing gene and establish a definitive diagnosis of CS. 
7.1.2 Functional Assay of CHD7 Protein 
We have developed a novel and simple assay to assess accurately 
the functional impact of amino acid sequence CHD7 variants using 
overexpression approach. These results suggest that the four CHD7 
studied variants (G1982W, R2319C, L1302P, 1801insDGHGT) are not 
polymorphisms but that the variant proteins are not functional. In 
conclusion, these variants can be considered as disease-causing of CS.  
We successfully applied the CRISPR/Cas9 genome editing system to 
invalidate the CHD7 gene in HeLa and SH-SY5Y cells. This system was 
also used to introduce one (L1302P-CHD7) out of three missense variants 
in the SH-SY5Y cells. We then investigated the functionality of this variant 
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using our system. This result also confirms that L1302P variant is 
pathogenic.  
7.2 Future Perspectives 
7.2.1 Molecular Diagnosis of CHARGE Syndrome 
Mutation in the CHD7 gene is the major cause of CS. However, after 
molecular analysis using Sanger sequencing, no CHD7 mutation is 
identified in 5-10% of typical CS patients (Bergman et al., 2008). 
Identification of other candidate genes has evolved rapidly. So far, only two 
other genes have been proven to be implicated in CS, the EFTUD2 and 
SEMA3E genes (Lalani et al., 2004; Legendre et al., 2017). Recently, other 
candidate genes RERE and KMT2D have been reported causing 
CHARGE-like attributes (Jordan et al., 2018; Badalato et al., 2017). 
Therefore, to develop and to improve the targeted gene NGS panel, these 
genes should be considered to be included in these panels. 
7.2.2 Development of Functional Assay for CHD7 Protein 
Currently, 93 unclassified variants have been reported in the CHD7 
database. These Variants remain of Unknown clinical Significance (VUS) 
because of the lack of genetic information that may help to establish the 
pathogenicity. Therefore, it would be helpful if we could extend our 
biological assay system to other CHD7 missense variants that are currently 
classified as VUS. 
The functional analysis may also identify variants with an intermediate 
function that may have intermediate or moderate effects on pathogenicity 
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(Lovelock et al., 2013). In this work, the studied variants were determined 
easily as functional or non-functional since the transcript amount of each 
reporter gene was statistically not different from the wild-type or control 
(mock). The next challenge that should be addressed is how to determine 
accurately the pathogenicity of variants in which the transcript amount of 
the reporter genes is between wild-type and control (mock). It would be 
possible to calculate the cut-off point of the expression level by conducting 
several experiments with a larger variant sample. 
Several experiments using Cas9/sgRNA plasmids and HDR that did 
not result in desired modification should be repeated. Some techniques 
should be modified and improved, including transfection efficiency. Another 
transfection technique such as nucleofection using the Nucleofector II 
(Amaxa Biosystem) should be applied. Furthermore, if necessary, sgRNA 
and ssODNs should be redesigned to ensure the generation of the 
G1982W and R2319C variants. Moreover, using CRISPR/Cas9 
technology, it will be interesting to study the functionality of heterozygous 
CHD7 variants by introducing mutation at single alleles to model CS caused 
by heterozygous alterations (Paquet et al., 2016). We believe that the 
CRISPR/Cas9 derived genome-editing technique will enable the 
performance of functional studies and help us to understand the role of 
CHD7 gene and mechanisms underlying their physiological and 
pathophysiological effects. 
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ANNEX 
 
Annex 1. SDS Polyacrylamide Gel Electrophoresis 
5% gradient gel composition 
Lower gel (separation gel): 
Water  2.5 mL 
40% Acrylamide 0.5 mL 
Lower Buffer 1 mL 
Temed 4 µL 
APS 40 µL 
Upper gel (concentration gel): 
Water  1.3 mL 
40% Acrylamide 0.2 mL 
Lower Buffer 0.5 mL 
Temed 2 µL 
APS 20 µL 
 
10% gradient gel composition 
Lower gel (separation gel): 
Water  2 mL 
40% Acrylamide 1 mL 
Lower Buffer 1 mL 
Temed 4 µL 
APS 40 µL 
Upper gel (concentration gel): 
Water  1.3 mL 
40% Acrylamide 0.2 mL 
Lower Buffer 0.5 mL 
Temed 2 µL 
APS 20 µL 
*5% SDS-PAGE gel is used for analysis a protein with molecular weight 
upper 70 kDa 
*10% SDS-PAGE gel is used for analysis a protein with molecular weight 
between 20 and 70 kDa 
 
Composition of acrylamide/bis-acrylamide gel: 
Lower buffer pH 8.8: 1.5 M Tris; 0.4% SDS (w/v) 
Upper buffer pH 6.8: 0.5 M Tris; 0.4% SDS (w/v) 
 
APS: 10% ammonium persulfate (p/v) 
Developer and fixer solutions: Kodak X-OMAT EX II 
Molecular weight β-actin: 42 kDa 
Molecular weight CHD7: 340 kDa 
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Annex 2. Composition of Buffers and Solutions 
Electrophoresis Buffer: 
100 mL TG-SDS 10X (0.25 M Tris; 1.92 M Glycine, 1% SDS) 
dH2O to 1 L 
 
PBS-Tween Solution: 
100 mL PBS 10X 
1 mL Twin (Tween 20) 
dH2O to 1 L 
 
Lysis buffer, pH 7.5: 
10 mM Tris 
0.5% DOC (w/v) 
1% NP-40 (v/v) 
1 mM Pefabloc SC (Fluka Analytical) 
 
Laёmmli buffer 2X, pH 6.8: 
125 mM Tris 
4.5% SDS (v/v) 
30% glycerol (v/v) 
0.002% bromophenol blue (w/v) 
5% 1-Thioglycerol (v/v) 
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Annex 3. Antibodies for Western blot and Immunofluorescence 
Primary antibodies: 
- Rabbit monoclonal antibody anti-CHD7 (1/1000, Cell Signaling) 
- Mouse monoclonal antibody anti-HA (1/1000, Sigma-Aldrich) 
- Mouse monoclonal antibody anti-FLAG (1/2000, Sigma-Aldrich) 
- Mouse monoclonal antibody anti-β-actin (1/10000, Sigma-Aldrich) 
- Rabbit polyclonal antibody anti-UBF (1/100, Santa Cruz) 
- Mouse monoclonal antibody anti-nucleolin (C23; 1/100, Santa Cruz) 
 
Secondary antibodies: 
- Polyclonal antibody goat anti-mouse IgG peroxidase-linked (1/10000, 
Sigma-Aldrich) 
- Polyclonal antibody goat anti-rabbit IgG peroxidase-linked (1/5000, 
Sigma-Aldrich) 
- RRX-conjugated goat anti-mouse IgG (H+L) (1/100, Jackson 
ImmunoResearch Laboratories) 
- FITC-conjugated donkey anti-rabbit IgG (H+L) (1/50, Jackson 
ImmunoResearch Laboratories) 
